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Résumé 
Les quatre principales activités de la gestion de risque thérapeutique comportent 
l’identification, l’évaluation, la minimisation, et la communication du risque.  Ce mémoire 
aborde les problématiques liées à l’identification et à la minimisation du risque par la 
réalisation de deux études dont les objectifs sont de: 1) Développer et valider un outil de 
« data mining » pour la détection des signaux à partir des banques de données de soins de 
santé du Québec; 2) Effectuer une revue systématique afin de caractériser les interventions 
de minimisation de risque (IMR) ayant été implantées. 
L’outil de détection de signaux repose sur la méthode analytique du quotient séquentiel de 
probabilité (MaxSPRT) en utilisant des données de médicaments délivrés et de soins 
médicaux recueillis dans une cohorte rétrospective de 87 389 personnes âgées vivant à 
domicile et membres du régime d’assurance maladie du Québec entre les années 2000 et 
2009. Quatre associations  « médicament-événement indésirable (EI) » connues et deux 
contrôles « négatifs » ont été utilisés. La revue systématique a été faite à partir d’une revue 
de la littérature ainsi que des sites web de six principales agences réglementaires. La nature 
des RMIs ont été décrites et des lacunes de leur implémentation ont été soulevées. 
La méthode analytique a mené à la détection de signaux dans l'une des quatre combinaisons 
médicament-EI. Les principales contributions sont: a) Le premier outil de détection de 
signaux à partir des banques de données administratives canadiennes; b) Contributions 
méthodologiques par la prise en compte de l'effet de déplétion des sujets à risque et le 
contrôle pour l'état de santé du patient.  La revue a identifié 119 IMRs dans la littérature et 
1,112 IMRs dans les sites web des agences réglementaires. La revue a démontré qu’il existe 
une augmentation des IMRs depuis l’introduction des guides réglementaires en  2005 mais 
leur efficacité demeure peu démontrée.  
 
Mots-clés : Gestion du risque thérapeutique, minimisation du risque, pharmacovigilance, 
data mining, détection de signaux. 
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Abstract 
The four main components of therapeutic risk management (RM) consist of risk detection 
(identification), evaluation, minimisation, and communication.  This thesis aims at 
addressing RM methodologies within the two realms of risk detection and risk 
minimisation, through the conduct of two distinct studies: i) The development and 
evaluation of a data mining tool to support signal detection using health care claims 
databases, and ii) A systematic review to characterise risk minimisation interventions 
(RMIs) implemented so far. 
The data mining tool is based on a Maximised Sequential Probability Ratio Test 
(MaxSPRT), using drug dispensing and medical claims data found in the Quebec health 
claims databases (RAMQ).  It was developed and validated in a cohort of 87,389 
community-dwelling elderly aged 66+, randomly sampled from all elderly drug plan 
members between 2000 and 2009.  Four known drug-AE associations and two "negative" 
controls were used. The systematic review on RMIs is based on a literature search as well 
as a review of the websites of six main regulatory agencies.  Types of RMIs have been 
summarized and implementation gaps identified. 
The data mining tool detected signals in one of four of the known drug-AE associations.  
Major contributions are: a) The first signal detection data mining tool applied to a Canadian 
claims database; b) Methodological improvements over published methods by considering 
the depletion of susceptibles effect and adjusting for overall health status to control for 
prescription channelling.   The review yielded 119 distinct RMIs from the literature and 
1,112 from the websites. The review demonstrated that an increase in RMI numbers among 
websites occurred since the introduction of guidances in 2005, but their effectiveness 
remains insufficiently examined. 
 
Keywords: Therapeutic risk management, risk minimisation, drug safety, 
pharmacovigilance, data mining, signal detection. 
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Chapter 1. Thesis Introduction 
1.1 Historical perspectives of drug safety surveillance and 
therapeutic risk management 
Between the years of 1956 and 1961, widespread use among pregnant women of the 
sedative thalidomide, was linked to the congenital malformation of phocomelia (deformed 
limbs) in almost 10,000 newborn babies world-wide[1.2.3]. These unfortunate cases were 
observed in 46 different countries, including Germany, England, and the United States. In 
fact, the “thalidomide tragedy” is the catastrophe that reformed the regulatory drug testing and 
drug approval processes on a global scale, eventually leading to the emergence of the field of 
pharmacovigilance, or safety surveillance[4].  Since then, regulatory agencies around the world 
have implemented surveillance methods, mainly based on spontaneous reporting in order to 
support timely signal detection, the identification of new AEs[5].. In parallel, 
pharmacovigilance regulations have been harmonized through the International Conference 
on Harmonization (ICH) E2E.  Although Canada is not formally part of ICH, it is an observer 
and also follows ICH E2E.  
 
Despite the success of medications at reducing morbidity and increasing life expectancy, 
drugs can also be associated with adverse events (AEs), some of which are serious, 
debilitating, and even life-threatening. In 2005, the Cox 2 Inhibitor, rofecoxib, and its 
reported link to myocardial infarct and stroke resulted in the product's withdrawal from the 
market, and the subsequent voluntary withdrawal of the entire class of drugs[6]. This subject 
has been largely debated [7,8], as some wonder what precautions could have been taken in 
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order to avoid or reduce the occurrence of these AEs, and whether i) limiting the product as a 
treatment of last resort to be used by those for whom other treatments had not been successful 
and; ii) more stringent adherence to the labelling instructions by prescribers; may have 
permitted this product to remain on the market. This would have allowed the continued and 
much-needed benefit for those individuals for whom rofecoxib was the only effective 
treatment[7],. 
The suggested rofecoxib activities described in points i) and ii) above are examples of  
possible components of a therapeutic risk management system/plan, i.e. a set of 
pharmacovigilance activities and interventions designed to identify, characterise, prevent or 
minimise risks relating to medicinal products, and the assessment of the effectiveness of those 
interventions. [9] 
1.2 Components of therapeutic risk management 
Risk management consists of four main activities: risk detection, risk assessment, risk 
minimisation and risk communication[9] A product is considered to be “safe” if it has an 
appropriate benefit-risk balance for the intended population and use i.e. if the clinical 
significance and probability of its beneficial effects outweigh the likelihood and medical 
importance of its harmful or undesirable effects[10]  
The goal of therapeutic risk management is to optimize the benefit-risk balance of a drug 
immediately after product launch.  To be more specific, it can be elaborated as an interactive 
process of (1) assessing a product’s benefit-risk balance, (2) developing and implementing 
tools to minimise its risks while preserving its benefits, (3) evaluating tool effectiveness and 
reassessing the benefit-risk balance, and (4) making adjustments, as appropriate, to the risk 
minimisation tools to further improve the benefit-risk balance[10].  Such "adjustments" are 
often incorporated into communication plans.  Risk minimisation consists of interventions 
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beyond labelling that aim at optimizing the benefit-risk profile of drugs.  Examples of RMI 
are communication materials and restricted distribution programs (also referred to as Risk 
Evaluation and Mitigation Strategies, REMS, in the US) [10]. 
1.3 Current challenges in risk detection and risk minimisation 
processes 
1.3.1 Risk detection challenges 
The limitations of pre-approval clinical trials at identifying AEs are well-known, mainly due 
to the restrictive inclusion/ exclusion criteria of trials which generally exclude individuals 
with certain co-morbidities and concomitant medications, as well as special populations such 
as children, pregnant women, and elderly patients [11]. Clinical trials also tend to enrol limited 
numbers of subjects, usually a maximum of a few thousands, which are inadequate to identify 
rare AEs or those with long delays of onset [12]. Furthermore, trial populations include patients 
with a pre-specified indication, which does not permit the study of off-label use, an important 
component of drug safety surveillance [11].  As a result, identification of many safety risks has 
historically occurred in the post-marketing setting through pharmacovigilance activities[13]..   
Pharmacovigilance is generally based on spontaneous reporting data: AEs are reported to 
pharmaceutical companies or regulatory organisations, by health care professionals (HCPs) or 
consumers who suspect that they may be experiencing a treatment-related medical event. As 
beneficial as these spontaneous reporting systems have been at identifying risks, they also 
have well-known limitations; the primary one being “underreporting” as in many instances 
HCPs or patients do not report these “side effects” as they do not “suspect” that they could in 
fact be due to the medications [14]. Other deterrents to reporting include time to complete the 
reporting form and lack of knowledge of surveillance systems [15]. Furthermore, in Canada and 
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most parts of the world, this process is voluntary, meaning that in many immeasurable cases 
even suspected[15] AEs may not be reported.   Reporting is also influenced by factors such as 
previous knowledge about a risk (i.e. "listed" effects), severity of the drug, and time since 
marketing. 
 
Central to signal detection through spontaneous reporting is the causality assessment: the 
evaluation of the likelihood that a particular treatment is the cause of an observed AE [16,17]...  
With the presence of a positive causality assessment, the evidence of association between AE 
and event is high, and the identification of a new risk by spontaneous reporting implies a 
strong association between the drug treatment and the occurrence of the event[18]  Thus, even a 
few well-documented cases can lead to generation of a signal, despite the under-reporting 
limitation of SRS [19]. In fact, the withdrawal from the market of many drugs has been due to 
reports of safety risks identified through SRS [20,21]. Examples of such drug-AE pairs include: 
fenfluramine for cardiac valvulopathy, terfenadine for drug interactions/ventricular 
arrhythmias, troglitazone for hepatotoxicity, cisapride for drug interactions/ventricular 
arrhythmias, astemizole for drug interactions/ventricular arrhythmias, cerivastatin sodium for 
rhabdomyolysis, and efalizumab for progressive multifocal leukoencephalopathy[22,23,24,25]. 
 
Other methods of safety surveillance include meta-analyses of randomized clinical trials. 
Some of these clinical trials may be post-marketing clinical trials that are organised to study 
the long-term safety of a medication, a new indication of the drug, or to provide additional 
supporting data of safety risks identified from SRS [21]. Some regulatory withdrawals that 
were based on results of randomized clinical trials include: alosetron hydrochloride for 
ischemic colitis and complications of constipation, encainide due to excess mortality, 
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aprotinin due to increased mortality risk, and rofecoxib due to myocardial infarct and 
stroke[22,23,24,25]. 
In addition to clinical trials and the spontaneous reporting process, pharmacoepidemiologic 
studies, (i.e. observational studies of the use and effects of drugs in large populations [26]) have 
been used as risk assessment/ evaluation tools in order to further characterize risks initially 
identified by safety surveillance systems [27]. Hence, traditionally, these studies have been 
conducted in a "reactive" mode, i.e. after a signal has been detected in the real-world.  This 
was rather inefficient since it involved lengthy processes to gather adequate data for accurate 
and reliable results. Consequently, before risk management, the timeline for risk detection, 
characterisation, and evaluation processes, was long.  
The act of looking for and /or identifying new adverse events (AEs) or signals is known as 
signal detection (SD) [5].  As an attempt to improve the efficiency and the timeliness of the 
systems in place, data mining was introduced. Data mining is a process that supports SD by 
using computerised algorithms to discover hidden patterns of potential signals in large 
databases[28]. Most data mining algorithms have been implemented in national spontaneous 
reporting databases or databases of pharmaceutical companies.  However the national 
spontaneous database in Canada is too small to perform quantitative data-mining, as it 
contains only about 225,000 suspected adverse reaction reports that occurred in Canada 
during the 46 years between 1965 and 2011, and data mining is currently not conducted in 
Canada [29]. Recently, attempts have also been made world-wide to use administrative claims 
database to conduct data mining[30,31,32]. Provincial claims databases are widely available in 
Canada (e.g. the Ontario Health Insurance Plan (OHIP) database, the Régie de l’assurance 
maladie Québec (RAMQ) database of Quebec, the Saskatchewan Drug Plan and Extended 
Benefits database amongst the most well-known) and have been extensively used for 
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pharmacoepidemiologic studies [33]. These databases include information on all prescribed 
medications dispensed to the members of the public drug program as well as all physician-
patient encounters that are billed on a fee for service [34].  This results in an accumulation of 
longitudinal data on drug exposures and AEs on very large segments of the population[35]. 
Consequently, they may be a useful tool for signal detection in pharmacovigilance.  Data 
mining using administrative claims databases has been conducted in large US databases but, 
to our knowledge, not in Canadian databases. 
 
1.3.2 Risk minimisation challenges 
Following risk detection and risk evaluation activities, strategies to minimise the identified 
risk(s) may be enacted if deemed necessary. These would normally be in the form of risk 
minimisation interventions (RMIs), which are beyond product labelling[35]. RMIs are tools 
which aim at reducing the risk of AEs among patients using medications, while preserving 
their benefits throughout the drug’s life cycle[10]. Their main functions are to:  
i) Communicate particular information regarding optimal product use ii) Provide guidance on 
prescribing, dispensing, and/or using a product in the most appropriate situations or patient 
populations. Examples of RMIs include Dear Health Care Professional letters, safety 
warnings, education programs, and restricted distribution, to name a few[10].  
 
Although regulatory authorities have long ago issued guidance documents concerning 
pharmacovigilance (1991 in Canada), guidelines concerning therapeutic risk management 
have only been recently integrated into the regulatory process of the USA (2005), and Europe 
(2006) [10,9]. Although Canada has not yet integrated risk management into its drug regulation 
or legislation, it is reviewing risk management plans submitted by pharmaceutical companies.   
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Consequently, little is known about appropriate considerations in the establishment of RMIs. 
Due to the novelty of risk management, many drug manufacturers, as well as regulators, are 
still uncertain of what RMIs are available for use; which are appropriate for the various 
products; and what interventions should be incorporated in a particular product's risk 
management plan. 
8 
 
 
 
 
9 
 
 
Chapter 2. Objectives and outline of thesis 
This thesis addresses methodological gaps that currently exist in the published literature on 
therapeutic risk management, namely with respect to risk detection (identification), through a 
data mining study in a health claims database, and risk minimisation, through a systematic 
review of risk minimisation interventions. 
 
Study I:  Application of a Data Mining Algorithm to a Canadian Claims Database: 
A data mining study was performed using the Quebec administrative claims databases 
(RAMQ) with the following objectives: i) To apply a data mining algorithm to support signal 
detection within the Quebec claims database; ii)To assess its performance through measures 
of sensitivity (detection of risk, and timeliness) and specificity; iii) To test the robustness of 
the tool in relation to different methodological considerations, namely with respect to the 
depletion of susceptibles effect and control for prescription channelling. 
A retrospective cohort study was conducted in which a data mining algorithm was applied to 
a random sample of 87,389 elderly community-dwelling members of the Quebec public drug 
program  (data from 1st January 2000 to 31st December 2009). Four known drug-AE pairs 
were analysed using the Maximised Sequential Probability Ratio Test (MaxSPRT), which 
compared monthly expected counts of AEs to observed counts of AEs. The time to detection 
of the potential signal using this method was compared to the actual historical date of the 
safety warning’s posting by Health Canada. To determine the specificity of the method, two 
drug-event associations that were not considered to be a safety issues, were used as negative 
controls.  
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Study II:  Review of Risk Minimisation Interventions in Drug Safety 
Manuscript entitled: Impact of regulatory guidances and drug regulation on risk 
minimisation interventions in drug safety: a systematic review (accepted for publication in 
Drug Safety on December 28, 2011) 
A systematic review (literature search and website search) of RMIs implemented between 1st 
January 2000 and 31st December 2009 was performed with the following objectives: i) To 
describe RMI type; year of RMI implementation; jurisdiction; and specificity of target 
population, target AE, and drug class; ii) Determine whether the introduction of guidances on 
therapeutic risk management had an effect on the characteristics of RMIs published in the 
literature or on regulatory agencies websites.  
Together these studies and resulting publications are expected to serve as resources to identify 
methodological gaps of current RMIs, support signal detection, and provide new knowledge 
on data mining for the advance of drug safety surveillance within the Canadian population  
11 
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Chapter 3. Signal detection in drug safety surveillance 
3.1. Principles of signal detection  
A key component of, and main reason for, pharmacovigilance is the act of looking for and /or 
identifying new adverse events (AEs) or signals[5] i.e. Signal detection .  
The CIOMS VIII defines a signal as “Information that arises from one or multiple sources 
(including observations and experiments), which suggests a new potentially causal 
association, or a new aspect of a known association, between an intervention and an event or 
set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood 
to justify verificatory action.” [36]. 
The process of signal detection ideally begins at the product’s introduction to the market. 
Nevertheless, in practice, it is carried out at various stages of a product’s life cycle, such as 
when a safety concern is already suspected, or when monitoring for very serious safety risks 
of special interest[28].  
This chapter provides a description of some components of signal detection: methods, data 
sources and finally a summary of some published studies that have been performed in the 
past.   
There are two main methods for identifying safety issues: Qualitative Methods whereby 
experts manually review individual case reports, and Quantitative Methods or data mining 
involving the use of computerised algorithms to discover hidden patterns of associations or 
unexpected occurrences (i.e. ‘signals’) in large databases[28].  
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3.1.1 Qualitative methods of signal detection 
Qualitative Signal Detection is the original form of signal detection in which experts 
manually review individual case reports to identify unanticipated effects [37]. In the past, this 
has been done using analyses and sometimes meta-analyses of case reports of randomized 
clinical trials, as well as the spontaneously reported AE case reports. Assessing the 
unexpectedness and causality of these events is a complex task, performed through a 
combination of activities including examining and comparing: patient characteristics, the 
underlying disease, as well as background rates of the event in the patient population [38]. For 
this reason collecting well-documented reports is extremely important with qualitative signal 
detection, and even just a few well-documented cases can lead to generation of a signal [14]. 
The causality (imputability) assessment: the evaluation of the likelihood that a particular 
treatment is the cause of an observed AE [16,17], is very important to the process of identifying 
signals qualitatively. Several methods have been developed to determine causality such as: 
the World Health Organisation (WHO) and Uppsala Monitoring Centre (UMC) tool for case 
causality assessment[16], which is used by many countries world-wide including Health 
Canada; the algorithm used by the AFSSApS (Agence française de sécurité sanitaire des 
produits de santé), commonly referred to as the “French causality assessment algorithm[39]”; 
and the algorithm used by the US Food and Drug Administration (FDA[40]). Common 
elements present within most causality assessment methods, that would allow for a 
compelling imputability analysis, are generally temporal sequence to onset of AE; previous 
drug-AE history; dechallenge/rechallenge information; and exclusion of alternative known 
causes e.g. concomitant medications [17], along with some additional criteria depending on the 
method. In general the causality assessment methods are very efficient except when used for 
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assessing AEs that have long delays of onset (e.g. cancer) or in populations where the AE is 
frequent.  In these circumstances causality is difficult to establish. 
Qualitative signal detection using few high-quality AE reports are not uncommon. In fact the 
temporary voluntary suspension of the drug natalizumab was performed after just two clinical 
trial reports of progressive multifocal leukoencephalopathy. The product was later 
reintroduced to the market with a strict risk management plan in place [41].  
 
This traditional case-by-case qualitative assessment of reports continues to be, used 
effectively specifically in situations of low background rates of adverse event (AE) 
occurrence. However it poses a problem in instances where there is a very high amount of 
data, where the background rate of the AE in the population is high (i.e. too much background 
noise to be able to detect a signal), or there are complex associations such as drug-drug 
interactions.   As technology progressed over time, computerised processes to support these 
tasks have developed, and quantitative methods for identifying safety findings, such as data 
mining, have become more common [42,43]. 
 
  
3.1.2 Quantitative methods of signal detection 
Quantitative methods have become useful in instances of very high amounts of data, complex 
associations such as drug-drug interactions, or within populations where the background rates 
of AEs are high [28,42,44]  . Consequently, data mining algorithms for signal detection have 
evolved as an integral component of the pharmacovigilance process in order to identify 
previously unknown adverse events (AEs) of a drug (i.e. Drug-event pairs or drug-AE pairs).   
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Quantitative methods can be divided into: i) Denominator-independent methods and, ii) 
Denominator-based methods. Both are based on disproportionality analyses (DPA) which 
examine the relative occurrence of observed drug-event pairs compared to an expected value 
based on overall reporting patterns [28,37,44].  
3.1.2.1 Denominator-independent methods 
With denominator-independent methods, rates of exposure to the drug of interest in the 
population are not required. These methods are very commonly used in national or company-
sponsored spontaneous reporting (SR) databases which only possess reports of AEs. 
Consequently the exposure rates within the database are not an accurate reflection of the 
population’s true exposure to the medication of interest (denominator[44]). Below is a 
description of the various denominator-independent methods found in the literature. 
 
Frequentist (non-Bayesian) methods:  These are the simplest approach to quantitative signal 
detection using disproportionality analysis. For each combination of drug-AE in a 
spontaneous reporting database, a two-by-two table of counts is obtained based on the number 
of reports involving the drug of interest (referred to as i) and the number of reports involving 
a specific AE (referred to as j), [45,46] . This is portrayed in Table I below.   
 
Table I.  Two-by-two table for frequentist methods in disproportionality analysis 
Number of reports With drug i Without drug i Total 
With adverse event j nij=a b a + b 
Without adverse event j c d c + d 
Total a + c b +d a + b + c + d 
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Many different forms of reporting ratios can be calculated and used to determine existence of 
a pair’s disproportionality:  
Relative Reporting Ratio (RRR) =  [a/(a + b)] / [a/(a + c) / (a + b + c + d)] 
Proportional Reporting Ratio (PRR) = [a/(a + c)] / [b/(b + d)]  
Reporting Odds Ratio (ROR) =  ad / bc 
 
The PRR is analogous to a relative risk (RR) in a pharmacoepidemiologic cohort study, while 
the ROR is analogous to the Odds Ratio (OR) in a case-control study. Table II details 
advantages and disadvantages of quantitative methods described in this section[28]. 
 
Bayesian Methods:  These compensate for areas where frequentist methods, described above, 
are lacking, i.e. by accounting for statistical uncertainty due to small counts[28].   Small counts 
are usually the case in a post-approval setting where AEs are rare.  There are two main 
Bayesian methods. The first, used by the FDA and developed by DuMouchel, involves the 
technique of empirical Bayes screening (EBS) [47, 48]. Mathematically it is based on a two 
gamma mixture distribution, and ranks drug-event combinations by degree of “interest” in 
terms of the number of reports of that particular drug-event pair, vs. what would be expected 
if the drug and event were statistically independent[44]    
The two main formats of this method are the Gamma Poisson Shrinker (GPS) method, used 
when dealing with pair-wise associations of drug and AE (i.e. one drug, one AE) and the 
Multi-item GPS (MGPS)[49] method used when dealing with multi-item associations (e.g. 
Where two drugs in combination may be causing the AE) [50].  
The second Bayesian method, used by WHO, is referred to as the Bayesian Confidence 
Propagation Neural Network (BCPNN) and involves calculation of an “information 
component” (IC) for each drug-event pair The formula of the IC comprises: i) the number of 
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case reports with a specific drug, ii) the number of case reports with a specific AE,  iii) the 
number of reports with the specific drug-AE combination, and iv)  the total number of drug –
AE reports in the database. In this way. the IC  is a reflection of the value, precision and time 
trend of the information within the database. A positive IC value indicates that the particular 
combination of drug and AE is reported to the database more often than statistically expected, 
as compared to reports already present within the database[51].  
3.1.2.2 Denominator-based methods 
These are methods used when drug exposure rates are available, which then provide a 
“denominator” for the identification of disproportionality in the occurrence of AEs within the 
exposed group as compared to the occurrence of AEs in a reference group. Most often they 
are used to identify temporal changes in reporting rates or frequencies by constructing a 
probability model and a corresponding test statistic in order to assess the probability that the 
observed temporal changes reflect random sampling variability[44]  .  
 
Figure I below displays an example of a theoretical quantitative signal detection method. The 
number of patients using the medication of interest and experiencing a particular AE is 
compared to the number of patients using a reference drug product who also experience this 
AE. The point at which the users of the medication of interest appear to be experiencing a 
higher number/proportion of AEs than expected, is where a potential signal is said to be 
identified.  
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Figure I. Quantitative signal detection simulation example - Denominator-based 
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The two main denominator-based methods used on drugs are i) the Poisson method, and ii) 
the Sequential Probability Ratio Tests (SPRTs). 
 
In accordance with the assumptions of the Poisson distribution [52], the Poisson method is used 
when the number of AEs is rare and occurs in large exposed populations.  It requires three 
items of information: (i) Number of AE reports (observed), (ii) Estimated background 
incidence of AEs (number of expected cases) and, (iii) Estimated number of patients treated 
with the drug (i.e. exposure). Rare drug-event occurrences are modeled using estimated 
background incidence of an adverse event (AE) and the number of patients treated. This is 
done using a Poisson distribution to obtain the probability of obtaining coincidental drug-AE 
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associations per time period. Under various hypotheses of under-reporting, the expected 
number of cases will be compared to the observed number of cases, during the particular time 
period being studied. If the observed number exceeds the critical value in the Poisson 
distribution, then a signal is generated [44, 53]. 
 
The Sequential Probability Ratio Test (SPRT) is a sequential sampling technique used 
extensively in analyses of randomized clinical trial data. Also known as the classical or 
Wald’s SPRT, it compares observed counts to expected counts in order to determine if a 
disproportionate number of events has occurred in the study group as compared to a 
reference/ control group. It is useful for safety monitoring on a weekly or monthly basis 
permitting early AE detection[54,55,56]. An AE signal would be generated if the log likelihood 
ratio (LLR) exceeds a pre-determined value, calculated based on a single alternative RR such 
as RR=2 (See example in Figure I). The key in this method is the fact that the p-values are 
adjusted for the multiple testing[57,58].    
 
The Maximised SPRT (MaxSPRT) is a Poisson-based methodology that is an altered method 
of Wald’s SPRT. Kulldorff [57] et al modified the test such that it does not require a specific “a 
priori” specification of a single level of increased risk that would define a signal (as with the 
classical SPRT). It instead uses a composite alternate hypothesis, HA of Relative Risk (RR) 
>1[31]. In this way, it works well across the various ranges of RRs, and the test statistic, i.e. the 
log likelihood ratio (LLR) becomes a maximum likelihood under the composite alternative 
hypothesis divided by the likelihood under the null hypothesis H0. (RR=1)[57]. Where: 
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It is useful for monitoring data of potential safety findings, on a weekly or monthly basis 
permitting early AE detection54,55,56] and is broadly used in vaccine safety surveillance. The 
key being that the p-values of the continual/sequential analyses, are adjusted for the multiple 
testing[57,58].    
 
Table II details the advantages and disadvantages of the various types of quantitative signal 
detection methods described in the previous section. 
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Table II. Summary of advantages and disadvantages of the various quantitative signal detection methods 
Denominator-independent Methods 
Measure of 
association
/ Method 
Advantages Disadvantages 
ROR [60,61] *Covariable adjustments possible through logistic 
regression analysis 
*In logistic regression analysis, interaction terms can 
be used for the analysis of drug-drug and drug-disease 
interactions 
*Calculation and interpretation are straightforward 
(value>1 implies increased risk) 
*Odds ratio cannot be calculated if the denominator is zero 
(i.e. either b or c = 0 in the two-by-two table) 
*Results not always reliable with small numbers in two-by-
two table (see Table I) 
PRR [61,62] *Can still be calculated when c of the two-by-two table 
(see Table I) is zero 
*Represents a direct measure of the strength of the 
signal 
*Use of proportionate approach avoids potential biases 
related to underreporting if the overall level of reporting 
is high for a new drug 
*Can handle concomitant medication use by 
conducting subgroup analysis  
*Calculation and interpretation is straightforward 
(value>1 implies increased risk) 
*Easily implemented in standard software packages  
* Can handle covariate adjustment through 
stratification. 
*Standard error cannot always be calculated 
*Cannot be calculated when a=0 in the two-by-two table (see 
Table I) 
*Statistical properties (e.g. sensitivity, specificity) of the 
standard signalling thresholds may vary when the methods 
are applied to different datasets. 
*A large association between an AE and a drug that is not of 
specific interest can reduce the likelihood of detecting a true 
signal  
* Cannot be calculated if there are no AEs of interest reported 
for the comparison drug(s) (i.e., if b=0 in two-by-two table 
(see Table I)). 
*Because it is a ratio of two proportions, its value is unstable 
with small sample sizes. E.g. when the AE of interest is rare, 
the PRR can easily miss detecting a signal when there is only 
one AE following the drug of interest 
IC [61,62] *Widely applicable to all data types (i.e. frequent or 
rare AEs) 
*Difficult interpretation for those who are not familiar with 
Bayesian statistics 
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*Large and complex numbers of calculations can be 
made efficiently 
*Can be used for pattern recognition in higher 
dimensions by arranging various drug–AE 
combinations in a single dimension for comparison) 
* Shown to be robust in handling incomplete data such 
as missing treatment indication, medical history and 
concomitant medications 
BCPNN 
[44,51,62,] 
*Use of proportionate approach avoids potential biases 
related to variable underreporting.  
*Can handle concomitant medication use by 
conducting subgroup analysis  
*Use of the Bayesian framework provides for 
“estimate shrinkage” when the number of drug-AE 
reports is small, which can reduce the occurrence of 
false positive associations based on small sample 
variability. 
*Allows for the efficient application of large numbers 
of calculations as well as the application of logistic 
regression analysis to adjust for confounding and 
interaction factors 
* Statistical properties (e. g. sensitivity, specificity) of the 
standard signalling thresholds may vary when the methods 
are applied to different datasets. 
* A large association between an AE and a drug that is not of 
specific interest (i.e. for large values of 'b' in the two-by-two 
table (see Table I)) can reduce the likelihood of detecting a 
true signal between that AE and the drug of interest. 
MGPS 
[50,61,62] 
*Use of proportionate approach avoids potential biases 
related to variable reporting) and underreporting.  
*Can easily handle concomitant medication use by 
conducting subgroup analysis  
*Use of the Bayesian framework provides for estimate 
'shrinkage' when the number of drug-AE reports is 
small, which can reduce the occurrence of false 
positive associations based on small sample 
variability. 
* Uses Empirical Bayes methodology that is good at 
*Statistical properties (e.g. sensitivity, specificity) of the 
standard signalling thresholds may vary when the methods 
are applied to different datasets. 
 
*A large association between an AE and a drug that is not of 
specific interest (i.e. for large values of 'b' in the two-by-two 
table (see Table I)) can reduce the likelihood of detecting a 
true signal between that AE and the drug of interest. 
*Elimination of confounders and limitations cannot be 
undertaken by any mathematical model 
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minimizing the effect of sampling variance on the 
interpretation of the relative reporting rate. 
* Can handle covariate adjustment through 
stratification. 
Denominator-based methods 
Poisson 
method 
[44,61] 
*Correction for different covariates can be easily 
established using poisson regression  
*No measure of association is provided; only p-value to 
assess disproportionality 
*Only useful when studying rare events (i.e. assumption of 
the Poisson distribution) 
Classical 
SPRT[54,57] 
*Test statistic p-values are adjusted for the continual 
analyses of the data (i.e. multiple testing). 
*Allows for earliest possible analysis of AE signals.  
*Requires a specific “a priori” specification of the level or 
magnitude of the increased risk 
*Test statistic can be difficult to interpret 
*Confounder adjustment in the literature is limited to method 
of stratification 
MaxSPRT 
[57,63] 
*Works well across various RR ranges due to its use of 
a composite alternative hypothesis of relative risk (RR) 
>1 rather than a single alternative hypothesis. 
* Sensitive to uncertainties in estimated expected number of 
events 
*Test statistic can be difficult to interpret 
* Confounder adjustment in the literature is limited to method 
of stratification 
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3.1.3 Data sources for quantitative signal detection 
3.1.3.1 Pharmacovigilance databases:  
Spontaneous reporting (SR) databases created by regulatory authorities contain AE reports 
submitted by: pharmaceutical companies; health care professionals; and consumers. The most 
common regulatory SR databases include the Adverse Event Reporting System (AERS) being 
used by the US FDA, the United Kingdom’s Yellow Card Scheme of the MHRA(Medicines 
and Health Care products Regulatory Agency), and the French national database of 
AFSSApS. In Canada, Health Canada maintains the Canada Vigilance database which is 
reviewed manually by clinical experts. In addition, in the EU (European Union), there is an 
ongoing initiative to create a central database for all member states, i.e. EudraVigilance [64] 
Although beneficial, these databases also have some disadvantages: i) since they include 
mainly spontaneous reports, they are subject to under-reporting, even in countries such as 
France with mandatory AE reporting. Under-reporting rates can vary between 36% and 99% 
[65,66]; ii) The quality, completeness and accuracy of reports can vary considerably; iii) There 
is difficulty in controlling for biases, such as indication or overall health status, to allow for 
adequate comparability of AEs across drugs[67]; and iv) They contain only ADRs creating a 
lack of accurate denominator (exposure) information and difficulty with the estimation of 
drug use. Furthermore, the coding of the ADRs may vary depending on the region of the 
database. Prior to 1997, the US FDA used the Coding Symbols for Thesaurus of Adverse 
Reaction Terms (COSTART)[49]; while the majority of the rest of the world, including the 
national French database, previously used the World Health Organization’s Adverse Reaction 
Terminology (WHO-ART) [68,69].   .  
The majority of databases now use the international coding system initiative of the 
International Conference on Harmonization (ICH): the Medical Dictionary for Regulatory 
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Activities (MedDRA) the first version of which was released in 1995, and is currently at 
version level 14.1. However many databases possess coding from previous dictionaries for 
older reports (as with FDA AERS pre-1997 events), and yet other databases may be delayed 
in updating their coding dictionary to MedDRA [69,70]. The WHO adverse reaction database 
known as Vigibase continues to use the WHO-ART coding system [71].  
Pharmaceutical companies also maintain safety databases.  These are very similar to the 
regulatory databases except that they: (i) accumulate reports globally and (ii) are smaller and 
less diverse, as the reports are limited to company products. In some instances they may be 
too small, or the comprising products too heterogeneous, for meaningful analyses [28]. Table 
III details some SR databases and quantitative signal detection methods that have been 
applied to them.  
Although it is mandated by Health Canada, most pharmaceutical companies input data in a 
company global database usually managed by the company head office (in either the United 
States or Europe), where data mining may be conducted. Health Canada does not conduct data 
mining directly in its Canada Vigilance database but rather incorporates Canadian cases in the 
global WHO adverse reaction database known as Vigibase. The WHO Vigibase is maintained 
by the Uppsala Monitoring Centre (UMC) in Sweden which, on a quarterly basis, applies a 
data mining method in order to identify potential safety signals [51]. There is only one record 
of a data mining study performed by Gavali et al[73] within the Health Canada database where 
although the signal detection test statistic values were high, a statistically significant signal 
was not obtained, possibly due to the small size of the database. The study authors 
recommended trying the signal detection processes again in larger databases[73] . 
 
26 
 
Table III. Data mining studies using spontaneous reporting databases published in the literature  
Authors Year  Country Database 
type 
Database name Method type Method 
name 
Bate et al. 
[74]    
1998 Sweden / 
Global 
Regulatory 
SR 
WHO Vigibase Denominator 
-independent 
BCPNN 
Lindquist et 
al. [51]    
2000 Sweden / 
Global 
Regulatory 
SR 
WHO Vigibase Denominator 
-independent 
BCPNN 
Evans et al. 
[75]    
2001  Regulatory 
SR 
UK Yellow Card 
System/ 
Adverse Drug 
Reactions Online 
Information 
Tracking 
(ADROIT) 
Denominator 
-independent 
PRR 
Egberts et 
al [76].    
2002 Netherlands Regulatory 
SR 
Netherlands 
Pharmacovigilance 
Foundation data 
base 
Denominator 
-independent 
ROR 
Szarfman et 
al. [49]    
2002 USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
GPS & 
MGPS 
van 
Puijenbroek 
[61]    
2002  Netherlands Regulatory 
SR 
Netherlands PV 
Foundation Lareb 
Denominator 
-independent 
IC/ ROR / 
PRR 
Poisson/ 
Chi 
squared 
van 
Puijenbroek 
[77].    
2003  Netherlands Regulatory 
SR 
Netherlands PV 
Foundation Lareb 
Denominator 
-independent 
ROR 
Hauben  [78].  2004  USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
MGPS 
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Authors Year  Country Database 
type 
Database name Method type Method 
name 
Hauben  [79].  2004  USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
 
Schnell et 
al [80].    
2005 USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
PRR 
Roux et al 
[81]    
2005 France Regulatory 
SR 
AFSSAPS database Denominator
-independent 
PRR 
Thiessard et 
al [82].    
2005 France Regulatory 
SR 
AFSSAPS database Denominator
-independent 
PRR, ROR, 
SPRT, 
Yule’s Q, 
Poisson 
method, 
IC, EBAM 
Conforti et 
al [83].    
2006 Italy Regulatory 
SR 
Italian Interregional 
Group of 
Pharmacovigilance 
(GIF) Database 
Denominator 
-independent 
PRR 
Hochberg 
[84]    
2007  USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
A single 
data 
mining 
algorithm 
Shalviri et 
al [85].    
2007 Iran Regulatory 
SR 
Iranian Pharmaco-
vigilance Database 
Denominator 
-independent 
ROR/ IC/ 
PRR 
Lehman et 
al [42].    
2007 USA Company SR Merck Post 
marketing safety 
database 
Denominator 
-independent 
Empirical 
Bayes 
method 
Hammond 
et al [86]    
2007 UK Company SR GSK Spontaneous 
reporting database 
Denominator 
-independent 
MGPS 
Salvo et al 
[87]    
2008 USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
Case/ non-
case (ROR)
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Authors Year  Country Database 
type 
Database name Method type Method 
name 
Li et al [88]    2008 China Regulatory 
SR 
Guangdong ADR 
SRS 
Denominator 
-independent 
ROR / 
PRR/ IC 
Chen et al 
[89]    
2008  USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
ROR / 
PRR/ IC/ 
GPS 
Chen et al 
[90]    
2008  USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
ROR / 
PRR/ IC/ 
GPS 
Li et al [91]    2009 China Regulatory 
SR 
Guangdong ADR 
SRS 
Denominator 
-independent 
IC 
Poluzzi et 
al. [92]    
2009 USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
Case / non-
case (ROR)
Ahmed et al 
[93]    
2009 France Regulatory 
SR 
French PV DB Denominator 
-independent 
GPS / 
BCPNN 
Gavali et al 
[73]    
2009 Canada Regulatory 
SR 
Canadian Adverse 
Drug Reaction 
Monitoring 
Program DB 
Denominator 
-independent 
PRR 
Hochberg 
et al [94]    
2009 USA Regulatory 
SR 
FDA AERS Denominator 
-independent 
GPS / PRR 
Alvarez et 
al [95]    
2010 Europe Regulatory 
SR 
EudraVigilance Denominator 
-independent 
PRR 
Chen et al 
[95]    
2010 China Regulatory 
SR 
Jiangsu province 
SR DB 
Denominator 
-independent 
PRR / ROR 
/ PNN 
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3.1.3.2 Prescription Event Monitoring (PEM)  
PEM has been developed in the United Kingdom (UK) to monitor certain newly-marketed 
drugs and can be considered a hybrid of both spontaneous AE reporting; and administrative 
claims databases. It consists of a national observational cohort of first users of a drug 
immediately after its launch into real-world clinical setting, and a cohort of patients who 
receive a comparator drug[[97,98]. In the UK, health care is universal, with the majority of 
the population registered with a general practitioner (GP) who provides primary health care 
and writes prescriptions. The patient takes the prescription to a pharmacist who dispenses 
the medication and then sends a claim to a central Prescription Pricing Authority 
responsible for reimbursement of the pharmacist. The PEM system is handled by the Drug 
Safety Research Unit (DSRU) who is provided with electronic copies of all prescriptions 
issued throughout the UK for the drugs being monitored by PEM. After a period of three to 
12 months (usually 6 months) from the first prescription for each patient, the DSRU sends a 
questionnaire to the prescribing physician requesting information on events which occurred 
since the drug was first prescribed, regardless of event causality. All data are computerised 
in the DSRU and important events are investigated by the DSRU personnel who, provided 
they have GP permission, possess the patient’s life-time medical records, death certificate 
etc. For each of these patients the DSRU prepares a longitudinal record comprising all 
prescriptions for the monitored drug [98]. PEM has a numerator (the number of reports), a 
denominator (the person-time units of exposure), and a known time period (i.e. the 
difference between the start and stop dates of the drug for each patient)[98]   .  
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The two quantitative methods that have been applied to PEM for signal generation are PRR 
and the incident rate ratio (IRR): a disproportionality measurement that compares the 
incident density of a particular event in a drug cohort with the incident density for that same 
event in a comparator group of other drug cohorts for which PEM studies have been 
conducted [99]   .  
With Incidence Density (ID) for a given time period, t for each event term in the DSRU 
dictionary, ID is calculated as follows:  
IDt = (Number of events during treatment period for t  / Number of patient-months of 
treatment for period)   X 1000 [98]    
 The limitations of PEM are that it relies on the voluntary participation of general 
practitioners (GPs), and cohorts are relatively small in size (usually about 10, 000 users of 
the drug of interest) (restricted ability to study rare AEs). As with most databases, there is 
no method of measuring compliance or the use of non-prescription medication [98,99]   . 
Table IV below details some PEM studies. 
 
Table IV - Quantitative signal detection studies performed through prescription-event 
monitoring found in the literature 
Authors Year Country Method Type Method Name 
Heeley et al [99]   2002 UK Denominator-
independent  
PRR & IRR 
Layton et al 
[100]   .  
2006 UK N/A IRR 
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3.1.3.3 Health claims databases 
Administrative health claims databases have been created in the context of a drug and 
medical services reimbursement program. They include longitudinal medical records 
including information on: all prescribed medications dispensed to the members, and 
covered by the drug program; all physician-patient encounters and diagnoses; and in some 
instances, hospital admissions and laboratory results[33,34,38]. This results in an accumulation 
of longitudinal data on drug exposures and AEs on very large segments of the population.  
 
Medical services database:  In order to be reimbursed by the medical program, physicians 
submit reports on medical services provided (which may include, inpatient, outpatient, 
ambulatory, emergency and sometimes hospital services), as well as the diagnoses code, to 
the insurance provider for reimbursement. All services billed on a fee-for-services are 
recorded. Among the data elements included in this database are:  the code of the diagnosis 
(most databases use the International Classification of Diseases (ICD) coding system 
versions 9 or 10), medical act rendered, the date, the location of the service, and, patient 
health insurance number [33,34].  
 
Prescription database: Prescription drug databases record outpatient prescription drugs 
dispensed to the members of the health plan.  The information recorded consists of: the 
generic name of drug, national drug code for dispensing, dispensing date, dosage, days 
supplied, route of administration and patient health insurance number [33,34,102].  
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Beneficiary database: This database contains information concerning demographic 
characteristics of the patient such as age/ date of birth, gender, region of residence 
(metropolitan, urban, rural), date range of membership in the insurance program, and 
patient health insurance number [33]   . 
Usually the medical services and prescription drug databases may be linked through a 
unique patient identifier/ patient health insurance number that remains unchanged over time 
and is scrambled by the insurance provider  Linkage provides an accumulation of health 
care data on entire populations on a long term [34]   .   
 
Administrative health claims databases are available in Canada and have been used mainly 
for pharmacoepidemiologic studies [33]   . Examples of these databases are those based on 
the universal healthcare established per province such as the Ontario Drug Benefits 
database, the Saskatchewan Health Services Databases, and the Régie de l’assurance 
maladie Québec” (RAMQ) database. In the US, there are Health Maintenance Organization 
(HMO) databases such as the private insurance companies of Kaiser Permanente, or the 
Medicaid program  databases from the public health program (Medicare) consisting mostly 
of the elderly, or individuals on social assistance [103]. While observational studies are 
hypothesis-driven, signal detection is hypothesis-generating.  The HMO databases have 
been used for quantitative signal detection but so far, no attempt has been made in 
Canadian databases[31,63]. Table V below also details some administrative claims databases 
that have been used in published quantitative signal detection studies. Advantages of claims 
databases, as a data source to conduct safety surveillance are the following: i) Potential to 
perform active or passive, and real-time surveillance; ii) Allowance for longitudinal 
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monitoring of large patient cohorts; iii) Potential to identify AEs with long latency; iv) 
Provision of both numerator and denominator information on the populations allowing for 
the estimation of drug use and disease incidence, as well as the evaluation of temporal 
relationships between the drug and AE[28].;  v) Existence of a variety of patient-level 
information on covariables, allowing for the potential verification of signals through 
executing pharmacoepidemiologic studies. 
With these databases, duplicate records can be easily identified and excluded by examining 
person or type-specific AE information, eliminating follow-up diagnoses codes, or 
accepting only the initial event diagnosis per patient identifier. Because the databases do 
not rely only on the reporting of AEs, they could provide information on real-world AE 
experiences, and have the potential to detect unrecognized or underappreciated AE signals 
as compared to SR databases [38,104,105]   . 
The limitations of using health claims databases include the potential for restricted 
generalisability as the population may be limited depending on the members of the 
insurance plan. E.g. private health insurance plans may exclude individuals of low socio-
economic status. The RAMQ prescription plan covers primarily the elderly population. 
Furthermore, the follow-up of patients may be restricted as some patients may switch 
insurers every few years [103]   .  
The reliability of the ICD-9 or ICD-10 diagnostic codes reported by the HCPs may be 
problematic since validation is not required for reimbursement.  However, the reliability 
may be improved using other data elements such as medical procedure or drug prescription 
as proxy for the presence of a disease.   
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Only those medications that are reimbursable by the particular health insurance plan would 
be available in the database for analysis. This would generally exclude over-the-counter 
medications, as well as some very new drugs that have not yet been reviewed and approved 
by the insurers. 
 
Table V – Quantitative signal detection studies performed in administrative claims 
databases found in the literature 
Authors Year Country Database used Method type Method 
name 
Brown et al 
[63]    
2007 USA 9 different HMOs Denominator-
based 
MaxSPRT 
Choi et al 
[30].  
2010 Korea National Health 
Insurance Claims 
Denominator-
based 
RR  
Trifiro et al 
[32].  
 
2011 Denmark, 
Italy, 
Netherlan
ds, and 
United 
Kingdom 
EU-ADR database 
(8 databases from 
Denmark, Italy, 
Netherlands, and 
United Kingdom   
 Various. 
GPS and 
others  
 
3.1.4   Data elements required for quantitative signal detection using 
administrative claims databases  
The data elements found in administrative claims databases that are needed to conduct 
quantitative signal detection are the following: i) a suspected drug (medication dispensed); 
ii) a suspected AE (using the diagnostic code in medical billings or in hospitalization 
databases) and; iii) an identifiable patient (scrambled identifier). Dispensing date and date 
of AE occurrence confirm that the exposure precedes an event.  As shown in Table IV, 
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most of the studies published in the literature used diagnoses on medical claims, and not 
hospitalization, as the data source for AEs.  For some AEs, especially those that are 
chronic, this timeline may be subject to errors given that there may be a delay between the 
date of onset of symptoms of the AE and the date of diagnosis.  
 
3.1.5 Performance of data mining algorithms for drug safety signal 
detection 
Prior studies published in the literature indicate that the main means of assessing 
performance of data mining algorithms are through: i) Ability to generate a signal in cases 
of a known drug-AE pair (true-positive; sensitivity), ii) Comparing the time to detection of 
the potential signal between traditional signal detection and quantitative signal detection 
method [49,74,75]; iii) Statistically significant measures of association in the absence of a true 
signal (false-positive; specificity). 
 
Results of studies published in the literature on the performance of data mining algorithms 
are described below. 
A study by Szarfman et al [49] was conducted using the FDA’s safety database, AERS. The 
GPS method was used to examine differences in year of detection of 30 known drug-AE 
signals. Data mining identified 30 signals as positive, 20 signals were identified using the 
data collected 1 to 5 years before the signals had been detected by standard methods, nine 
the same year and one signal 1-year after. GPS was also used to explore the differences in 
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time of detection of 160 drug-AE signals between 1985 and 1996 that had previously been 
identified in the Center for Drug Evaluation and Research CDER Monitoring Adverse 
Reports Tracking System. , Using the method and the data collected, 97 positive data 
mining signals were detected, 1 to 4 years before they were historically identified as 
signals. 36 the same year, and 27 of them 1 to 3 years later. This study demonstrated that a 
retrospective data mining of this database using the GPS and MGPS (GPS results compared 
to previous MGPS study) methodologies identified AEs many years earlier than qualitative 
signal detection through case reports alone[49].   
 
Through the PRR methodology, the UK Yellow Card Database as a data source for signal 
detection was shown to be a valuable aid to signal generation. In Evans et al [75]   , 15 newly 
marketed drugs were analysed. They first examined whether the method would identify 
known hazards, before looking at possible AEs which had not yet been recognized. Using 
this methodology, 481 signals were observed that met inclusion criteria (i.e. a PRR >=2, a 
chi2 value >=4, and the existence of three or more cases of the drug-AE pair being studied), 
70% of these were found to be AEs already identified, 13% were believed to be related to 
the underlying disease, and 17% required further investigation. Approximately five 
unrecognized signals per drug were identified using the method [75].  
 
The Netherlands Pharmacovigilance Foundation has used the data mining methodology of 
ROR to identify three drug-AE pairs i) antidepressant drugs and non-puerpural lactation; ii) 
non-steroidal anti-inflammatory drugs with diuretics, and onset or worsening of congestive 
heart failure; and iii) terbinafine- with occurrence of  arthralgia, fever and urticaria [76].   
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The analysis of association between antidepressant drugs and the occurrence of non-
puerpural lactation. demonstrated that 38 cases of non-puerperal lactation were reported, of 
which 15 were associated with the use of antidepressant drugs. Antidepressants overall 
were associated with a higher risk of non-puerperal lactation as compared to other drugs 
(ROR 8.3; 95% CI 4.3 to 16.1). Serotonergic antidepressants were associated with a higher 
risk (ROR 12.7; 95% CI 6.4 to 25.4), while other antidepressants were not (ROR 1.6; 95% 
CI: 0.2 to 11.6) compared with the group of all other drugs. 
The onset or worsening of congestive heart failure (CHF) associated with the combined use 
of non-steroidal anti-inflammatory drugs (NSAIDS) and diuretics was also tested as an 
example of a drug-drug interaction.  The analysis showed that the use of diuretics or 
NSAIDs itself was not statistically significantly associated with an increased risk for onset 
or worsening of symptoms of CHF. However, the odds ratio of the statistical interaction 
term NSAIDs-diuretics, was statistically significantly elevated (adjusted ROR 2.0; 95% CI 
1.1 to 3.7) 
To study a possible relationship between fever, urticaria and arthralgia, ROR were 
calculated, which were adjusted for age and gender of the patients, source of the reports and 
year of reporting. Both urticaria (adjusted ROR 1.72; 95% CI 1.35 to 2.18) and arthralgia 
(adjusted ROR 3.14; 95% CI 1.52 to 6.47) were significantly associated with reports on 
terbinafine. The strongest predictor covariates of the dependent variable were urticaria 
(adjusted ROR 1.66; 95% CI 1.29 to 2.14) along with the interaction terms arthralgia and 
fever (adjusted ROR 2.35; 95% CI 1.32 to 4.17) and arthralgia-urticaria (adjusted ROR 
3.33; 95% CI 1.03 to 10.73). These results imply an association between the use of the 
antifungal agent terbinafine and the co-occurrence of arthralgia, fever and urticaria [76]. 
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Bate et al. used the WHO UMC database and the BCPNN methodology to create signal 
detection method to provide initial assessment, selection, and act as a quantitative aid to 
signal detection of drug-AE combinations, consequently allowing for the consistent 
detection of new AEs [47,51]. In this study they conducted initial testing of the data mining 
approach examining whether the test statistics were positive for drug-ADR combinations 
already known to exist and that it was non-significant for drug-ADR combinations known 
not to exist [74]. Tests to determine whether earlier signals would have been found with the 
new method were then conducted both against general reference sources (Physicians’ Desk 
Reference and Martindale) and existing literature reports in another sensitive international 
signalling system database of the publication Reactions Weekly)[74].  The study displayed 
the power of the method at finding signals early (captopril-coughing) and to avoid false 
positives signals with the occurrence of common drugs and ADRs in the database (digoxin-
acne; digoxin-rash). An application of the BCPNN on quarterly data showed that out of 
1,004 AEs identified, 12 were found to be new AEs not already recorded within regulatory 
documents [74]  
 
Many studies have also been published with the French national database, mainly using the 
PRR method. Roux et al [81] applied the PRR to the French national pharmacovigilance 
database, AFSSAPS in order to statistically identify potential signals of previously 
unknown drug-AE associations, using criteria of a PRR >=2, a chi2 value >=4, and the 
existence of three or more cases. Statistically significant drug-AE associations were 
verified against the Vidal (French drug reference) dictionary. Associations not previously 
listed in the dictionary were considered as potential signals. Application of the data mining 
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algorithm produced 523 drug-AE associations of which 107 were not listed within the 
Vidal dictionary, and considered potential signals. Most potential signals were false 
positives. The process helped focus case review on a very small subset (9.6%) of the 
dataset [81]. 
 
Thiessard et al [82] compared the methods of PRR, ROR, SPRT, Yule’s Q, the Poisson 
method, IC, and EBAM (empirical bayes arithmetic mean) within the AFSSAPS database. 
The resulting number of signals generated varied with each of the methods used, however 
was high for each. Using SPRT, 6.3% of all drug-AE pairs in the database, were considered 
as signals 9.1% were considered signals with the EBAM method. The remaining methods 
generated signals for between 18.7% and 33.6% of drug-AE pairs within the database. A 
comparison of ranked percentiles showed quasi-equivalence between the methods of PRR, 
ROR and Yule’s Q. The PRR was found to be more effective with small sample sizes as 
compared to the EBAM, the Poisson method and the SPRT : the PRR generated significant 
signals for pairs that were reported just once or twice within the database, which were not 
identified with the other methods. However, the IC, and Yule’s Q were less sensitive to 
small numbers than the PRR[82].  
 
Performance of quantitative signal detection methods was also assessed in administrative 
claims databases.  In a study conducted by Brown et al[63]., nine different administrative 
databases of the HMO Research Network’s Center for Education and Research on 
Therapeutics (CERT) and the MaxSPRT methodology were used. It was shown that four 
out of five of the known drug-AE pairs studied, did indeed produce a signal using the 
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methodology, which is indicative of a favourable sensitivity [63]. No signal of excess risk 
was identified for the two negative control pairs, implying that the specificity of the method 
was also adequate. 
 
Choi et al[30] used a Korean national health insurance claims database and a RR-based 
methodology for signal detection of rosuvastatin AEs. Any serious adverse event (SAE) for 
which the lower limit of the RR’s 95% confidence interval was greater than 1, was defined 
as a signal. All detected signals were reviewed to determine whether the signals 
corresponded with published AEs exclusive to rosuvastatin. Among 96 236 elderly 
outpatients who received rosuvastatin, or other statins, 376 different SAEs were observed, 
and 40 304 drug-SAE pairs were observed. Twenty-five (6.6%) drug-SAE pairs were 
detected as signals [30].  
Sensitivity within the Szarfman et al[49] study, was estimated by counting current labelled 
events or current warnings and contraindications signalled by any mapped AE code: 
number of detected AEs/(number of detected AEs + number of  undetected AEs). 
Specificity was estimated by counting individual AE codes that did not map to a labelled 
event i.e. number of true negative/ (number of true negative + false positive). The study 
showed a high degree of specificity for all thresholds used since the first signals were 
detected by MGPS. The sensitivity for warnings and contraindications was higher than the 
one observed for the analysis across all labelled events. Lowering the thresholds for 
important event codes or detecting higher order synergic associations between drugs and 
multiple events increased sensitivity[49]. 
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Hochberg et al[84]  in a study comparing GPS, PRR, and  a urn model, analysed sensitivity 
and specificity, by establishing and using rules for assigning each drug-AE combination to 
an approximate “level of evidence”  to describe the strength of evidence for causality 
contained in the corresponding information source. The GPS method had the highest 
specificity in that it had the highest rate of matching against the reference event database 
for drug-event associations with at least minimal external supporting evidence. However, 
GPS also detected the smallest number of signals and did not uniquely highlight any 
unlabelled supported signals. The PRR method detected the highest number of unlabelled 
supported and unique unlabelled supported signals followed by the urn model[84].  
 
Choi et al[30] calculated the PPV of their method by dividing the total number of the signals 
known to be published as AEs, by the total number of detected signals. Of 25 signals 
detected by the RR-based data-mining approach, eight corresponded with published 
rosuvastatin-specific AEs, with a PPV of 32%. When detected signals were compared to 
other statin-specific or shared list of AEs from the reference literature, 18 signals 
corresponded. The PPV was estimated to be 80%. 
 
In the Brown et al study[63], sensitivity and specificity were relatively simple concepts in 
that detecting a signal where a known safety risk occurred (4 out of 5 cases) was deemed a 
“good sensitivity”, and not detecting a signal in instances where a safety risk was known 
not to exist (2 out of 2 case studies), was implied to indicate a “good specificity”. 
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Data mining and signal detection are hypothesis-generating activities in that any potential 
signal generated would need to be further analysed, investigated and verified in order to 
confirm that a signal does indeed exist. The main limitation of data mining is the generation 
of a large number of false-positive signals, each requiring further analyses. As such, many 
jurisdictions and companies do not invest the resources in conducting data mining, as 
investigating each signal could be quite inefficient [5].  
 
In conclusion, this literature review shows us that qualitative signal detection through 
spontaneously reported case studies, and clinical trials, has become inadequate at 
identifying signals on its own. New methods to quickly identify safety risks are an 
important necessity in order to protect patients from unwanted AEs.  
From Tables III and IV, and the study descriptions above, it is observed that most data 
mining studies have been conducted in SR databases, using denominator–independent 
methodology. Few studies have been applied to administrative claims databases using 
denominator-based methods, even fewer have attempted to apply a sequential monitoring 
approach to quickly identify safety risks after product launch, and none such studies have 
been conducted using a Canadian health care claims database. In addition, there are 
important gaps in the data mining and signal detection processes that should be addressed 
such as further exploring the potential of sequential monitoring / early signal detection, and 
investigating additional means to control for confounding.  
Provincial health care claims databases are widely available in Canada and may be a useful 
tool for the application of denominator-based data mining algorithms to support signal 
detection in pharmacovigilance. 
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Chapter 4. Quantitative signal detection using the 
Quebec administrative health care claims databases 
4.1 Rationale 
Quantitative signal detection is currently not performed in the national spontaneous 
reporting database of Canada (Canada Vigilance) due in part, to small sample size and 
insufficient resources to substantiate all signals that are detected. Provincial health care 
claims databases are widely available in Canada.  In Quebec, the claims databases include 
the prescription drug database as well as the medical services database, both being 
administered by the Régie de l'assurance maladie du Québec (RAMQ).  The prescription 
drug database includes all prescribed medications that are covered by the public program 
and that are dispensed to drug plan members. The medical services database includes 
billings by physicians on a fee-for-service, whether the service is rendered in an outpatient, 
inpatient, or emergency room setting.  Both databases are populated on a real-time basis, 
i.e. the information is entered and transmitted either at the time of the service (pharmacy 
dispensation) or soon after (physician billings).  A hospitalization database, Med-Echo, is 
also available in Quebec which records information on hospital discharges from the great 
majority of hospitals.  Although it provides accurate information on diagnoses, its 
usefulness for signal detection is questionable given that it is populated only once per year. 
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Data elements found in the prescription database and the medical services database provide 
information on drug exposure and occurrence of adverse events. Linkage between the two 
databases is conducted through the patient's health insurance number, which remains 
unchanged over time.  Such linkage allows for the accumulation of longitudinal population 
data on drug exposure and occurrence of adverse events on a very long term.  
 
Since the great majority of elderly residents of Quebec are covered by the public drug 
program, the resulting database is very comprehensive and provides optimum 
generalizability.  In addition, from a therapeutic risk management perspective, the elderly 
population has been identified as a high-risk population by regulatory authorities, and as 
such, involve a dedicated section in risk management plans of drug products [10].Their 
increased susceptibility for medication-induced adverse events,  morbidity, and mortality 
may be due to several factors such as metabolic changes, comorbidity, concomitant drug 
usage, and consequently an increased potential for drug-drug interactions[106]. Although the 
ICH specifies requirements for clinical trials in instances where a product is expected to be 
used by the elderly [107], there is still an important evidence gap at the time of product 
approval for drugs not intended for use in the elderly, and those that may be used off-label 
in this group, given that the elderly are rarely included in randomized controlled trials that 
are conducted prior to approval of such products. They are therefore considered, in many 
instances, as subjects of safety surveillance activities in the post-approval setting. The 
prospect of using a data source, such as the claims databases of the “Régie de l’assurance 
maladie Québec” (RAMQ), which contains approximately 97% of the province’s elderly 
population, is likely enviable of the fields of data mining, PMS, and pharmacovigilance 
46 
 
overall [108].A tool focusing on the geriatric patient population shall prove highly relevant to 
support the detection of safety signals in a real life setting. 
Studies found in the literature have shown that claims databases may be a useful tool to 
support safety signal detection[30,63].  Analytical tools vary, however, with respect to their 
applicability.  Some of the tools have been developed specifically for the surveillance of 
previously identified risks[63], i.e. in the setting of an active surveillance program, and as 
such require the exclusion of patients who have experienced the adverse event of interest in 
the recent past.  Others[30,64] do not require such exclusions given that they have been 
developed for passive surveillance purposes, i.e. with the objective of uncovering 
previously unknown adverse effects.  To our knowledge, the usefulness of claims database 
to support safety signal detection in the context of a passive or active surveillance program 
has never been compared. 
Furthermore, published studies have used a limited number of covariates in their model, 
consisting mainly of age and sex.  Conversely, in the field of pharmacoepidemiology, there 
has been a dramatic methodological development over the past decade, with advanced 
methods for summarizing and adjusting for confounders measured or unmeasured in claims 
databases.  Applying any of these methods to control confounding in a signal detection 
study would represent significant progress in this area of research.   
Over the past two decades, the Quebec administrative claims databases have been used 
extensively to conduct drug utilization and risk evaluation studies, i.e. hypothesis-testing 
studies.  To our knowledge, they have not yet been used to support safety signal detection, 
i.e. hypothesis-generating studies. 
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4.2 Research hypothesis 
Existing data mining algorithms would be applicable to the Quebec administrative claims 
databases and would be successful at detecting drug safety signals. 
4.3 Study objectives 
4.3.1 Main objective 
To apply and validate a data mining algorithm for signal detection using the Quebec 
prescription and medical services databases. 
 
4.3.2 Specific objectives 
 
1)  To apply the MaxSPRT data mining algorithm to support signal detection, within the 
Quebec claims database;  
2) To assess the tool performance through measures of sensitivity and specificity;  
3) To determine whether adjusting for patient overall health status improves the 
performance of the tool 
4) To offer methodological improvements over existing data mining models that have been 
published in the literature  
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4.4 Methods 
4.4.1 Study design 
A retrospective cohort study was conducted in a random sample of 87,360 community-
dwelling elderly members (age 66+) of the Quebec public drug program identified from 1st 
January 2000 to 31st December 2009. The Poisson-based Maximised Sequential 
Probability Ratio Test (MaxSPRT) was used as the data mining algorithm. Four known 
drug-AE pairs, for which there was a safety warning issued by Health Canada during the 
study period, and two drug-AE pairs not known to be associated ("negative controls") were 
used. Covariates included: age group (66-69; 70-74, 75-79, 80-84, 85+),gender 
(dichotomous), Chronic Disease Score (CDS) (grouped into: 0;  0-5; 5 - 10, 10).  
The analytical method is an adaptation of the method developed by Brown et al[63] with the 
following methodological improvements: i) the consideration of the depletion of 
susceptibles effect; ii) further adjustment for confounding by overall health status, through 
the von Korff Chronic Disease Score, based on prescription drug use.  Furthermore, the 
applicability of the method for active or passive surveillance was determined, respectively, 
by excluding and including patients with a history of the adverse event.  Each of these 
methodological aspects is described in greater details in the sections below. 
4.4.2 Selection of drug-adverse event pairs 
The following criteria were used to select four known drug-AE combinations: 
i) Involve drugs used commonly in the elderly population 
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ii) Approved by Health Canada and included in the list of reimbursed medications of 
Quebec within the study period cohort (January 1, 2000 - December 31, 2009).  
iii) Subject of Health Canada Warnings that were published during the study period 
The criteria used to select a comparator drug for each study drug chosen was as follows:  
i) Also approved by Health Canada and included in the list of reimbursed medications 
of Quebec within the study period cohort  
 
ii) Also used commonly in the elderly population 
 
iii) Used for the same indication as the  study drug in order to control for indication bias 
iv) AE of interest was not listed in the comparator drug’s Product Monograph as a 
potential adverse reaction of the comparator drug 
The criteria used to select the negative-control drug-AE combinations were as follows:  
i) Also approved by Health Canada and included in the list of reimbursed medications 
of Quebec within the study period cohort  
 
ii) Also used commonly in the elderly population 
iii) AE of interest chosen was one that was a) relatively serious / medically significant, 
b) not listed on the product monograph of the study drug, c) Possessed relatively 
clear and concise ICD-9 codes and d)Occurred with relatively common frequency in 
non-users of the drug of interest (in order to optimize statistical power) 
The criteria used to choose comparator drugs of the negative-control pairs were:  
i) Involved drugs used commonly in the elderly population 
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ii) Approved by Health Canada and included in the list of reimbursed medications of 
Quebec within the study period cohort  
iii) AE of interest was not listed on the product monograph of the comparator drug 
Because no association was expected with these pairs, it was not necessary to choose a 
comparator drug used for the same indication as the study drug in the negative-control 
pairs. 
 
Table  VI – Drug-AE case studies used in data mining analysis 
Drug-AE pair Comparator 
Drug 
Date of Health 
Canada Warning 
(where applicable)
1. rosuvastatin- rhabdomyolysis 
 
Other statins: 
atorvastatin, 
fluvastatin, 
lovastatin, 
pravastatin, 
simvastatin 
June 2004 
2. rosiglitazone- Cardiac safety concerns  metformin  November 2007 
3. rosiglitazone – Increased fractures in female patients 
 
metformin  February 2007 
4. pioglitazone-Increased fractures in female patients metformin April 2007 
5. amitriptyline –increased fractures (negative-control) metoprolol N/A 
6. alendronate – acute hepatitis (negative-control) atenolol N/A 
 
4.4.3 Data sources 
The following RAMQ databases were used to conduct the study: i) the prescription 
database; ii) the medical services database; iii) the beneficiary database. 
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Prescription database: In Quebec, the public drug programs includes approximately 97% 
(circa 800,000) of elderly residents, all welfare recipients, as well as all residents and their 
dependents who are not covered by a private drug insurance (approximately 30% of 
residents aged 18-64). The database records information on all outpatient prescriptions 
included in the formulary of reimbursed medications: Drug name, dispensing date, dosage, 
prescribed duration, number of units dispensed, route of administration, deductible and co-
payment. Drug indication is not recorded.   Drugs acquired in-hospital, over-the-counter, or 
out-of-pocket, are not covered by the public drug program and hence, are not included in 
the RAMQ prescription database.  
 
Medical services database: Due to Canada’s universal health care system, medical 
services, including consultations, examinations, procedures, among others, are provided 
free of charge at the point of service to all residents of the province, regardless of age and 
income.   The resulting medical services database contains information that physicians 
submit to RAMQ for reimbursement of fee-for-service, whether rendered in an inpatient, 
outpatient, or emergency department setting.  Exceptions are services rendered by a 
minority of physicians who are on a salary basis. Among the information included in the 
database are: date and location of the medical service, nature of services (coded according 
to the Federation of General Practitioners of Quebec (FMOQ), the Federation of Specialist 
Physicians of Quebec (FMSQ), the Canadian Classification of Surgical Acts etc.), and 
diagnosis (coded according to ICD-9).  The latter, however, is not obligatory for 
reimbursement and when present, its reliability may be questionable [109]. 
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Beneficiary database: For each resident of the province, the beneficiary database contains 
information concerning patient demographics: age (for confidentiality reasons, recorded in 
5-year intervals), gender, residential region (recorded as CLSC (Centre local de services 
communautaire) region) and dates of membership in medical services and drug programs.  
Through the level of deductible and co-payment, one can derive gross measures income 
status. 
The RAMQ databases may be linked through the patient health insurance number, which is 
unique for each patient and remains unchanged over time.  The RAMQ databases are 
populated in near-real time, and hence theoretically would be available to conduct 
prospective drug safety surveillance. 
 
4.4.4 Populations 
4.4.4.1 Target population 
The target population consists of community-dwelling elderly residents (age 66 +) of 
Quebec.  A cut-off at age 66 was set since claims data are required for one year prior to 
their inclusion in the study, and the public drug program is comprehensive starting solely at 
age 65. 
 
4.4.4.2 Source population 
The source population consisted of a random sample of 87,389 elderly patients (age 66+) 
who were members of the RAMQ public drug plan between 1st January 2000 and 31st 
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December 2009.  Since it was a random sample, no specific event led to entry in the cohort.  
The date of entry was randomly chosen, for each individual, during the study period and the 
period of membership in the drug program.   For the investigation of signals related to 
alendronate, the study population was restricted to females only.  All members of the cohort 
were followed until the first of the following events: i) death, ii) institutionalization, iii) end 
of coverage in drug program; iv) end of study period (31 December 2009). 
 
4.4.4.3 Study population 
Five sub-cohorts of incident users of the exposure drugs described in section 4.4.2 above 
were assembled (i.e. rosuvastatin, rosiglitazone, pioglitazone, amitriptyline, alendronate). 
For each cohort, incident use was defined as absence of dispensing of the drug during the 
year prior to current treatment. The use of incident exposure aims at controlling for 
potential depletion of susceptibles effect, whereby long-term users of a drug are at lower 
risk of the AE than new users [110].This is consistent with the new-user design [111]. Section 
4.4.10 below “Control of biases” describes this phenomenon in further detail. 
The index date for the exposed groups was the date of first dispensing of the drug of 
interest during the study period.  Contrary to published studies (Brown et al [31,63]), for the 
main analyses, history of the AE of interest for a given drug-AE pair was not an exclusion 
criterion given that in a true passive safety surveillance setting, it is not known which event 
will occur.  Exclusion of such patients will be addressed in a sensitivity analysis described 
below (section 4.4.11). 
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4.4.5 Follow-up 
For the signal detection models, subjects were followed until the first of the following 
events: i) Three months after the date of treatment (sensitivity analyses of six months and 
12 months) ii) Switching to the comparator drug; iii) Occurrence of the AE; iv) End of drug 
treatment (+14 days residual risk period); or v) Death, institutionalization, hospitalization 
(as drugs dispensed in-hospital are not recorded in the RAMQ prescription database), vi) 
End of coverage in public drug or medical services program, vii) 31st December 2009.   
 
4.4.6 Study variables for each drug-adverse event pair 
Appendix I summarizes the variables of this study, and codes used for their acquisition. 
 
4.4.6.1 Rosuvastatin – rhabdomyolysis 
Dependent variable 
ICD-9 codes for rhabdomyolysis was 728.8  in the RAMQ medical services database.  
Independent variable 
The “code denomination commune” for the study drug of rosuvastatin (46860 ) and for the 
comparators of “other statins” (47232; 47609; 47083; 47604; 45500; 45570;  47595; 
45564)  from within the RAMQ prescription services database were used.  
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4.4.6.2- Rosiglitazone – acute myocardial infarction 
Dependent variable 
ICD-9 codes for the AE of acute myocardial infarction: 410, 410.0, 410.1, 410.2, 410.3, 
410.4, 410.5, 410.6, 410.7, 410.8 and 410.9 in the RAMQ medical services database. Codes 
related to follow-up were excluded,   
Independent variable 
The “code denomination commune” for the study drug of rosiglitazone (47371, 47652, 
46642) and for the comparator of metformin (05824; 47208; 47807) from within the 
RAMQ prescription services database.  
4.4.6.3  Rosiglitazone - increased fractures in female patients  
Dependent variable 
ICD-9 codes for the AE of fractures: 800 to 829 and 733.1, in the RAMQ medical services 
database.  
 
Independent variable 
The “code denomination commune” for the study drug of rosiglitazone (47371, 47652, 
46642) and for the comparator of metformin (05824; 47208; 47807) from within the 
RAMQ prescription services database.  
 
4.4.6..4- Pioglitazone-increased fractures in female patients 
Dependent variable 
ICD-9 codes for the AE of fractures: 800 to 829 and 733.1, in the RAMQ medical services 
database.  
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Independent variable 
The “code denomination commune” for the study drug of pioglitazone (46678; 47392) and 
for the comparator of metformin (05824; 47208; 47807) from within the RAMQ 
prescription services database.  
 
Negative-control drug-AE pairs 
4.4.6.5- Amitriptyline – increased fractures in female patients  
Dependent variable 
ICD-9 codes for the AE of fractures: 800 to 829 and 733.1 in the RAMQ medical services 
database.  
Independent variable 
The “code denomination commune” for the study drug of amitrptyline (00429 ; 00442 ; 
46011) and for the comparators of metoprolol (38275, 46763,46780)  from within the 
RAMQ prescription services database.  
 
4.4.6.6- Alendronate – acute hepatitis 
Dependent variable 
ICD-9 codes for the AE of acute hepatitis: Acute hepatitis 573.3 & 570.x in the RAMQ 
medical services database. 
 
Independent variable 
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The “code denomination commune” for the study drug of alendronate (46295; 47165; 
43670, 47662; 47747) and for the comparators of atenolol (46315; 46325)  from within the 
RAMQ prescription services database.  
 
4.4.7 Covariates 
In the hypothesis-generating setting of real-time safety surveillance, where it is not yet 
known which AE will occur, control of confounding can only be made for a restricted 
number of covariates which tend to be universal for all drug-AE associations, i.e. age and 
gender.  Unlike pharmacoepidemiologic studies which are etiological and aim at testing 
hypotheses, it is not possible to control for risk factors for the AE (given that the AE is not 
yet known).  Consequently, like previous published studies, age group and gender were the 
two main covariates.   
Confounders that were considered for all analyses consisted of age group and gender.  
Stratification was used to control for these sources of confounding. 
 
Prescription channelling [112] refers to the selective prescription groups of patients who have 
a certain susceptibility or specific pre-existing morbidity, where it consists of self-selection 
or prescribers' preference. For example, medications with the same indication that are 
introduced on the market at different times, and thus in different competitive situations, 
may be channelled to different groups of patients. This channelling of a medication may 
lead to what would appear to be an increased risk of AE associated with a given drug, when 
in fact treated patients are already at greater risk [113, 114].. There is evidence that for diseases 
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with a stepped-care approach, the drug history of patients, as available from some 
databases, can show channeling of drugs to patients with markers of relatively severe 
disease [112]. 
One way of controlling for prescription channelling is by considering patient co-morbidity 
or overall health status.  Overall health status is often recognized as an important 
confounder in pharmacoepidemiologic studies and may therefore be associated with the 
prescription channelling.  Overall health status is therefore not specific to a given drug-AE 
pair; rather it can be considered as universal and hence, would be appropriate to consider in 
a surveillance study where it is not possible to control a priori for confounders such as other 
risk factors for the AE, given that said AE is not yet known.  Overall health status is 
assessed using claims databases, either through prescription or medical services data.  
Several methods have been published in the literature, and given the nature of the RAMQ 
databases, the von Korff Chronic Disease Score (CDS) was retained.  The CDS is derived 
from the drugs a patient is using over a one-year period and has been found to be a good 
predictor of death in the following year [115]. There is evidence that for diseases with a 
stepped-care approach, the drug history of patients, as available from some databases, can 
show channeling of drugs to patients with markers of relatively severe disease [112].  von 
Korff et al developed the CDS composition, where drugs were assigned scores (0 to 5) and 
such that the CDS would i) increase with the number of chronic diseases but not if drugs of 
the same class were used; ii) increase as the treatment regimen became more complex; iii) 
allocate a higher score to more severe diseases and iv) measure medications used for the 
diseases (as opposed to the symptoms) [115]. The CDS has been adapted and calibrated by 
(Béland et al. [116]) to reflect diseases not previously considered by von Korff et al, such as 
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anxiety and depression. It was also updated to include new drugs and new classes of drugs 
newly available in Quebec over the past decade. Some of the drugs and corresponding 
weights of the CDS are as follows: Diuretics-1; Statins-1; Cardiovascular drugs (one class-
3; two classes-4; three classes-5) etc. Based on the distribution of scores obtained for 
members of the source population, the following database categories were created: 0;  0- 
5; > 5 - 10, >10). The CDS is a method to assess patient overall health status through the 
summarization of prescription drugs; hence, it is not specific to a given drug-AE 
association and may be used systematically for all drug comparisons.  While previous 
studies on signal detection controlled for age and sex only, CDS was also an adjustment 
variable in this study with the premise that it would be an improvement over existing 
analytic methods of signal detection. 
 
4.4.8 Statistical analyses 
The Poisson-based Maximised Sequential Probability Ratio Test (MaxSPRT), described in 
section 3.1.2.2 (Denominator-based methods) of the literature review, was used as the data 
mining algorithm.  
An exposure denominator that takes into account both the number of exposed patients as 
well as their length of exposure, i.e. person–time, was used. Exposed and unexposed 
person-time were calculated using units of patient-months. Exposed person-time began on 
the day after commencing treatment with the drug, and continued until the end of the last 
dispensed prescription plus an additional 14 days so as to account for the residual risk 
period. Exposure gaps of 14 days or less were considered as continued exposure since the 
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majority of claims in Quebec are for 30 days.  A gap of one half of the days last supplied 
was used as a cut-off in order to account for non-persistence [117]. Hence, all gaps exceeding 
one half of days last supplied was considered to be discontinuation.  Unexposed person-
time was quantified as patient-time with no exposure to the drug of interest. 
 
At each monthly time point, the number of expected events in the treatment group was 
calculated based on the observed risk of the event in the parallel comparison group i.e.  
 
 
 
Using monthly data, the LLR test statistic comparing observed counts to expected counts, 
was calculated at time t of each drug-event pair. A potential AE signal was generated if the 
LLR exceeded a pre-defined critical value. A different critical value was established for 
each drug-AE pair using pre-calculated computer-based simulations provided by Kulldorff 
et al [57]. MaxSPRT critical values are calculated such that the null is rejected when the LLR 
reaches an upper limit and accepted when the observation has been ongoing for a pre-
determined length of time. It is, defined in terms of the expected number of events 
accumulated under the null hypothesis (H0) Kulldorff et al provide a table of values within 
their study, which indicates the upper bounds used for the rejection of the H0for various 
denominations of alpha levels, and expected number of events under the H0. These values 
can be employed by subsequent users of the MaxSPRT method. 
 
Cumulative number of AEs in reference 
group             
Cumulative pt-exposure of treatment X
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For this study, critical values were set up such that the alpha level was 0.05; the minimum 
number of events under the H0 was five (based on evidence that the minimum number of 
AEs required to uncover a signal for a rare AE is between three and five [88]), and the 
maximum length of follow-up was 120 months i.e. the available study period in the 
database (1st January 2000-31st December 2009).  The time to detection of the potential 
risk (signal) using this method was compared to that of the posting of the actual safety 
communication by Health Canada (dates provided in Table V of section 4.4.2 “Selection of 
drug-adverse event pairs”). 
 
4.4.9 Statistical power 
Applying this method in real time, the sample size of the study would not be known until 
analysis has actually begun. Furthermore, the sample size would also be limited by the size 
of the database, which was the case with the current study. Consequently, the statistical 
power of the study to detect drug-AE associations was determined after analyses of each 
pair with the use of a table of pre-determined values provided by Kulldorff et al [57]  (Table 
II). Kulldorff et al calculated various values of power based on: the type I error, the upper 
length of surveillance, and the true RR of the AE of interest. Tables IX and X in the 
“Results” section display the statistical power calculated for each of the analyses.  
 
4.4.10 Control of biases 
Because the hazard function that describes the change in risk over time after treatment 
initiation is rarely constant over time, it is necessary to account for duration of drug use.  In 
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many instances, risk of AE increases with time immediately after treatment initiation and 
decreases thereafter. This phenomenon is referred to the "depletion of susceptibles" effect 
whereby individuals who did not experience symptoms of the AEs during the period at 
highest risk will likely not experience it at later stages [119].  As shown by Moride and 
Abenhaim (1994)[111], failure to take into consideration time since treatment onset may 
introduce a bias in the measure of association between a drug and an AE, especially when 
comparing the risk associated with various products. Thus, continuing follow-up of a drug 
in one patient for a long period of time could reduce the strength of a signal, as less AEs 
would be reported as time lapses.   In order to eliminate this source of bias, we have used a 
"new user" design in the definition of the cohorts [118].  All patients exposed to the drug of 
interest or to the comparator had not received any prescription for this given drug in the 
previous six months.  
Prevalence bias is a type of selection bias that may occur in studies when prevalent cases 
rather than new cases of a condition are selected. Prevalent cases are patients who have 
survived with their AEs.  Hence, it is not known whether the drug is a risk factor for the 
occurrence of the AE, or whether it is a prognostic factors in patients who have the AE.  
Previous studies have excluded patients with a history of AE during the 6 months prior to 
the occurrence of the current AE [63]. It was decided not to exclude on such basis in the 
current study given that in a true signal detection setting, one would not know which AE 
will occur; hence it is not possible to exclude on such history.  However, controlling for 
overall health status would allow control for prevalence bias as well. 
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4.4.11 Sensitivity analyses 
Sensitivity analyses were performed in order to test the robustness of the method, and the 
effect of controlling for different combinations of confounders  
Time windows for follow-up 
In addition to the default follow-up time of 3 months, additional time windows of 6 months 
and 12 months were also analysed for all drug-AE pairs, in order to determine the effect of 
controlling for depletion of susceptibles effect as described in section “Control of bias’” 
4.4.10 above. 
Age, sex 
Age: As described in section 4.4.7“Covariates” above, to control for age (five-year 
intervals), subgroup analyses were applied to all drug-AE pairs in a similar manner to a 
standardised mortality ratio (SMR) process (i.e. a method whereby expected numbers are 
calculated per group (i.e. age or gender) and then totalled. With the SMR, the numbers of 
deaths that were actually observed in the population are also calculated and totalled. The 
ratio of the total number of deaths observed, to the total number of deaths expected is then 
calculated subsequently) [120]. 
Following the formula indicated in the “Statistical analysis” section above, separate 
expected AE counts were calculated for each of the subgroups on a monthly basis, by first 
calculating risk values for each, and then multiplying the risk by the monthly cumulative 
patient exposure for each of the same. These expected event counts were then averaged for 
the entire treatment cohort at the monthly level, before applying the LLR test.  
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Sex:  Subgroup analyses based on sex were also applied to all drug-event pairs with the 
exception of two pairs studied only in female patients: the “pioglitazone-” and 
“rosiglitazone-increased fractures” pairs. A similar method to that performed for the age 
adjustment was applied to the subgroups of “male” and “female” subjects. Given that the 
RAMQ provided age groups in 5 year intervals as opposed to exact birth dates, only a crude 
control could be achieved, which is a limitation of the study. 
Age, sex, overall health status 
After adjustments on age and sex, the effect of overall health status was also analysed for 
the rosiglitazone-acute MI drug-AE pair by including the subgroup of CDS. CDS is 
described in further detail in section 4.4.7 “Covariates”above. For each patient of the 
cohort, CDS was calculated based on the drugs used during the year prior to initiation of 
treatment use. Scores were subsequently stratified into subgroups which were determined 
based on the observed distributions of CDS in the study population: (0;  0- 5; > 5 - 10, 
>10). 
Include versus exclude history of MI 
The initial analysis of the drug-AE pairs did not control for or exclude prior occurrences of 
the AE of interest. In order to control for prevalence bias, where a medication appears to 
cause an AE in patients already suffering from the AE, patients who had previously 
exhibited the event of acute MI within the 6 months prior to incident exposure within the 
rosiglitazone-acute MI pair were excluded from the analysis. 
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4.4.12 Results 
Table VII. Baseline Characteristics of study cohort 
    N % 
Total   87389 100
Gender       
  Female 49718 56.89
  Male 37671 43.11
Age at cohort entry      
  66-69y  49002 56.07
  70-74 15843 18.13
  75-79 11379 13.02
  80-84 6413 7.34
  85 and over 4739 5.42
  Not Indicated 13 0.01
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Table I shows the baseline characteristics of the study cohort. A large majority of the 
population were between the ages of 66 and 69.  
 
Data mining results: Known drug-AE pairs 
Rosuvastatin-rhabdomyolysis (“other statins” reference): Figure II displays the background 
rates of rhabdomyolysis within users of simvastatin and rosuvastatin. Due to the few 
number of AEs, the database appears to be too small for application of the MaxSPRT 
method. Instead, a simple Poisson method was applied to determine where an unexpectedly 
high amount of AEs were observed in rosuvastatin users, as compared to users of “other 
statins”.  
Figure II. Background rates of rhabdomyolysis during study group in statin groups 
within RAMQ Database 
 
The Poisson method also did not show a potential signal in the pair as can be seen below in 
Figure III: The observed number of events of rhabdomyolysis within the rosuvastatin group 
remained lower than the expected number of events (based on reference groups of 
Health Canada 
Warning
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simvastatin and atorvastatin). It also remained far lower than the upper boundary that would 
have indicated a signal as per the Poisson method. 
Figure III. Rosuvastatin-rhabdomyolysis poisson data results – three month follow-up 
 
 
 
Rosiglitazone-acute myocardial infarction (metformin reference):The three-month time 
window shows the detection of a safety issue at 107 months from product launch. The six-
month time window shows a signal at 108 months, and the 12-month time window does not 
show a signal.  
 
Rosiglitazone-increased fractures in female patients (metformin reference):There was no 
potential signal observed with the rosiglitazone-increased fractures pair with any of the 
Health Canada 
Warning 
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follow-up time windows or adjustments. There was no significant increased risk when 
comparing observed to expected counts. The power of the analyses was less than 0.2.  
 
Pioglitazone-increased fractures in female patients (metformin reference):There was no 
potential signal observed with the rosiglitazone-increased fractures pair with any of the 
follow-up time windows or adjustments. There was no significant increased risk when 
comparing observed to expected counts. The power of the analyses was less than 0.2 
Data mining results: Negative controls 
Alendronate – acute hepatitis (atenolol reference) and Amitriptyline – increased 
fractures (metoprolol reference): 
Table VIII below shows that neither of the negative-control pairs produced any potential 
signal throughout any of the follow-up time periods. These results were not affected by 
adjustments on age and sex. However, using the six-month follow-up period, there was a 
peak that came close, in the alendronate-acute hepatitis group at January of 2003.  
 
Table VIII below also provides an overall summary of the unadjusted MaxSPRT data 
mining results for the remaining drug-AE pairs. The only drug-AE pair that shows a 
potential signal is the rosiglitazone-acute MI pair, during the three-month and six-month 
follow-up time windows. This study had a power of 0.5 to 0.6. The other known-drug-AE 
pairs did not show a potential signal, nor did the negative-control pairs. However the power 
for all of these remaining analyses was between 0.1 and 0.2. Each drug-AE pair is 
discussed in further detail below. 
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Table VIII. Unadjusted results of MaxSPRT data mining method applied to drug-AE pairs 
Drug–AE Pair  Follow-
up 
Time 
Period 
Cumul. 
number 
of person 
months 
in cohort 
Number 
of person-
months in 
cohort at 
signal 
Maximum 
Expected 
Number of 
Events 
under Ho 
Expected 
Number of 
Events 
under Ho 
at signal 
LLR 
Critical 
Value  
(p < 
0.05) 
Date of 
Health 
Canada 
Warning 
Number of 
events 
observed at 
signal 
Month 
and Year 
Signal 
Detected  
Number 
of 
months 
to signal 
Study 
Power 
rosiglitazone – 
acute 
myocardial 
infarction (vs. 
metformin) 
3 
months 
52906 51704 92 89 3.95                          
Nov 2007 
118 Oct 2009 107 0.252 to 
0.869 
(Interpol-
0.458) 
(RR=1.3) 
 6 
months 
90941 89782 118 118 3.99 Nov 2007 151 Nov 2009 108 0.366 to 
0.997 
(Interpol - 
0.567) -  
(RR=1.3) 
 12 
months 
91059 N/A 136 N/A 4.03 Nov 2007 N/A  
(max=153) 
No signal No signal 0.421 to 
0.502 
(RR=1.1) 
rosiglitazone-
Increased 
fractures in 
female patients 
(vs. metformin) 
3 
months 
3064 N/A 15 N/A 3.57 Feb 2007 N/A  
(max =12) 
No signal No signal Less than 
0.122 
 6 
months 
5452 N/A 22 N/A 3.68 Feb 2007 N/A  
(max =14) 
No signal  No signal Less than 
0.122 
 
 12 
months 
9849 N/A 36 N/A 3.78 Feb 2007 N/A  
(max =23) 
No signal No signal Less than 
0.195 
 
pioglitazone 
Increased 
fractures in 
3 
months 
1731 N/A 6 N/A 3.35 Apr 2007 N/A  
(max =7) 
No signal No signal Less than 
0.091 
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female patients 
(vs. metformin) 
 6 
months 
2953 N/A 9 N/A 3.47 Apr 2007 N/A  
(max =10) 
No signal No signal Less than 
0.106 
 
 12 
months 
5109 N/A 14 N/A 3.57 Apr 2007 N/A  
(max =16) 
No signal No signal Less than 
0.122 
 
amitriptyline-
Increased 
fractures in 
female patients 
(vs. metoprolol) 
3 
months 
11173 N/A 51 N/A 3.35 N/A N/A  
(max =39) 
No signal No signal Less than 
0.091 
 6 
months 
15846 N/A 67 N/A 3.47 N/A N/A  
(max =63) 
No signal No signal Less than 
0.106 
 
 12 
months 
24095 N/A 86 N/A 3.57 N/A N/A  
(max=100) 
No signal No signal Less than 
0.122 
 
alendronate -
acute hepatitis 
(vs. atenolol) 
3 
months 
26411 N/A 13 N/A 3.57 N/A N/A  
(max =17) 
No signal No signal 0.112 to 
0.318 
(Interpol-
0.182) 
 6 
months 
43166 N/A 18 N/A 3.63 N/A N/A  
(max =25) 
No signal No signal 0.112 to 
0.318 
(Interpol-
0.182) 
 12 
months 
77046 N/A 22 N/A 3.68 N/A N/A  
(max =32) 
No signal No signal 0.136 to 
0.451 
(Interpol-
0.241) 
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Effect of adjustments on age and sex- Rosiglitazone-acute myocardial infarction case 
study (metformin reference):VIII below displays a direct comparison of the three-month 
and six-month follow-up time windows within the “rosiglitazone-acute MI” pair. The three-
month time window shows the detection of a safety issue at 107 months from product 
launch. Adjusting these results on age and sex improves the time to detection to 93 months. 
The six month time window initially shows a potential signal at 108 months. The age & sex 
adjustment improved it to 93 months. All with powers between 0.5 and 0.6.  
Effect of adjustments on age, sex and CDS - Rosiglitazone-acute myocardial infarction 
case study (metformin reference): 
Cumulative adjustments of the CDS in addition to age and gender at the three-month 
interval allow for an even earlier detection of a potential signal at 83 months in September 
2007, two months before Health Canada’s issuance of the safety warning. The CDS 
adjustments at the six-month interval (combined with age and gender) led to detection at 61 
months in November 2005, 24 months before Health Canada’s warning. 
Effect of exclusion of previous AE occurrence - Rosiglitazone-acute myocardial 
infarction case study 
At the three-month time window, excluding individuals with prior experience of acute MI 
within six months prior to exposure to the drug of interest, further sped up the detection of 
a potential signal to 29 months, with a power between 0.5 and 0.6. However, at the six-
month time window, excluding prior AE’s within six months pre-exposure leads to no 
detection at the six-month time window, involving a power of just 0.2. 
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Table IX  MaxSPRT data mining results of rosiglitazone – acute myocardial infarction pair using three-month and Six-month 
follow-up time periods 
Follow-
up  
Time 
Period 
Adjustment LLR 
Critical 
Value  
(p < 
0.05) 
Cumul 
Number 
of 
person –
months 
in cohort 
Number 
of 
person-
months 
in cohort 
at signal 
Maximum 
Expected # 
of Events 
under Ho 
Expected 
# of 
events 
under Ho 
at signal 
Date of 
Health 
Canada 
Warning 
Month 
and 
Year 
Signal 
Detected  
# of 
months 
to 
signal 
Number 
of events 
observed 
at signal 
Power of 
study 
Interpolated 
Power 
Calculation 
3 months None 3.95 52906 51704 92 89 Nov 2007 Oct 2009 107 118 0.252 to 
0.869 
(RR=1.3) 
0.458 
 Age & Sex 3.92 52906 42763 84 68 Nov 2007 August 
2008 
93 94 0.309 to 
0.904 
(RR=1.3) 
0.507 
 Age Sex & 
CDS 
3.86 52906 36060 71 50 Nov 2007 Sep 2007 83 72 0.252 to 
0.869 
(RR=1.3) 
0.458 
 Age, Sex, 
CDS & 
Exclusion of 
MI in 
previous 6 
months 
3.72 52788 4532 30 5 Nov 2007 Mar 2003 29 13 0.599 to 
0.983 
(RR=1.6) 
0.599 
6 months None 3.99 90941 89782 118 118 Nov 2007 Nov 
2009  
108 151 0.366 to 
0.997 
(RR=1.3) 
0.576 
 Age & Sex 3.96 90941 72573 108 90 Nov 2007 August 
2008 
93 119 0.366 to 
0.997 
(RR=1.3) 
0.576 
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CDS = Chronic Disease Score 
 Age Sex & 
CDS 
3.92 90941 38175 91 42 Nov 2007 Nov 
2005 
61 65 0.309 to 
0.944 
(RR=1.2) 
0.507 
  Age, Sex, 
CDS & AE 
excl in 
previous 6 
months 
3.83 90941 N/A 51 N/A Nov 2007 No signal No 
signal 
N/A 
(max=58) 
0.223 
(RR=1.2) 
0.223 
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Figure IV below displays the number of counts of the observed vs. expected AEs; as well 
as the signal detection graph, for the three-month follow-up of rosiglitazone-acute MI pair 
adjusted for age, sex, and CDS. Although the potential signal from the data mining method 
was observed at 83 months, the imbalance in observed vs. expected AE counts is seen to 
commence as of 56 months in Jun 2005 (39 events vs. 34 events). 
Figure IV. Rosiglitazone-acute MI data mining results – three month follow-up 
adjusted for age, sex and overall health status (CDS) 
 
 
 
 
 
 
 
 
 
 
 
Figure V below displays the number of counts of the observed vs. expected AEs; as well as 
the signal detection graph, for the six-month follow-up of rosiglitazone-acute MI pair 
adjusted for age, sex, and CDS. Although the potential signal from the data mining method 
was observed at 61 months, the imbalance in observed vs. expected AE counts is seen to 
begin as of 13 months in Dec 2001 (10 events vs. 8 events) 
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Figure V. Rosiglitazone-acute MI data mining results – six month follow-up adjusted 
for age, sex and overall health status (CDS) 
 
 
 
 
 
 
 
 
 
4.4.13 Discussion 
4.4.13.1 Strengths  
This study is the first data mining study for signal detection to be applied to a Canadian 
health claims database. Literature searches have revealed only one previous study applied 
to a Canadian database. This was however the Health Canada SR database [73], and 
compared the denominator-independent methodologies of PRR, ROR, the Chi-square 
statistics methods, and the Du Mouchel method to calculate possible signals. This is in 
stark contrast to our method which used an administrative claims database, and a 
denominator-based method to determine the presence of potential signals.  Thus to our 
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knowledge, this is the first study to attempt detection of potential safety signals through a 
Canadian claims database, and using a denominator-based method. The use of the RAMQ 
database provided strengths such as a large sample size and longitudinal data that is 
extremely comprehensive for the elderly population of the province of Quebec (97% 
covered in public drug program). Furthermore the use of this database avoids common data 
mining and signal detection challenges of underreporting and reporting bias that occur in 
the SR databases, and virtually eliminates any potential for selection bias. Because of the 
diversity and completeness of data within this database, the potential for future signal 
detection activities of verification and confirmation through pharmacoepidemiologic 
studies is also quite promising. This study also accounts for the depletion of susceptibles in 
a data mining study by varying the length of follow-up for each of the drug-AE pairs in 
order to observe variations on the strength and time to detection of potential signals. This is 
a characteristic that other studies have not factored in the past. Finally, the calculation of 
expected events in this study is based on a parallel reference group. This also is a unique 
approach taken in this study as the previous Brown et al studies [31,63] calculated the events 
based on the assumption that the comparator group contained at least some historical data. 
For this reason, a constant risk value of the comparator group had been applied to prior 
studies [31,63]. However this study instead uses a variable risk that is calculated at each 
monthly time point, in order to determine the expected counts for that particular month. 
This is deemed to be more pragmatic than the historical approach, and would also account 
for seasonal changes, as well as changes in the product’s usage profile over time.  
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4.4.13.2 Weaknesses 
Size of database 
The size of the database that the RAMQ provided for the analysis was a relatively small 
proportion (approximately 11%) of the RAMQ database (n=87389). This number is rather 
small in comparison to other databases used in prior data mining studies (Brown et al n= 
approx. 8million; Choi et al n=1,093,262; Coloma et al n=59,929,690). It is presumed that 
the effects of this limited database size on this study were the low power, and inability to 
detect signals in 2 out of four of the case studies, i.e. the rosiglitazone and pioglitazone-
increased fractures pairs. The power of the negative-control pairs was also very small, 
leading to some reservations in the interpretation of the specificity of the tool.  
Age group within database 
In Quebec, all persons 65 years or older are eligible for coverage under the RAMQ 
services[121], thus it contains 97% of the elderly population for both medical services and 
prescription data, and is ideal for post-marketing studies of this group. This is beneficial for 
signal detection activities in this particular group, which is one that has been targeted by the 
FDA and EMA for risk management activities. The medical services database also includes 
more than 99% of the claims for the remainder of the population of Quebec [122], however 
not all individuals are covered by the prescription services which contains only 55% of the 
total population for medication exposure data [123, 124]. This limits its applicability to signal 
detection in groups outside of the elderly population as i) the sample size provided may be 
too small for analysis, and ii) the generalizability of the results to the overall population of 
Quebec may be questionable.  
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Potential inaccuracy of ICD-9 codes 
As mentioned in “Health Claims Databases” section 3.1.3.3, the reliability of the ICD-9 
diagnostic codes reported by the HCPs may be questionable as validation is not required for 
reimbursement. Although there are studies which indicate that the specificity of ICD-9 
codes reported by Physicians for reimbursement, including those for cardiovascular risk 
factors, are usually 95% or greater [109, 125], there were no studies located concerning the 
validation of the codes for acute MI in Canada. Furthermore, there is a general lack of 
Canadian validation of the ICD-9 codes used in this study overall. In general, use of the 
incorrect ICD-9 code, or misdiagnoses could result in a misclassification of the events, and 
possibly many events being omitted from the analysis. This in turn could reduce the size of 
the signal and increase the time to detection of the signal as well. Thus the risk of 
inaccuracy of the ICD-9 codes used in this study could be contributing to the lack of a 
signal, and low power observed with some of the case studies. In addition, in some cases 
the misclassification of the event could lead to the event’s counts being  so rare that too few 
events are identified in order to apply analyses at all. This is believed to be one of the 
causes of the missed signal in the rosuvastatin-rhabdomyolysis case study as described 
further below.  
Calculation of expected events Additional weaknesses observed throughout this process 
include the inability to detect very rare AEs such as rhabdomyolysis using this method. 
However, application of the Poisson method also did not produce a potential signal. This 
could in part be due to the use of inaccurate ICD-9 codes, as the precise code for 
rhabdomyolysis is a five-digit code, however the RAMQ database only contains up to four 
digits for ICD-9 codes. It could also be due to the database not being large enough (14,583 
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rosuvastatin users for the entire 10-year timer period), however, these results are consistent 
with a study by Choi et al that did not pick up rhabdomyolysis as an AE signal when 
analyzing AEs of rosuvastatin in a Health Claims database in China [30] which consisted of 
96, 236 users of rosuvastatin over a one-year period. On the other hand, Szarfman et al [49], 
and Brown et al [63] did determine a signal using the cerivastatin -rhabdomyolysis case 
study, and a data mining algorithm. Cerivastatin however is a drug that was approved by 
the CM of Quebec in 1997, three years before the inclusion dates of our sample, making it 
an inadequate case study for our method. Cerivastatin was also voluntarily withdrawn from 
the world market in 2001 due to its association with rhabdomyolysis and death, implying 
that it possibly had a much larger RR than our case study of rosuvastatin-rhabdomyolysis. 
Because of the extremely rare nature of the AE of rhabdomyolysis among users of “other 
statins”, it is not possible to use this particular automated methodology and this particular 
database to identify this sort of AE. This feature indicates that it is necessary to continue 
traditional qualitative or non-automated signal detection methodology, and that the 
automated data mining methods should be used as an adjunct to traditional qualitative 
methods [28,38]. This is a conclusion consistent with general consensus of data mining 
methodology. Furthermore, there is a general lack of Canadian validation of the ICD-9 
codes used in the analyses which would affect the accuracy of the results.  
Only a basic, less refined control of the covariable of “age” was achieved due to the fact 
that the RAMQ database provides age groups in 5 year intervals rather than the exact birth 
dates.  
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As with most pharmacoepidemiologic studies, there is the possibility of the presence of 
unmeasured confounders, that cannot be adjusted for. This could distort the results of the 
study.  
Feasibility of using this method depends on the availability of data on a quarterly basis.  
Given the current situation in Quebec where delays for RAMQ data extraction are very 
large, the administrative system is not set up for this.  Furthermore, drug dispensings 
become available in the RAMQ database only when the drug is reimbursed by the public 
drug plan.  In practice, delays for inclusion in the drug formulary are increasing which 
therefore hampers the ability to conduct data mining immediately following product launch.  
In this demonstration study, the analytical methods were developed and the performance of 
the tool was assessed.  Currently, limitations in the timeliness of the availability of the 
RAMQ database is a major barrier to the implementation of data mining for drug safety 
signal detection in Canada.  
 
4.4.13.3 Controlling for confounding and biases 
The main limitation of data mining is that the ability to detect safety signals is offset by a 
very large number of false-positive signals, each requiring further investigations. In order to 
reduce the number of false-positive signals obtained during the data mining process, 
confounding factors are controlled for. A potential signal was observed with the unadjusted 
rosiglitazone-acute MI case study. This is in fact consistent with the results of the Motola et 
al study [126] which showed disproportionality with cardiovascular ADRs among the 
rosiglitazone study group. In addition, subgroup analysis of our study data by age and 
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gender had a profound effect, causing the potential signal to be detected around one year 
earlier in the rosiglitazone- acute MI group (See Table IX above).  
As a means to control confounding by overall health status, the CDS was applied to the 
“rosiglitazone- acute MI drug-AE pair. The CDS was described in detail in section 4.4.7 
“Covariates”. It is an indicator of overall health status of a patient developed by von Korff 
and is acquired based on the drugs a patient is using over a one-year period[115]. It is 
believed that this is a straightforward method that can be applied at various levels of 
research. Nonetheless, calculating the CDS is still a fairly tedious procedure and it is 
suggested that it only be applied to drug-AE pairs showing the most potential effect as was 
done in this study where it was applied only to the rosiglitazone-myocardial infarction pair. 
Many previous studies have not included any adjustments or attempts to control for 
confounding [47,89,95,]. Other studies methods to control for confounding have been primarily 
limited to stratification on demographics such as age, sex, and gender [49,50]. Choi et al [30]  
included only elderly patients in order to control for confounding by age, and Poluzzi et al 
controlled for prevalence bias by excluding individuals who previously exhibited the AE of 
interest. They also controlled for concomitant medications by conducting qualitative case-
by-case analyses of the spontaneous reports included in the study. There have also been 
discussions on the possibility of using a form of a Propensity Score known as the High 
Dimensional Propensity Score (HDPS). This is a multi-step process that encompasses 
covariates of two main categories i. Demographics (age, sex, calendar time, race) ii. 
Candidate Empirical Covariates (outpatient diagnostic ICD codes; inpatient procedure 
codes, and drugs dispensed).  The prevalence, recurrence, and priority of these codes are 
also assessed in order to determine the most adequate ones to include in the multivariate 
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logistic regression formula that would define the HDPS [127]. This method is indeed more 
advanced than the application of CDS used for our study; however HDPS construction is 
quite complex and believed to require much more resources than the CDS. 
 
4.4.13.4 Effect of depletion of susceptibles 
As discussed in the methods section 4.4.10 “Control of biases”, the phenomenon of 
depletion of susceptibles [111] is a situation whereby patients who remain on drugs for a 
prolonged period of time, are those who can tolerate them, while those who are susceptible 
to side effects select themselves out of the population at risk. Thus, continuing follow-up of 
a drug in one patient for a long period of time could reduce the strength of a signal. 
Accounting for the depletion of susceptibles in a data mining study is not a characteristic 
that other studies have factored in the past. 
From Table VII, one can note that for the non-adjusted rosiglitazone-acute MI data, 
although the power for the six-month intervals is higher than that of the three-month  
interval (0.6 vs. 0.5), it is the three-month interval that gives a stronger and earlier signal. 
We believe that this exemplifies the effect of the depletion of susceptibles phenomenon. 
The meta-analysis conducted by Nissen and Wolski[128, 129] which initially showed the 
increased risk of acute MI in rosiglitazone users, did not have access to individual patient 
files and could not determine the actual time to onset of the acute MI. All clinical trials 
included in the analysis were of duration of at least 24 weeks (6 months). Consequently, the 
theory of depletion of susceptibles with regards to the 3-month time interval is difficult to 
support. However, Table VI of our signal detection study also shows us that there is no 
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potential signal observed with the 12-month time window of unadjusted results, although 
the 6month time window did produce a signal This is also believed to be attributable to a 
depletion of susceptibles effect masking the signal in the signal detection study for the 
longer period of 12 months. This is consistent with the results of the meta-analysis by 
Nissen and Wolski where trials of less than 12 months’ duration showed a higher risk of 
acute MI (OR, 1.76 (95% CI, 0.93-3.33) than trials of 12 months and longer (OR, 1.22 
(95% CI, 0.95-1.57). The RR for the 6 month and 12 month time periods (1.3 and 1.1. 
respectively) were slightly lower than the ORs of Nissen and Wolski although they do fit in 
the 95% confidence intervals. These risk estimates demonstrate that our calculation of 
expected events is in line with the literature and it is expected that it may be difficult to 
detect a signal at the 12month time point given that the risk is lower for that length of 
follow-up. We believe the reason for the lower risk in the longer time period is the fact that 
those who are susceptible to experiencing AEs select themselves out of the population at 
risk. E.g. in the DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone 
Medication) trial, some common reasons for stopping rosiglitazone and placebo were: 
edema (439 [4.8%] in the rosiglitazone group and 41 [1.6%]) in the placebo group, 
physician’s advice (50 [1.9%] and 39 [1.5%]), and weight gain (50 [1.9%] and 15 [0.6%], 
indicating that susceptibility to AEs plays a large role in decisions to discontinue therapy 
[130]. 
It is also possible that the reduced ability to detect a signal in the 3month time period 
(adjusted for age, sex and CDS) is due to the fact that the time to onset of MI could, on 
average be more than 3 months. Thus the follow-up period may be too short to detect a 
substantial signal at an earlier time point. This further supports the use of varying follow-up 
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time periods during signal detection processes in order to increase potential for signal 
detection.  
4.4.13.5 Exclusion of previous AE occurrences 
The exclusion of previous occurrences of acute MI also allowed for a signal in the 3-month 
period, but none in the 6-month period. It is believed that the exclusion of prior acute MI 
events reduced the power of the 6 month time period such that the AE could not be detected 
in this group (0.223 for 6months vs. 0.599 for 3months). This is believed to be the main 
reason that the 3month time window has a better signal at this point. This exclusion of 
previous AEs also shows evidence that the drug could be playing a larger role at 
exacerbating previous events of acute MI as well as causing new events.  
 
The use of comparator drugs with the same indication as the study drugs, are expected to 
control for indication bias. Survivor bias is also controlled for due to the analysis beginning 
at the start date from the drug’s reimbursement. Finally, misclassification is also addressed 
due to the use of incident exposure, and exposed vs. unexposed person-time denominator in 
the calculations.  
 
4.4.13.6 Challenges encountered in the study 
No safety risk was observed with the remaining two known drug-AE pairs of rosiglitazone 
and pioglitazone-increased fractures in female patients. However in a prior study, Motola et 
al were able to demonstrate that pioglitazone showed significant RORs compared to other 
anti-diabetic drugs within the FDA-AERS database [126]. Our inability to detect a signal 
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could be due to the low statistical power noted with the analyses of these two pairs (both 
approximately 0.1), implying that the database may in fact be too small for analysis of 
certain drugs with either low exposure rates or low occurrence of the AEs. However, it is 
also important to note that the data mining and signal detecting processes are hypothesis-
generating methods which would require further analyses (e.g. traditional 
pharmacoepidemiologic studies) in order to confirm that a signal or true safety risk actually 
does exist. Thus having a low power is more common among these studies than others. .  
Although the negative control drug-AE pairs did not produce signals, the alendronate-
hepatitis pair did come close at January of 2003 using the six- month follow-up time 
period. This peak could in part be due to the surge in exposure that occurred between Dec 
2002 and October 2003. Furthermore, the power of the data mining methods of these two 
negative-control drug-AE pairs also appears to be relatively low (0.1 and 0.2 respectively).  
 
With the unadjusted rosiglitazone-acute MI pair results there appears to be a question of the 
possible existence of notoriety bias. i.e. after the issuance of the warning, the reporting of 
acute MI increased thus resulting in a signal. However because the actual figures of 
observed vs. expected events (Figure IV for 3month period and Figure V for the 6 month 
time period) show the imbalance of events beginning as of June 2005 and December 2001 
respectively, this is unlikely to be the case.  
 
Accounting for time to onset of AE, or residual time periods after exposure, is an aspect 
that would be difficult to include in future application of the methodology given that in a 
real world prospective case scenario, the AE of interest is unknown. Thus, controlling for 
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such factors is not possible. As such, the study did not take into effect a lag time to onset of 
AE, and used a standard residual period of 14 days. No other studies attempting either of 
these facets were located during the literature review. However for future use, if a particular 
and specific AE has been defined for analysis, then this may be possible. The UMC uses an 
algorithm to filter what AEs should be analysed, prioritizing those that are: serious and  
new events; of increasing  reporting frequency; clinically of special interest due to their 
typical association with drugs (e.g. rhabdomyolysis, agranulocytosis and Stevens-Johnson 
syndrome) and; ‘international signals’ that are reported from multiple countries [131,132]. 
Consequently if an organization wishes to routinely study AEs such as those listed above, 
then  further limiting the number of false positive signals by defining time to onset of AE, 
and/ or residual time periods after exposure may be a viable option. 
 
4.4.13.7 Future perspectives 
Using less severe symptoms as proxies for diseases that are difficult to diagnose, or very 
rare AEs may be a solution to data mining of very rare events, (e.g. rhabdomyolysis: 
proxies of less severe symptoms such as  myopathy, myoglobinuria, myositis, muscle 
weakness etc.) specifically since ideally one would want to identify the AE before it 
becomes as severe as rhabdomyolysis. However using proxies could lead to the unwanted 
effect of additional “background noise” false positive signals, which would make the 
process more tedious.  
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Accounting for time to onset of AE, or residual time periods after exposure in order to 
further reduce the false positive signals is an idea that may be worth exploring in instances 
where particular AEs have been identified for study.  
 
Use of the database for the next step in signal detection, i.e. verification / confirmation of 
the signal, is also a potential next step with the RAMQ database because it contains much 
information on potential confounders such as concomitant medications. 
 
Finally, applying the method to the RAMQ database, in a real-time manner using newly 
marketed drugs. The potential AEs to be studied could be AEs known to be associated with 
the class effects of the drug, or mechanism of action, or high-profile AEs.  However this 
would depend on the RAMQ updating the database on a schedule that would allow for this. 
This would also most likely be limited to medications used in the elderly, since the RAMQ 
database may not possess a representative number of other groups of the population. 
 
4.4.14 Conclusion 
 
In the context of therapeutic risk management, this study helps us to identify certain gaps in 
the field of risk detection through the use of statistical methods. The data mining algorithm 
of MaxSPRT is indeed applicable to the RAMQ database and the database seems to be 
conducive to quantitative signal detection. This further supports the use of administrative 
claims databases vs. SR databases for data mining. There are however still limitations with 
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the size of the database, and thus the power of certain drug-AE pair analyses. Consequently 
the method may need to be refined for each drug-AE pair individually in order to improve 
its performance. The sensitivity of the tool was demonstrated with just one of the four 
known drug-AE pairs through the detection of a safety concern, and the time to detection of 
the potential signal.  The specificity of the tool was also established since none of the 
negative-control pairs analysed resulted in a potential signal being identified. However the 
power of each of these analyses could cause some ambiguity with regards to interpretation 
of the results. The definition of the time window is a crucial element for the ability to detect 
signals in order to avoid the depletion of susceptibles effect. This is an aspect that future 
researchers should take into consideration in order to possibly identify signals earlier, and 
take action at protecting patients much sooner. This tool is expected to be adaptable for use 
by academic researchers, industry and regulators in order to improve drug safety 
surveillance in the Canadian population, and serve as a supplement to current methods of 
qualitative signal detection, helping advance the field of therapeutic risk management
 89 
 
 
90 
 
 
 
Chapter 5. Review of Risk Minimisation Interventions: Impact 
of regulatory guidances and drug regulation on risk 
minimisation interventions in drug safety: a systematic review 
5.1 Introduction to risk management and risk minimisation 
interventions 
5.1.1 Risk management 
Therapeutic Risk Management is a comprehensive and proactive application of scientifically-based 
methodologies and involves assessing, communicating, and minimising risk throughout a drug`s life 
cycle [10]. This field has received growing interest over the past decade as manufacturers and regulatory 
authorities increasingly seek to prevent the occurrence of adverse events (AEs) associated with 
pharmaceutical drug products. Risk minimisation interventions (RMIs) used in therapeutic risk 
management have existed for several decades; however it was not until June 2005 that both the Food 
and Drug Administration (FDA) and the European Medicines Agency (EMA) integrated into their 
regulations, guidelines concerning Risk Management. Since the publication of these regulatory 
guidelines an increasing number of risk minimisation/mitigation interventions have been implemented.  
5.1.2 Risk minimisation interventions 
According to the EMA, a Risk Minimisation system is: a set of activities used to reduce the probability 
of an adverse reaction occurring or its severity should it occur [9]. RMIs are tools which aim at reducing 
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the risk of AEs among patients using medications, while preserving their benefits throughout the 
drug’s life cycle [10]. They vary widely and can be specific to country, target audience, and stage of 
drug’s life cycle at which it is implemented such as: marketing authorisation; prescription of drug; 
dispensing of drug etc. Figure VI shows some RMIs and indicates stages at which they can be 
implemented. The next section contains descriptions of RMIs. 
Figure VI. Examples of RMIs based on main implementation stage of product life cycle  
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5.1.2.1 Restricted Distribution(RD) is an example of a set of restrictions and conditions implemented 
during the marketing authorisation process of a drug. RD is generally used in situations where 
restrictions are imposed on various aspects of access to the drug such as: who can prescribe the 
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medication; where the product can be dispensed or administered; or the amount of the product that can 
be dispensed to a patient at a time [133]  
 
5.1.2.2 Therapeutic Drug Monitoring(TDM) is a method used mainly with drugs having a narrow 
therapeutic range, where the patient’s drug level is monitored regularly in order to ensure that the level 
of the drug in the bloodstream does not reach levels more likely to cause AEs [134]. Many drugs also 
have monitoring systems of laboratory results that ensure that a marker for a particular AE is being 
kept within normal limits. Such is the case with clozapine, where white blood cell counts need to be 
monitored in patients on a regular basis while using the medication[133].  
 
5.1.2.3 Registries (R) are used where prescribers and/ or patients of a drug are required to be enrolled 
in a registry so that restrictions and conditions can be monitored or, screening for abnormal laboratory 
test results maintained. Such is the case with isotretinoin [135]   
 
5.1.2.4 The Black Triangle Scheme (BTS) is a process whereby newly marketed drugs in the UK are 
assigned an inverted black triangle to indicate that they are new drugs and that reporting of AEs to the 
regulatory authority is encouraged. This black triangle is present within various formularies where the 
drug is listed, compendiums, as well as on advertising material [136].  
 
5.1.2.5 Education Programs(EP): In some cases, there are interventions implemented by a Health 
Institution whereby patients and / or prescribers are provided education on a product, and its side 
effects, at the point of prescription or dispensing. This ideally results in swift action, and fewer AEs.  
 
5.1.2.6 Informed Consent(IC): This process can also occur at the point where the patient is prescribed 
and / dispensed a drug product. E.g. the sponsor could choose to develop a patient agreement where 
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before receiving the product, the patient formally acknowledges their understanding of a 
contraindication [137]  
 
5.1.2.7 Patient Alert Cards(PtAC): Although patient reports have been accepted by regulatory 
agencies in regions such as Canada (Health Canada) and the USA (FDA) for several years, it was not 
until October 2005 that non-Healthcare professionals nationwide in the UK were able to report AEs 
directly to their regulatory authority, MHRA (Medicines and Healthcare Products Regulatory Agency) 
through the Yellow Card System (established in 1964). Other interventions (patient alert cards) have 
been created based on this Yellow Card System [138]. 
 
5.1.2.8 Education Material(EM): Also at the point of dispensing a product, written information can be 
provided to the patient in order to better educate the patient on the potential AEs associated with the 
drug. An example of this would be Medication Guides implemented by the FDA in 1999. They are 
distributed to outpatients at the time of product dispensing to provide additional education on risks of 
product  use. [137] 
Dear Health Care Professional Letters (DHCP Letter) are drafted by the manufacturer and regulator of 
a product, and disseminated to Health Care Professionals to convey important drug safety information. 
agency[139,140]  
 
Public advisory warnings, and safety alerts also occur with marketed drugs and often follow the 
dissemination of a DHCP Letter. These warnings / alerts are generally placed on a regulatory agency’s 
website or disseminated to interested members of the public with drug safety newsletter subscriptions. 
The general media may also obtain the information and relay it to the general public[9, 10]. 
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Medication guides, Dear Health Care Professional Letters, Regulatory agency safety warnings / alerts, 
Public advisory warnings, and Medication guides are all categorised as Education material.  
 
5.1.2.9 Black Box Warnings(BBW) are issued exclusively by the FDA in the USA, with extremely 
serious adverse reactions, or if Education materials are found to be ineffective. A Black Box Warning 
is the sternest warning by the U.S. FDA that a medication can carry and still remain on the market It is 
named for the black border surrounding the text of the warning that will appear on the package insert, 
label and other literature describing the medication (e.g., magazine advertising). In addition, a 
medication guide will be mandated by the FDA for the product of interest [141]. 
 
5.1.2.10 Product Withdrawals(W): Failing all efforts to minimise the risk of an adverse reaction, a 
regulatory agency may require a company to withdraw a product from the market as a last resort. In 
this article, only product withdrawals that were regulatory agency-mandated were considered as risk 
minimisation interventions. In extremely rare situations, a product may be re-introduced to the market 
post-withdrawal, with a specific and stringent risk management plan in place. These are usually in the 
form of a Restricted Distribution or a Registry. 
 
5.1.3 Guidelines on Therapeutic Risk Management 
Although Regulatory Authorities have issued guidance documents for drug manufacturers concerning 
pharmacovigilance quite some time ago (1991 in Canada), guidelines concerning Therapeutic Risk 
Management have only recently been integrated into the regulatory process by both the USA, and 
within Europe in 2005[9,10]. Here the FDA for example outlines RMIs as processes or systems intended 
to minimize known risks with the goal of :  
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Communicating particular information regarding optimal product use 
Providing guidance on prescribing, dispensing, and/or using a product in the most appropriate 
situations or patient populations.  
Not all drug products are the subject of RMIs, as only those posing particular safety concern who have 
received an evaluation and affirmation of the need, shall have them applied.  
Also mandated in the guidances, are directives concerning the evaluation of the RMIs. These are 
provided in order to ensure that the resources invested in them are actually achieving the desired goals 
of continued benefits with minimized risks. Consequently each RMI should also have a plan for 
periodically evaluating its effectiveness after implementation [10] .  
 
Canada is aware of the benefits and importance of incorporating Risk Management Planning 
throughout the entire life cycle of a drug product, and in February of 2009 posted a notice concerning 
implementation of Risk Management Planning and their intent to follow International guidances on 
Pharmacovigilance processes [142]. These regulatory changes involve the implementation of well-
defined risk evaluation stakeholders in the management of potential and identified risks associated 
with medicines. 
 
Due to the novelty of this subject, many drug manufacturers, as well as regulators, are still uncertain of 
what Risk Minimisation Interventions are available for use; which are appropriate for the various 
products; and consequently what interventions should be incorporated in a particular product's Risk 
Management Plan. Furthermore, the use of databases for these analyses is a promising approach to 
observing whether RMIs were in fact efficient at reducing the risk associated with the drug products. 
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5.2 Review of risk minimization interventions 
5.2.1. Objectives and hypothesis 
The systematic review, was a review of the literature and regulatory websites that would characterise 
RMIs used by industry, regulators, and institutions. In this review, we set out to:  
(1) Identify the RMIs published in the literature, in the past and present on a global basis.  
(2) Identify the knowledge gaps in the methodology and databases used for implementation and 
evaluation of RMIs.  
(3) Determine whether the issuance of regulatory guidelines concerning risk management had an 
influence on the type and/ or frequency of risk minimisation interventions being used.  
Our main hypothesis of this review was that the introduction of guidelines on Therapeutic Risk 
Management would have increased the number and quality of RMIs being implemented in the field.  
5.2.2 Methods 
We collected the following information from Embase and MEDLINE literature sources, and regulatory 
websites concerning RMIs that were implemented and/ or published between January 2000 and 
December 2009:  
Nature of the RMI, target population, therapeutic area as per the Anatomical Therapeutic Chemical 
(ATC) classification system, AE(s) of special interest, regulatory region, and year of 
publication/posting. The characteristics of the RMIs were also compared across two five-year time 
periods: before the publication of the guidances (pre-guidances period: 2000-2004) and after the 
implementation (post-guidances period: 2005-2009). 
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5.2.3 Results 
A total of 119 unique interventions were identified in the literature (54 published in 2000 -2004, and 
65 published in 2005 - 2009). Interventions included Education Material (n=37, 31%), Black Box 
Warnings (n=22, 19%) and Therapeutic Drug Monitoring (n=11, 9%). The Website review produced a 
total of 1,112 interventions: 326 posted between 2000 and 2004, and 786 between 2005 and 2009. The 
main interventions observed were: Education Material (n=956, 86%), Black Box Warnings (n=45, 4%) 
and Withdrawals (n=39, 4%). For the literature review the pre and post guidances values of the three 
main RMI categories were as follows: Education material n=13 (24%) vs. n=24 (37%); Black box 
warning, n=6 (11%) vs. n=16 (25%); TDM n=6 (11%) vs. n=5(8%). For the website review, these 
numbers were the following: Education material n=279 (86%) vs. n=677 (86%); Black box warning, 
n=20(6%) vs. n=25 (3%); TDM n=5 (1.5%) vs. n=14 (1.8%). In the literature review, the distribution 
of RMI ATC between the two five-year time periods remained relatively consistent. A similar trend 
was seen with the RMI AE SOC category.  
 
5.2.4 Discussion 
Strengths and Weaknesses  
This comprehensive review is the first of its kind, and to our knowledge, there are no publications 
which specifically summarise RMIs over this length of time, or that attempt to analyse the effect of the 
publication of guidances. Secondly, this article is a systematic and aggregate analysis of various 
features of RMIs, and no other article has taken on such a comprehensive approach at detailing and 
analysing trends concerning the RMIs published within the literature. Finally, the global perspective 
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taken with this review permits its application world-wide as the information is relevant across regions 
and can be used by many countries for RMI information. 
 
Although the website review was quite detailed, the search is not completely exhaustive for a few 
reasons: (1) There were challenges concerning access to data. For example PMDA’s website, only 
provides information from 2004 onwards. This could potentially bias the results with regards to the 
post-guidances numbers of the website review (2) Only a selected number of the regulatory authorties’ 
websites were reviewed. Which could exclude  RMIs specific to the individual EU countries websites  
not posted in the English language were also excluded which could result in the exclusion of important 
RMIs, however the fact that the EMA site was also searched expectantly included information for 
many of the non-English speaking EU countries; Particular RMI classification, and categorizing could 
also lead to discrepancies concerning the results of this review versus other reviews that may be 
conducted in the future.  
 
The fact that the USA and EU are the two regions that implemented the guidances in itself would 
imply that they most likely would increase their RMIs post-guidances. In fact, both regions created 
dedicated websites for Risk Minimisation Activities (Medication Guides and approved REMS in the 
USA; and approve Risk Management Plans in the EU). This was indeed the case with the USA for 
both the literature and website reviews, however the EU only reflected an increase in their website 
review RMIs. The USA also has a unique RMI step in the black box warning which other countries do 
not have. This could be adding an extra RMI to the life cycle of a drug which would not exist in other 
countries. The large proportional increase of RMIs observed in the USA region in the literature review 
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but not the website review could be largely due to the fact that there are many more journals available 
in the USA as opposed to the rest of the world and consequently a publication bias. Thus, a literature 
review provides a larger source of US information as opposed to Canadian or European information.  
A specific look at RMIs implemented in Canada shows that there is a large deficiency with regards to 
literature sources. This could in part be explained by publication bias, however there also seems to be a 
lack of research concerning this aspect of risk management by Canadian researchers. This suggests 
great potential for future research in this area. During the pre-guidances period of the website review, 
Canada displays a large role in the proportion of global RMIs, and is in fact the region with the 
majority of RMIs during that time period, the USA following closely behind. This changes drastically 
during the post-guidances period: although the number of RMIs that Canada produces is approximately 
the same, the increase in RMIs by other regions, offsets Canada’s proportion. Again, the fact that the 
EU and USA increased their alertness concerning RMIs and risk management plans is believed to be 
the major reason for this [9,10]. Although Health Canada has recognized the importance of risk 
management planning, it is still apparent that they have not been able to implement these activities as 
favourably as would be ideal.  
Risk minimisation gaps identified 
To mirror the requirements of the FDA’s Pediatric Research Equity Act (PREA) [143], which sets out 
requirements concerning pediatric assessments for drug applications/approvals: post-marketing 
activities for products with particular safety risk being used in children, should also have RMIs 
targeting children, which should be active throughout the life cycle of the drug. Within the risk 
management guidances both the FDA and the EMA encourage the development of additional risk 
minimisation activities designed to address safety concerns in instances where particular populations 
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may be at risk. The FDA and EMA outline that  such target populations include among others: 
children, the elderly, and pregnant or lactating women. It is believed that for this reason we see some 
RMIs targeting children and pregnant women. However, this number is still very low considering the 
guidances. Furthermore, the extremely low number of RMIs targeting the elderly is particularly 
concerning, thus highlighting an important gap in the current conduct of RMIs. 
Effect of regulatory guidances on RMI distribution 
This systematic review implies that the guidances on therapeutic risk management did lead to an 
important increase in the number of RMIs implemented within the USA and published in the literature. 
There was also an important increase among website review RMIS of the regions of the USA, EU and 
Japan. The regulations did not appear have an effect on the distribution of RMI types across the pre-
and post-guidances periods for either the literature review or the website review. Furthermore, the 
literature review did not show variation in the distribution of the ATC Classifications, or the AE SOC 
classes of the target drugs for the RMIs in the pre-vs. post-guidances period. Although this is a work in 
progress, it appears that for the first five years post issuance, the guidances have only had an effect on 
increasing overall numbers of RMIs for only some of the regions.  
 
Future Perspectives 
The immediate next step of this analysis is actually a parallel ongoing study to identify the methods 
used to assess the effectiveness of these RMIs as is required by the guidances on Risk Management. 
Determining which are the most effective of the RMI’s based on the results of observed studies, and 
which are the most convenient methods to be used with the various types of RMIs. Future potential 
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studies could involve a detailed account of the methodological challenges faced by those who wish to 
assess the RMI effectiveness. What aspects to account for during the analyses, identifying gaps in the 
methods, and proposing means of overcoming them. Finally, this is an analysis with potential for 
longevity as the pharmaceutical, healthcare, and regulatory industries overall could also  benefit from 
the continued reviews of RMIs going forward.  
5.2.5 Conclusions 
In conclusion, the website review found that the guidances on therapeutic risk management did lead to 
an important increase in the number of RMIs implemented within the USA, EU and Japan. However 
the literature review only showed an increase within the USA. The discrepancy with the literature 
review vs. the website review demonstrates the existence of publication bias. Although interventions 
found in the literature are fewer in number, more innovative interventions and variety can be obtained 
from these sources. Interventions specific to drugs, therapeutic areas or populations are rare. More 
RMIs specific to drugs, therapeutic areas and most importantly: specific populations, need to be 
conducted in order to better comply with the risk management guidances. 
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5.3 RMI Review Article: Impact of regulatory guidances and drug 
regulation on risk minimisation interventions in drug safety: a 
systematic review 
Contributions of co-authors to article: 
As Principal researcher of this review, Lenhangmbong Nkeng (LN) had major contributions to the 
study: She proposed the idea of a review of risk management processes; designed and coordinated the 
review strategy; performed the MEDLINE review portion of the literature review, and the entire 
website review; completed initial extraction of data, interpreted the results; and drafted the manuscript.  
Anne-Marie Cloutier assisted with the strategy for literature and website searches completed review of 
the EMBASE database for the literature review, peer-reviewed a portion of the sources which were 
excluded by LN, proof-read the drafted article and provided feedback on the manuscript.  
Camille Craig peer-reviewed the remainder of the sources which were excluded by LN, proof-read the 
drafted article and provided feedback on the manuscript 
Dr. Jacques Lelorier reviewed the article and provided feedback on results, interpretation, and 
discussion of the manuscript.  
Dr. Yola Moride proposed the focus of the review to the subject of “risk minimisation interventions”, 
provided guidance on the research strategy, reviewed the article, and provided comments and 
additional ideas for inclusion in the manuscript.  
 
103 
 
 
 
  
Impact of regulatory guidances and drug regulation on risk minimisation interventions in drug safety: a 
systematic review 
 
Lenhangmbong Nkeng1,2, Anne-Marie Cloutier1,2, Camille Craig1,2, Jacques Lelorier2, Yola Moride1,2 
 
Affiliations:  
1. Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada 
2. Research Center, University of Montreal Hospital Center (CRCHUM), Montreal, Quebec, Canada 
 
Running Title:  
 
Impact of regulatory guidances on RMIs 
 
Word Count:  
3177 
 
Key Words: Risk minimisation, therapeutic risk management, drug safety. 
 
 
104 
 
 
 
 
Acknowledgements / Conflicts of Interest  
This project was funded through a grant by the Réseau Québecois de Recherches sur l’Usage des 
Médicament (RQRUM).   Lenhangmbong Nkeng has also received a studentship from the Canadian 
Patient Safety Institute for the conduct of this project, and is also the recipient of the Richard J. 
Schmeelk Fellowship Award and the Golden Key International Honour Society’s Biomedical Science 
Award. 
 
 
 
There are no conflicts of interest to declare for any of the authors. 
 
 
Corresponding author:  
Yola Moride PhD FISPE 
Associate Professor 
Faculty of Pharmacy 
Université de Montréal 
105 
 
 
 
Table of Contents  
ABSTRACT ...............................................................................................................108 
Background.................................................................................................................111 
Objectives ...................................................................................................................112 
Methods ......................................................................................................................113 
Search strategy .........................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  113 
Eligibility criteria .....................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  114 
Classification of RMI types ......................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  
............................................................................................................................................ 116 
Comparison of RMIs in the period before and after the regulatory guidances........................  
............................................................................................................................................ 116 
Results.........................................................................................................................116 
Literature search ......................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  116 
Website search..........................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  119 
Literature Review versus Website Review ................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  120 
Discussion...................................................................................................................120 
Conclusion ..................................................................................................................123 
REFERENCES ...........................................................................................................124 
TABLES 
Table I. Literature Review Distribution of RMIs by Country across Pre and Post-guidance Periods140 
Table II: Literature Review: Overall Distribution of RMI Type..............................................   
..................................................................................................................................................  142 
Table III. Literature Review: RMI Distribution per RMI Target Population...........................  
............................................................................................................................................ 143 
Table  IV. Website Review: Distribution of RMIs by Region .................................................   
..................................................................................................................................................  144 
Table V: Website Review: Overall Distribution of RMI Type ................................................   
..................................................................................................................................................  146 
FIGURES 
Figure I. Literature Review: Source Identification Flow Chart................................................   
............................................................................................................................................ 147 
106 
 
 
 
Figure II. Literature Review: Distribution of RMIs by Drug Anatomical Therapeutic Chemical (ATC) 
Classification ............................................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................   
............................................................................................................................................ 149 
Figure III. Literature Review: Distribution of RMIs by Adverse Event System Organ Class (AE SOC, 
MedDRA Terminology) ...........................................................................................................   
..................................................................................................................................................   
..................................................................................................................................................  
............................................................................................................................................ 150 
Figure IV. Website Review: RMI Identification Flow Chart ...................................................   
..................................................................................................................................................  151 
APPENDICES 
Appendix I – Literature Review Data Extraction Table...........................................................   
..................................................................................................................................................  151 
107 
 
 
 
Figure Captions 
Country Codes as per ISO 3166: 
USA=United States of America; GBR=United Kingdom; DEU=Germany; SWE=Sweden; FRA=France; 
CHE=Switzerland; DNK=Denmark; NLD=Netherlands; ESP=Spain; AUS=Australia; CAN=Canada; 
SGP=Singapore; JPN = Japan 
 
* EU = European Union member states 
INTL = International 
UNK = Unknown 
 
Regulatory Agency Accronyms 
TGA = Therapeutic Goods Administration; PMDA = Pharmaceutical and Medical Devices Agency; MHRA = 
Medicines and Healthcare Products Regulatory Agency; EMA = European Medicines Agency; FDA = Food and 
Drugs Administration; HC = Health Canada 
  
RMI Accronyms 
EM =Education material; BBW=Black box warning; TDM=Therapeutic Drug Monitoring; EP=Education 
program; RD=Restricted distribution; IC=Informed consent; W=Withdrawal, R=Registry; PtAC=Patient Alert 
Card; PtR - Patient registry PG=Pharmacogenetics; BTS=Black Triangle Scheme. 
 
Drug ATC: 
NS = Nervous System; A = Alimentary tract and metabolism; B = Blood and blood forming organs; L = 
Antineoplastic and immunomodulating agents; 
D = Dermatologicals; C=Cardiovascular system 
Comb = Combination 
 
AE SOC:  
CV=Cardiovascular disorder; N=Neoplasms, benign, malignant and unspecified; Psy=Psychiatric disorders; 
Con= Congenital, familial, and genetic disorders; Hep=Hepatobiliary disorders; Blood = Blood and lymphatic 
system disorders 
 
Div= Diverse (combination of AE SOC) 
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Impact of regulatory guidances and drug regulation on risk minimisation interventions in drug safety: a 
systematic review 
L.Nkeng, A-M. Cloutier, C. Craig, J. Lelorier, Y.Moride 
ABSTRACT 
 
Background: Therapeutic risk management has received growing interest in recent years particularly 
since the publication of regulatory guidances in 2005 and 2006, paralleled with a change in drug 
regulation. The characteristics of risk minimisation interventions (RMIs) that have been implemented 
or approved remain inadequately explored.   
 
Objective:  To review RMIs published in the literature or posted on regulatory agency websites over 
the past 10 years, and to assess whether the publication of regulatory guidances on risk management is 
associated with changes in the number and types of interventions. 
 
Methods:  
Sources were searched for RMIs published/posted between January 1, 2000 and December 31, 2009. 
For the literature search, MEDLINE and EMBASE databases were used using key words related to 
Drug Safety (i.e. “Drug Toxicity”) AND the individual risk minimisation intervention names. The 
website review involved searches of major regulatory authority websites such as:  European Medicines 
Agency, USA Food and Drug Administration, Canada’s Health Canada, the United Kingdom’s 
Medicines and Healthcare Products Regulatory Agency, Japan’s Pharmaceutical and Medical Devices 
Agency, and Australia’s Therapeutic Goods Administration. The following eligibility criteria were 
applied for inclusion in the review: Published/posted between 2000 and 2009 inclusive; involving drug 
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products; use in humans; involving risk minimisation interventions, or tools used to increase the 
reporting of adverse events. Natural healthcare products, devices, diagnostic chemicals, pregnancy 
registries without follow-up, medication errors, and products not used as therapy for illness, were not 
retained. For each source, the following characteristics were extracted: nature of the intervention, 
target population, therapeutic area, adverse event(s) of special interest, country/ regulatory agency, and 
year of publication.  
 
Results: A total of 119 unique interventions were identified in the literature (54 published in 2000 -
2004, and 65 published in 2005 - 2009). Interventions included Education Material (n=37, 31%), Black 
Box Warnings (n=22, 19%) and Therapeutic Drug Monitoring (n=11, 9%). The Website review 
produced a total of 1,112 interventions: 326 posted between 2000 and 2004, and 786 between 2005 and 
2009. The main interventions observed were: Education Material (n=956, 86%), Black Box Warnings 
(n=45, 4%) and Withdrawals (n=39, 4%). 
 
Limitations:  
Additional regulatory resource websites were available in the post-guidances periods that were not 
available in the earlier years of the pre-guidances periods, and may bias the post-guidances results. 
Also not all global regulatory websites were searched. Finally only English language websites were 
searched, limiting the variation of RMIs observed. Classification and categorizing for this particular 
review may not be consistent with future reviews by other researchers.  
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Conclusion: The USA is the sole region with a substantial increase in published risk minimisation 
interventions during the post-guidances period while EU, Japan, and USA all indicated an increase in 
the number of interventions on their websites.   
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Background 
Risk minimisation interventions (RMIs) are tools that aim at enhancing the benefit-risk of medicines 
beyond product labelling[1].  In the broad spectrum of RMIs, one may find educational interventions, 
on one end, and more stringent programs, such as Restricted distribution, on the other end. Among the 
most well-known education interventions are Dear Health Care Professional (DHCP) Letters issued by 
drug manufacturers or regulatory agencies,[3] Black Box Warnings, Medication guides, Regulatory 
agency safety warnings / alerts, and Public advisory warnings.  Therapeutic Drug Monitoring (TDM) is 
another type of RMI used mainly for drugs that have a narrow therapeutic range.  The patient’s blood 
level of the drug is monitored in order to ensure that it does not reach levels more likely to cause 
adverse events (AEs)[4]. Registries are also used where prescribers and/ or patients are enrolled so that 
restrictions can be monitored or, screening for abnormal test results maintained.  RMIs may target 
prescribers (e.g. education and training) or patients (patient alert cards, informed consent), and can be 
implemented by different stakeholders such as drug manufacturers, regulatory authorities, or a 
healthcare institution.   
 
Although RMIs have been in use for several decades, it was not until 2005-2006 that both the FDA and 
the EMA introduced their guidances on therapeutic risk management. The guidances define a risk 
management plan (RMP), conditions of requirement, and, risk minimisation activities that may be 
required in instances of specific safety concerns[1,2]. 
Since then, the field of therapeutic risk management has received growing interest. Due to the novelty 
of the subject, however, the characteristics of the various RMIs that have been implemented remain 
poorly explored.  Although reviews have been published in the literature [5,6,7]  few have aimed at 
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comprehensively examining trends of RMIs, or the effect of the publication of risk management 
guidances on their frequency and type. Leiderman [5]performed a review of selected examples of risk 
management programs and RMIs implemented prior to the introduction of guidelines. However the 
review was not comprehensive or systematic, nor was there the attempt or the ability to examine the 
effect of the regulatory guidances on the characteristics of RMIs.  Similarly, the review by Hirst et al 
[7]summarized some of the RMIs used between 1997 and 2005, with a main focus on product 
withdrawals during that time period (n=22).  In the Wise et al. review[6], the authors’ focus was the 
overall field of pharmacovigilance, and tools used for such. Consequently, the review was general and 
not specifically geared towards risk minimisation. 
 
Objectives 
Our study aimed at characterizing RMIs implemented during the five years before, and the five years 
after, the introduction of the regulatory guidances on risk management.  This was achieved through the 
conduct of a systematic review with the following specific objectives: (1) To identify the RMIs 
published in the literature or posted on selected regulatory agencies websites; (2) To describe the RMIs 
with respect to the target population, drug class, safety issue(s), nature of the intervention; (3) To 
determine whether the issuance of regulatory guidelines on risk management had an influence on the 
type and/ or frequency of RMIs being implemented. 
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Methods 
Search strategy 
The review was conducted through the literature as well as agency websites, and followed the 
PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies [8].  The 
literature search was conducted using MEDLINE and Embase databases. Medical Subject Heading 
(MeSH) terms were used where possible. However, few were located through individual RMI names. 
In addition, terminology varied slightly for the MEDLINE and Embase databases. Consequently, key 
words related to the following subjects were used: “Drug toxicity” (MeSH term) AND “Patient 
education” (MeSH term), OR“HCP education”,  OR“Prescriber education”, OR“Patient alert card”, 
OR“Patient registry”, OR“Medication guide”, OR“Drug legislation” (MeSH term), OR“Informed 
consent” (MeSH term), OR“Restricted distribution”, OR“Physician authorisation”, OR“Drug 
monitoring” (MeSH term), OR“Dear Health Care Professional Letter”, OR“Dear Doctor Letter”, 
OR“Black Box Warning”. All articles, including review articles, were scanned for potential relevant 
references (snowballing).  The Embase and MEDLINE initial reviews were performed by two separate 
researchers. The MEDLINE review was completed on January 22, 2010 by LN and the Embase review 
on January 29, 2010 by AMC. The resulting articles were scanned, and snowballing was performed by 
one individual (LN). The excluded articles were then scanned by one of two secondary individuals 
(AMC and CC) to ensure that that any qualifiable RMIs remained. Any disagreements were resolved 
with a majority (two out of three) decision (LN, AMC, and CC). 
The website review involved an initial search by one researcher (LN) of the following agency sites 
with the initial data collection process for each website completed on the dates indicated:  Health 
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Canada - safety alerts / advisory warnings (http://www.hc-sc.gc.ca/; June 16, 2010); EMA (Europe 
approved RMPs  
http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&murl=menu
s/medicines/medicines.jsp&mid=WC0b01ac058001d124; August 6, 2010); FDA (USA approved Risk 
Evaluation and Mitigation Strategies (REMS), and Medication Guides); FDA safety alerts / advisory 
warnings(http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalPro
ducts/; July 9, 2010); Therapeutic Goods Administration (TGA)  (Australia) advisories (October 13, 
2010); Medicines and Healthcare Products Regulatory Agency (MHRA) (UK) safety alerts / advisory 
warnings 
(http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessag
esformedicines/index.htm; September 20, 2010); Pharmaceutical and Medical Devices Agency 
(PMDA) (Japan) Pharmaceuticals Safety Information 
(http://www.pmda.go.jp/english/service/precautions.html; September 30, 2010). The excluded 
warnings / alerts were then scanned by one of two secondary individuals (AMC and CC) to ensure that 
the first had not excluded any important RMIs. Any disagreements were decided with a majority (two 
out of three) decision.  
 
Eligibility criteria 
 
To be included in the review, RMIs needed to have been published or posted between 1st January 2000 
and 31st December 2009, involved drug products, use in humans, RMIs, or tools used to increase the 
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reporting of AEs. The RMI could be sponsored by any organisation (e.g. regulatory authority, 
commercial organization, or institution etc.) Natural healthcare products, devices, diagnostic 
chemicals, pregnancy registries without follow-up, medication errors, and products not used as therapy 
for illness, were not retained.  
 
For each RMI, the following characteristics were extracted and recorded into a harmonised information 
matrix: nature of the RMI, target population, therapeutic area as per the Anatomical Therapeutic 
Chemical (ATC) classification system, AE(s) of special interest, regulatory region, and year of 
publication/posting. The characteristics of the RMIs were also compared across two five-year time 
periods: before the publication of the guidances (pre-guidances period: 2000-2004) and after the 
implementation (post-guidances period: 2005-2009).  
 
Some RMIs involve a combination of different intervention types.  For the review, if more than one 
RMI for a particular safety concern was published in a given year, they were counted as one RMI. 
Furthermore, only the most stringent component (e.g. Patient alert card or Restricted distribution), was 
retained for the synthesis of information. Regions for categorizing RMIs were based on regulatory 
jurisdictions (e.g. EU, USA, Canada, Japan, Australia). The region recorded corresponded to the site of 
the RMIs execution. If a source described an RMI as present in more than one region, it was 
considered an “international RMI”.  
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Classification of RMI types 
Classifying the RMI types was completed in the following manner: Education materials comprised 
Dear Healthcare Professional Letters, Regulatory agency safety warnings / alerts, Public advisory 
warnings, and Medication guides. Patient alert cards included both the UK Medicines and Healthcare 
Products Regulatory Agency (MHRA) yellow card reporting process, and patient alert cards 
themselves. Restricted Distribution incorporated restricted/controlled prescription and distribution; and 
Therapeutic Drug Monitoring (TDM) included both laboratory results’ monitoring systems (to ensure 
that a marker for a certain AE is being kept within normal limits), as well as therapeutic drug 
monitoring of the drug concentration itself. Withdrawals included voluntary withdrawals, regulatory 
agency-mandated withdrawals, as well as suspensions. 
Comparison of RMIs in the period before and after the regulatory guidances 
The proportion of RMIs published before and after the regulatory guidances were compared through 
chi-square tests or Fisher’s exact tests in instances of low numbers.   
 
Results 
Literature search 
Figure I displays the results of the literature search. A total of 2,103 articles were initially identified 
from the bibliographic databases. Of these, 135 met the inclusion criteria, and another 34 sources were 
obtained from snowballing yielding 169 sources.  After applying the inclusion / exclusion criteria 
listed above, a total of 119 distinct interventions were retained for the review.  Since some 
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interventions were associated with more than one publication, only one source was retained.  
Information extracted into the harmonized matrix is found in the Literature Review Data Extraction 
Table (Appendix I). 
 
In the pre-guidances period, 54 (45%) RMIs were published, while in the post-guidances period, there 
were 65 (55%).  This increase was, however, not statistically significant (p-value = 0.313).  
 
Table I displays the geographical distribution of publications. The majority of interventions were 
implemented in the USA (n=65, 55%) and the EU (n=22, 18%). Other regions included Australia (n=3, 
3%), Canada (n=2, 2%) and, Singapore (n=1, 1%). There were nine sources (8%) that involved an RMI 
that was simultaneously implemented in more than one region (i.e. International). There were 17 RMIs 
(14%) for which the region of implementation was unspecified and therefore unknown.  
Across the various regions, there were 11 different publications (each discussing an RMI), that 
together described a total of five duplicated RMIs implemented in different regions, i.e. RMIs of the 
same type, and same safety issue, however implemented in varying regions). 
According to Table II, the three most frequent RMIs published in the literature were: Education 
material (n=37, 31%), Black box warning (n=22, 19%), Therapeutic Drug Monitoring (TDM) (n=11, 
9%). These rankings were relatively consistent across pre- and post-guidances periods: Education 
material n=13 (24%) vs. n=24 (37%); Black box warning, n=6(11%) vs. n=16 (25%); TDM n=6 (11%) 
vs. n=5(8%); Education programs n=2 (4%) vs. n=7 (11%) for the pre- and post-guidances periods 
respectively.  
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There were 12 RMIs that were in fact a combination of different RMI types: Five combinations 
involved Restricted distribution in combination with either Registries alone or along with Education 
materials or Education programs.  Four were in the pre-guidances period; Three combinations involved 
Informed Consent (2 pre-, and 1 post- guidances) in combination with either Education material, or 
TDM; Two groupings of TDMs were observed, one with an Education material, and the other with an 
Education program. Both were implemented in the pre-guidances period; One Black box warning was 
combined with an Education material in the post-guidances period, and one Patient alert card with an 
Education material also during the post-guidances period.   
The distribution of the RMIs by ATC class, and subdivided into pre-guidances (2000-2004) and post-
guidances (2005-2009) is displayed in Figure II. Most RMIs involved drugs of the nervous system 
(n=40, 34%), followed by the alimentary tract and metabolism (n=17, 14%), and finally blood and 
blood forming organs (n=9, 8%). The distribution of RMI ATC between the two five-year time periods 
remained relatively consistent. The System Organ Classes (SOC) of AEs of interest (as per Medical 
Dictionary for Regulatory Activities, MedDRA) are reported in Figure III,  where the majority was 
simultaneously geared towards a combination of AE SOCs (n=45, 38%). Again the distribution of RMI 
AE SOC remained fairly consistent across the two five-year time periods. 
Overall, 70% of RMIs published over the 10-year period applied to the general population (refer to 
Table III).  The remaining 25 were specific to a sub-population, with eleven being women-specific and 
geared largely towards avoiding pregnancy and/or congenital malformations and teratogenic effects 
(n=6). These were mainly with medications such as isotretinoin and thalidomide. Other RMIs were 
specific to the paediatric population (n=10) (mostly for Nervous system drugs, n=7), and for the 
elderly (n=3, all involving Nervous system drugs).  
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Website search 
Figure IV displays the results of the website review search. Altogether, 1,112 interventions were 
identified through the website review. In Table IV it is seen that the overall number of RMIs more than 
doubled, from 326 in the pre-guidances period to 786 during the post-guidances period. As shown in 
Table V, the most frequent RMIs observed from the website review were as follows: Education 
materials (n=956, 86%), Black box warnings (n=45, 4%), Withdrawals (n=39; 4%). This distribution 
was also generally consistent across the different regions. The overall regional distribution was as 
follows:  USA n=538 (48%); Canada: n=258 (23%); EU: n=183 (17%); Japan: n=115 (10%) and 
Australia: n=18 (2%).  Changes in regional distribution across periods are shown in Table IV. 
Combination RMIs (n=41) were exclusive to three regions: EU (n=19), USA (n=12) and Canada 
(n=10). Among the combination RMIs, 9 involved Patient alert cards combined with Education 
programs and/or Education material, one of which was combined with TDM; 11 Withdrawals were 
combined mainly with Education materials, one including a TDM; 5 RMIs involved Restricted 
distribution in combination with Education programs and/or Education materials; 5 involved groupings 
of Black box warnings with Education materials; 5 TDM programs were combined primarily with 
Education materials, one including an Informed consent; 2 Registries were combined with Restricted 
distribution and/or Education material and; 1 involved a combination of informed consent and 
Education material. There was 1 informed consent that included a patient agreement, and 2 Education 
progam-Education material combinations. 
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Literature Review versus Website Review 
The review revealed major differences between the results of the Literature Search and the Website 
Review. In Table I it is seen that in the literature search, the USA was the sole region with a substantial 
increase in published RMIs during the post-guidances period, n=25 (46%) and n=40 (62%), 
respectively for pre- and post-guidances period. However, from Table IV the website review shows 
that many regions increased their RMIs during the post-guidances period, namely USA n=127 (39%) 
and n=411 (52%), EU n=37 (11%) and n=146 (19%), and Japan n=24 (7%) and n=91 (12%) 
respectively for the pre-and post-guidances periods. The two most common RMIs used in both reviews 
were similar: Education materials and Black box warnings. The percentage of Education materials 
observed in the website review (n=956, 86%) was greater than those of the literature review (n=37, 
31%), offsetting the percentages of all other RMIs.  Such differences in numbers and characteristics 
according to data source suggest the presence of a publication bias. 
 
Discussion 
From the literature review alone, there was no significant difference in the overall number of RMIs 
published in the literature during pre-and post-guidances periods. However, the USA had a large 
increase between these time periods in their numbers. This could in part be due to the fact that the USA 
is one of the two regions that implemented the guidances, and possibly both the FDA and US drug 
manufacturers became more active in this regard. In addition, the USA took additional measures to 
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launch a web page dedicated to the posting of approved REMS as well as medication guides. This 
could in part be a reason for their apparent increased number as other regions, such as Canada, 
continue to display only safety alerts, and do not have additional web pages for approved RMPs that 
may be implemented. Finally, the USA has a unique RMI step in the black box warning which other 
countries do not have. This could be adding an extra RMI to the life cycle of a drug which would not 
exist in other countries. The website review results differ: There is a clear increase in RMIs during the 
post-guidances period, and the increase of RMIs is reflected in two additional regions: EU and Japan. 
The large proportional increase of RMIs observed in the USA region in the literature review but not 
the website review could be largely due to the fact that there are many more journals available in the 
USA as opposed to the rest of the world. Thus, a literature review provides a larger source of US 
information as opposed to Canadian or European information. The literature review shows that 
population-specific RMIs mainly involve two sub-populations: Women and paediatrics. The RMI 
types targeting women do appear to be population-specific, displaying a predominance of Education 
programs. Within the guidances both the FDA and the EMA encourage the development of additional 
risk minimisation activities designed to address safety concerns in target populations versus those 
populations that have been included in clinical trials. Such target populations include among others: 
children, the elderly, and pregnant or lactating women. It is believed that for this reason we see some 
RMIs targeting children and pregnant women. However, this number is still very low considering the 
guidances. Furthermore, the extremely low number of RMIs targeting the elderly is particularly 
concerning, thus highlighting an important gap in the current conduct of RMIs.  
This comprehensive review is the first of its kind, and to our knowledge, there are no publications 
which specifically summarise RMIs over this length of time, or that attempt to analyse the effect of the 
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publication of guidances. Secondly, this article is a systematic and aggregate analysis of various 
features of RMIs, and no other article has taken on such a comprehensive approach at detailing and 
analysing trends concerning the RMIs published within the literature. Finally, the global perspective 
taken with this review permits its application world-wide as the information is relevant across regions 
and can be used by many countries for RMI information. 
 
Although the website review was quite detailed, the search is not completely exhaustive for a few 
reasons: (1) There were challenges concerning access to data. For example, the Japanese Regulatory 
Authority, PMDA, only provides information on its website as of 2004 onwards. This could potentially 
bias the results with regards to the post-guidances numbers of the website review as the site could be 
missing some RMIs that the PMDA may have implemented before 2004; (2) Only a selected number 
of the regulatory authorties’ websites were reviewed. For example, some RMIs specific to the 
individual EU country regulators could be missing from this review. This review also excludes 
websites that were not posted in the English language. All of these facts could result in the exclusion of 
important RMIs, however the fact that the EMA site was also searched expectantly included 
information for many of the non-English speaking EU countries; (3) It is important to note that since 
the initial search of the Health Canada Website (June 16, 2010), safety alerts originating prior to 2004 
are no longer available on the site itself and need to be requested from Health Canada directly.  For the 
review, if more than one RMI in a particular region, for a particular safety concern, was published in a 
given year, they were counted as one RMI. Furthermore, only the most stringent type (e.g. Patient alert 
card or Restricted distribution), was retained for the synthesis of information. This assumption could 
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also lead to discrepancies concerning the results of this review versus other reviews that may be 
conducted in the future.  
 
Conclusion 
This systematic review implies that the guidances on therapeutic risk management did lead to an 
important increase in the number of RMIs implemented within the USA, EU and Japan. However the 
discrepancy with the literature review demonstrates the existence of publication bias. From the 
literature review, it is clear that many RMIs are simultaneously geared towards heterogeneous AEs, 
drug classes, and patient sub-populations. More RMIs would need to be published in order to better 
assess trends in RMI characteristics. Although interventions found in the literature are fewer in 
number, more innovative interventions and variety can be obtained from these sources than on the 
website review. 
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Table I. Literature Review Distribution of RMIs by Country across Pre and 
Post-guidance Periods 
Country 
 
N(%) 
2000-2004 
 
N(%) 
2005-2009 
 
TOTAL N (%) 
 
Chi square p-
value (pre vs. 
post guidances) 
USA 25 (46.3) 40(61.5) 65(54.6) 
 
0.09i 
EU 10(18.5) 12(18.5) 22(18.5) 
 
0.99   
INTL 3(5.6) 6(9.2) 9(7.6) 
 
 0.51*i 
AUS 3(5.6) 0(0.0) 3(2.5) 
 
 0.09*d 
CAN 2(3.7) 0(0.0) 2(1.7) 
 
 0.20*d 
SGP 1(1.8) 0(0.0) 1(0.8) 
 
 0.45*d 
UNK 10(18.5) 7(10.8) 17(14.3) 
 
0.23d 
TOTAL 54(100.0) 65(100.0) 119(100.0)  
 
Country Codes as per ISO 3166: 
141 
 
 
 
USA=United States of America; AUS=Australia; CAN=Canada; SGP=Singapore 
 
European Union member states 
INTL =International (more than one region) 
UNK = Unknown / unspecified 
 
* Fisher Test  
i = Increased proportion in post-guidances period 
d = Decreased proportion in post-guidances period
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Table II: Literature Review: Overall Distribution of RMI Type 
RMI 
 
N (% of Education 
Material 
 
% of Total 
RMIs 
 
Education Material 37(100.0) 31.0 
 Patient / Public safety warning 17(45.9) 14.3 
 HCP safety warning 10(27.0) 8.4 
 DHCP Letter 6(16.2) 5.0 
 Medication Guide 3(8.1) 2.5 
 
Warning  with unspecified target 
audience 1(2.7) 0.8 
Black box warning 22 18.5 
TDM 11 9.2 
Education program 9 7.6 
Restricted distribution 8 6.7 
Informed consent 6 5.0 
Withdrawals 8 6.7 
Patient registry 4 3.4 
Pregnancy registry 1 0.8 
Pharmacogenetics 2 1.7 
Black Triangle Symbol 3 2.5 
Patient alert card 1 0.8 
Other 7 6.0 
TOTAL 119 100.0 
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Table III. Literature Review: RMI Distribution per RMI Target Population 
Population 
2000-2004 
N (% of Pre-
guidances 
RMIs ) 
 
2005-2009 
N (% of Post-
guidances 
RMIs) 
 
TOTAL  
N (% of Total 
RMIs) 
 
Chi square p-
value (pre vs. 
post guidances) 
Pediatric 4(7.4) 6(9.2) 10(8.4) 
 
1.00*i 
Adults 0(0.0) 1(1.5) 1(0.8) 
 
1.00*i 
Women 7(13.0) 4(6.2) 11(9.2) 
 
0.22*d 
Men 0(0.0) 1(1.5) 1(0.8) 
 
1.00*i 
Geriatric 1(1.8) 2(3.1) 3(2.5) 
 
1.00*i 
All 38(70.4) 49(75.4) 87(73.1.0) 
 
0.54i 
Unknown 4(7.4) 2(3.1) 6(5.0) 
 
0.41* d 
TOTAL 54(100.0) 65(100.0) 119(100.0)  
 
* Fisher Test 
i = Increased proportion in post-guidances period 
d = Decreased proportion in post-guidances period
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Table  IV. Website Review: Distribution of RMIs by Region 
Region 
2000-2004 
N (%) 
2005-2009 
N (%) TOTAL 
Chi square p-value 
(pre vs. post 
guidances) 
 
TGA (AUS) 7 (2.1) 11 (1.4) 18 (1.6) 0.38d 
 
PMDA (JPN) 24 (7.4) 91 (11.6) 115 (10.3) 0.04 i 
 
EU (MHRA + EMA) 37 (11.3) 146 (18.6) 183 (16.5) 0.003 i 
 
Health Canada (CAN)   131 (40.2)  127 (16.1) 258 (23.2) <0.001d 
 
FDA (USA) 127 (39.0) 411 (52.3) 538 (48.4) <0.001 i 
 
TOTAL 326 (100.0) 786 (100.0) 1112 (100.0) 
 
 
 
TGA = Therapeutic Goods Administration; AUS = Australia; PMDA = Pharmaceutical and Medical 
Devices Agency; JPN = Japan; MHRA = Medicines and Healthcare Products Regulatory Agency; 
145 
 
 
 
GBR = United Kingdom; EU = European Union; EMA = European Medicines Agency; CAN = 
Canada; FDA = Food and Drugs Administration; USA = United States of America 
 
i = Increased proportion in post-guidances period 
d = Decreased proportion in post-guidances period
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Table V: Website Review: Overall Distribution of RMI Type 
 
RMI Type 
 
N (%) 
 
Education Material 956 (86.0) 
Black box warning 45 (4.0) 
Withdrawals 39 (3.5) 
Therapeutic Drug Monitoring 19 (1.7) 
Restricted distribution 16(1.4) 
Registry 14 (1.3) 
Patient Alert Card 9 (0.8) 
Education program 12 (1.1) 
Informed Consent 2 (0.2) 
TOTAL 1112 (100.0) 
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Figure I. Literature Review: Source Identification Flow Chart 
169 sources reviewed in- depth
3110 titles identified in MEDLINE & Embase
(MEDLINE n=2112; Embase n=998)
2103 abstracts 
reviewed
1007 duplicate articles excluded
1968 abstracts excluded*  
+ 34 sources from snowballing
119 sources included in RMI 
literature review
50 duplicate RMIs excluded
*Reasons for abstract exclusions: 
Involving Pre‐2000 RMIs n=4
Not RMI n=1699
Not drug product n=82
Veterinary use n=3
Medication error n=20
General article/No specific drug n=160
Figure I. Literature Review: Source Identification Flow Chart
RMI = Risk Minimisation Intervention
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Figure II. Literature Review: Distribution of RMIs by Drug Anatomical 
Therapeutic Chemical (ATC) Classification 
 
 
 
NS = Nervous System; A = Alimentary tract and metabolism; B = Blood and blood forming organs; L 
= Antineoplastic and immunomodulating agents; 
D = Dermatologicals; C=Cardiovascular system 
Comb = Combination 
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Figure III. Literature Review: Distribution of RMIs by Adverse Event System Organ Class 
(AE SOC, MedDRA Terminology) 
 
 
 
 
SOC as per MedDRA: CV=Cardiovascular disorder; N=Neoplasms, benign, malignant and 
unspecified; Psy=Psychiatric disorders; Con= Congenital, familial, and genetic disorders; 
Hep=Hepatobiliary disorders; Blood = Blood and lymphatic system disorders 
 
Div= Diverse (combination of AE SOC) 
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Figure IV. Website Review: RMI Identification Flow Chart_ 
Appendix I – Literature Review Data Extraction Table 
 
  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
1 2000 Corry et al [66] 
Hospitals do not inform 
GPs about medication 
that should be 
monitored.  GBR EU 
Various - 
requiring 
regular 
monitoring Diverse Diverse 
EM – 
Commun
ica-tion All 
2 2000 Franic et al [77] 
Communicating the 
frequency of adverse 
drug reactions to female 
patients.  USA USA Various Diverse Diverse 
EM – 
Commun
ica-tion Women 
3 2000 Griffin et al [87] 
Prepulsid withdrawn 
from UK & US markets. 
GBR / 
USA 
INTL - 
2UK / 
USA cisapride 
Alimentary 
tract and 
metabolism 
Cardiac 
Disorder
s 
Withdra
wal All 
4 2000 
Morrison et al 
[121] 
Enhancing case 
managers' skills in the 
assessment and 
management of 
antipsychotic 
medication side-effects.  AUS AUS Various 
Nervous 
System Diverse 
Educatio
n 
Program All 
5 2000 Offit et al [130] Withdrawal of rotavirus USA USA Rotavirus Various - GI Withdra Pediatri
152 
 
 
 
  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
vaccine in the USA.  Vaccine vaccine Disorder
s 
wal c 
6 2000 
Silman et al 
[146] 
Proposal to establish a 
register for the long 
term surveillance of 
adverse events in 
patients with rheumatic 
diseases exposed to 
biological agents: the 
EULAR Surveillance 
Register for Biological 
Compounds.  GBR 
EU-
SWE/NL
D/UK 
Biological
s 
Antineoplastic 
and 
immunomodula
ting agents Diverse 
Patient 
Registry All 
7 2000 
Smalley et al 
[149] 
Contraindicated use of 
cisapride: impact of 
food and drug 
administration 
regulatory action.  USA USA cisapride 
Alimentary 
tract and 
metabolism 
Cardiac 
Disorder
s 
EM – 
Commun
ica-tion All 
8 2000 
Watkins et al 
[161] 
COMT inhibitors and 
liver toxicity.  USA 
INTL - 
3USA/E
U/CAN 
tolcapone/ 
entacapone
Nervous 
System 
Hepato-
biliary 
Disorder
s BBW All 
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  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
9 2000 FDA website [1] 
Food and Drug 
Administration. FDA 
talk paper: Janssen 
Pharmaceutica stops 
marketing cisapride in 
the US.  USA USA cisapride 
Alimentary 
tract and 
metabolism 
Cardiac 
Disorder
s RD All 
10 2000 Dahl et al [70] 
Pharmacogenetic 
methods as a 
complement to 
therapeutic monitoring 
of antidepressants and 
neuroleptics SWE 
Not 
indicated Various 
Nervous 
System Diverse 
Pharmac
o-
genetics All 
11 2000 
Lundmark et al 
[111] 
Therapeutic drug 
monitor of selective 
serotonin reuptake 
inhibitors influences 
clinical dosing 
strategies and reduces 
drug costs in depressed 
elderly patients.  SWE EU SSRI's 
Nervous 
System Diverse TDM 
Geriatri
c 
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  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
12 2000 
Lundmark et al 
[110] 
Therapeutic drug 
monitoring of sertraline: 
variability factors as 
displayed in a clinical 
setting. SWE 
Not 
indicated sertraline 
Nervous 
System Diverse TDM All 
13 2000 
Lotronex.com 
website [2] 
Prescribing program for 
Lotronex. Pharmacist 
information.  USA USA alosetron 
Alimentary 
tract and 
metabolism 
GI 
Disorder
s 
Withdra
wal Women 
14 2000 
Celgene.com 
website [3] 
Celgene. S.T.E.P.S. 
prevention and 
protection. USA USA 
thalidomid
e 
Antineoplastic 
and 
immunomodula
ting agents 
Congeni
tal, 
familial 
and 
genetic 
disorder
s 
RD / 
Educatio
n 
Program Women 
15 2001 Not indicated [4] 
Failings in treatment 
advice, SPCs and black 
triangles.  GBR 
Not 
indicated Various  Diverse Diverse 
Black 
Triangle 
Symbol Unk 
16 2001 Not indicated [5] 
Black-box' warning and 
letter are insufficient to 
protect patients, study USA 
Not 
indicated Various  Diverse Diverse BBW Unk 
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  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
finds.  
17 2001 Bourke et al [55] 
Joint charts in drug 
handling. Toward 
increased drug safety.  DNK 
Not 
indicated Various Diverse 
Drug 
Interacti
on Other Unk 
18 2001 Brown et al [57] 
 The incidence and 
reporting of adverse 
drug reactions in the 
Division of Psychiatry.  GBR EU Various  Diverse Diverse 
Black 
Triangle 
Symbol All 
19 2001 
Feltelius et al 
[74] 
 New drugs require new 
follow-up surveillance.  SWE 
Not 
indicated 
TNF-
blockers 
Antineoplastic 
and 
immunomodula
ting agents Diverse Other All 
20 2001 Kilborn et al [99] 
 Registry for torsades de 
pointes with drug 
treatment exists. USA 
Not 
indicated Various Diverse Diverse 
Patient 
Registry All 
21 2001 Singer et al [147] 
 Cardiac toxicity of 
arsenic trioxide.  USA USA 
arsenic 
trioxide 
Antineoplastic 
and 
immunomodula
ting agents 
Cardiac 
Disorder
s BBW All 
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22 2001 
Graham et al 
[85] 
Liver enzyme 
monitoring in patients 
treated with 
troglitazone. USA USA 
trioglitazo
ne 
Alimentary 
tract and 
metabolism 
Hepato-
biliary 
Disorder
s 
TDM / 
EM-HCP 
Commun
ica-tion All 
23 2001 Schwetz [142] 
New measures to 
manage risks associated 
with accutane. USA USA 
isotretinoi
n 
Dermatological
s 
Congeni
tal, 
familial 
and 
genetic 
disorder
s 
IC / EM-
Medicati
on Guide Women 
24 2001 Ensom et al [72] 
Pharmacogenetics- The 
therapeutic drug 
monitoring of the 
future? CAN INTL Various Diverse Diverse 
Pharmac
o-
genetics All 
25 2002 Thompson [154] 
Bosentan enters market 
with risk management 
program.   USA USA bosentan CV system 
Hepato-
biliary 
Disorder
s 
RD/ 
patient 
registry / 
Medicati
on Guide All 
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26 2002 Charatan [61] 
 FDA advisory panels 
recommend Lotronex be 
put back on market.  USA USA 
alosetron  
HCl 
Alimentary 
tract and 
metabolism 
GI 
Disorder
s 
EM - 
Medicati
on guide Women 
27 2002 Frances et al [75] 
Methylphenidate 
(Ritalin) use in France. 
[French].  FRA EU 
methylphe
nidate 
Nervous 
System 
Combin
ation-
Not 
specifie
d 
RD / 
Restricte
d 
Prescripti
on 
Pediatri
c 
28 2002 
Horowitz et al 
[91] 
Droperidol--behind the 
black box warning.  USA USA droperidol 
Alimentary 
tract and 
metabolism 
Cardiac 
Disorder
s BBW All 
29 2002 
Masand et al 
[115] 
Prescribing 
conventional 
antipsychotics in the era 
of novel antipsychotics: 
informed consent issues. USA USA Various 
Nervous 
System Diverse IC  All 
30 2002 
Magnus et al 
[112] 
GPs’ views on 
computerized drug 
interaction alerts: 
questionnaire survey.  GBR EU Various Diverse 
Drug 
Interacti
on Other All 
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31 2002 
Singapore H S A 
website [36] 
HSA product safety 
alert. Update on Eprex 
and pure red cell 
aplasia.  SGP SGP 
HSA 
(ESA) 
Blood and 
blood forming 
organs 
Blood 
and 
Lympha
tic 
system 
disorder
s 
EM – 
Commun
ica-tion All 
32 2002 
Australia TGA 
website [37] 
Epoetin alfa and pure 
red cell aplasia. 
Australian adverse drug 
reactions bulletin.  AUS AUS epoietin 
Blood and 
blood forming 
organs 
Blood 
and 
Lympha
tic 
system 
disorder
s 
EM – 
Commun
ica-tion All 
33 2002 
France AFSSPS 
website [7] 
Agence Francaise de 
Securite Sanitaire des 
Produits de Sante, les 
lettre aux prescripteurs, 
Eprex®: information 
importante de 
pharmacovigilance. 17 FRA EU epoietin 
Blood and 
blood forming 
organs 
Blood 
and 
Lympha
tic 
system 
disorder
s 
EM – 
Commun
ica-tion All 
159 
 
 
 
  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
December 2002 
34 2002 
Health Canada 
website [11] 
Important safety 
information—
EPREXTM (epoetin 
alfa)—Janssen-Ortho 
Inc. Health Canada. 26 
November 2001 CAN CAN epoietin 
Blood and 
blood forming 
organs 
Blood 
and 
Lympha
tic 
system 
disorder
s 
EM – 
Commun
ica-tion All 
35 2002 
FDA website 
[13] 
Danco Laboratories. 
Open letter to health 
care providers (Apr. 19, 
2002). (Dear doctor 
letter)  USA USA 
mifespristo
ne 
Genitourinary 
system and sex 
hormones 
Pregnan
cy, 
puerperi
um etc. 
EM – 
Commun
ica-tion Women 
36 2002 
Kivlahan et al 
[100] 
Developing a 
comprehensive 
electronic adverse event 
reporting system in an 
academic health center. USA USA Various Diverse Diverse Other All 
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37 2003 
Not indicated 
[16] 
Patients to have new 
role in improving 
methotrexate safety  
says NPSA.  GBR 
Not 
indicated 
methotrexa
te 
Alimentary 
tract and 
metabolism 
Unknow
n 
Black 
Triangle 
Symbol All 
38 2003 Edwards [71] 
Withdrawing drugs: 
nefazodone  the start of 
the latest saga. SWE EU 
nefazodon
e 
Nervous 
System 
Hepato-
biliary 
Disorder
s 
Withdra
wal All 
39 2003 
 LaPointe et al 
[49] 
Evaluation of the 
dofetilide risk-
management program. USA USA dofetilide CV system 
Cardiac 
Disorder
s 
RD / 
Educatio
n All 
40 2003 
Not indicated 
[15] 
Suicide risk warning for 
children now extended 
by CSM to cover 
venlafaxine.  GBR 
Not 
indicated 
venlafaxin
e 
Nervous 
System 
Psychiat
ric 
disorder
s 
EM – 
Commun
ica-tion 
Pediatri
c 
41 2003 
Muller et al 
[122] 
Therapeutic drug 
monitioring of tricyclic 
antidepressants: how 
does it work under 
clinical conditions?  DEU USA 
trycyclic 
anti-
depressant
s 
Nervous 
System Diverse TDM All 
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42 2003 
Fosamax.com 
website [17] 
Merck. Paget’s patient 
support program. USA USA 
alendronat
e sodium 
Alimentary 
tract and 
metabolism Diverse 
Educatio
n 
Program Women 
43 2004 
Not indicated 
[18] 
Paroxetine review 
makes safety warnings.  GBR 
Not 
indicated paroxetine 
Nervous 
System 
Unknow
n 
EM – 
Commun
ica-tion Unk 
44 2004 Check [62] 
 US panel recommends 
'black box' warnings for 
antidepressants.  USA USA Various 
Nervous 
System 
Psychiat
ric 
disorder
s BBW 
Pediatri
c 
45 2004 Cockey [65]  Ephedra banned.  USA USA ephedrine 
Alimentary 
tract and 
metabolism 
Cardiac 
Disorder
s 
Withdra
wal All 
46 2004 Crawford [68] 
Licensing thalidomide 
in Australia. AUS AUS 
thalidomid
e 
Antineoplastic 
and 
immunomodula
ting agents 
Congeni
tal, 
familial 
and 
genetic 
disorder
s 
RD 
/Physicia
n registry  
/ Patient 
registry/ 
Educatio
n  All 
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47 2004 Fraunfelder [79] 
Twice-yearly exams 
unnecessary for patients 
taking quetiapine.  USA USA quetiapine 
Nervous 
System 
Endocri
ne 
Disorder
s TDM All 
48 2004 Gebhart [82] 
Calls mount for black 
box warning on 
fluoroquinolones.  USA USA 
Fluoroquin
o-lones  
Antiinfective 
for systemic use
Metabo-
lism and 
nutrition 
disorder
s BBW All 
49 2004 Laugharne [104] 
Informing patients 
about tardive 
dyskinesia: A survey of 
clinicians' attitudes in 
three countries. AUS EU Various 
Nervous 
System 
Nervous 
System 
disorder 
IC / 
TDM for 
at risk 
patients All 
50 2004 
Schachter et al 
[140] 
Psychiatrists' attitudes 
about and informed 
consent practices for 
antipsychotics and 
tardive dyskinesia.  CAN CAN Various 
Nervous 
System 
Nervous 
System 
disorder IC All 
51 2004 
FDA website 
[19] 
US Food and Drug 
Administration: 2004 USA USA olanzapine 
Nervous 
System 
Metabo-
lism and 
EM – 
Commun All 
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Safety Alert: Zyprexa 
(olanzapine)  
nutrition 
disorder
s 
ica-tion 
52 2004 
Calhoun et al 
[59] 
Challenges to the FDA 
approval of 
mifepristone.  USA USA 
mifespristo
ne 
Genitourinary 
system and sex 
hormones 
Unknow
n 
EM – 
Commun
ica-tion All 
53 2004 
Baumann et al 
[51] 
Therapeutic monitoring 
of psychotropic drugs - 
An outline of the 
AGNP-TDM expert 
group consensus 
guideline. CHE EU 
Psychotrop
ic drugs 
Nervous 
System Diverse TDM All 
54 2004 Fuller et al [80] 
The Xyrem risk 
management program. USA USA 
sodium 
oxybate 
(GHB) 
Nervous 
System Diverse RD All 
55 2005 
Not indicated 
[20] 
Calcineurin inhibitors: 
Black box warning for 
pimecrolimus and 
tacrolimus. [German].  DEU 
Not 
indicated 
pimecroli
mus / 
tacrolimus 
Antineoplastic 
and 
immunomodula
ting agents 
Neoplas
ms BBW All 
56 2005 
Not indicated 
[21] 
FDA advisory 
committees recommend USA USA 
COX 
inhibitors 
Nervous 
System 
Cardiac 
Disorder BBW All 
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lation 
marketing of COX-2 
inhibitors with 'black 
box' warning.  
s 
57 2005 
Not indicated 
[22] 
Impotence drugs receive 
blindness warning. USA USA 
tadalafil/ 
vardenafil/ 
sidenafil CV system 
Eye 
Disorder
s 
EM – 
Commun
ica-tion Men 
58 2005 
Not indicated 
[23] 
Stronger warnings 
needed for asthma 
treatments. USA USA 
fluticasone 
propionate
/salmeterol
/ 
formoterol 
/  
salmeterol 
Respiratory 
system 
GI 
Disorder
s BBW All 
59 2005 
FDA website 
[26] 
Food and Drug 
Administration, “2005 
Safety Alert: Natrecor 
(nesiritide),” 13 July 
2005. USA USA nesiritide CV system 
Renal 
and 
urinary 
disorder
s 
EM – 
Commun
ica-tion All 
60 2005 
 
Melnikow et al 
[119] 
Preferences of Women 
Evaluating Risks of 
Tamoxifen (POWER) USA USA tamoxifen 
Antineoplastic 
and 
immunomodula Diverse 
Educatio
n 
Program Women 
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study of preferences for 
tamoxifen for breast 
cancer risk reduction.  
ting agents 
61 2005 
Baumann et al 
[52] 
 The AGNP-TDM 
Expert Group 
Consensus Guidelines: 
focus on therapeutic 
monitoring of 
antidepressants.  CHE EU Various 
Nervous 
System Diverse TDM All 
62 2005 Beltrani [53] 
 The "black boxing" of 
protopic and elidel.  USA USA 
tacrolimus 
/ 
pimecroli
mus 
Dermatological
s 
Neoplas
ms BBW 
Pediatri
c 
63 2005 
Bensouda-
Grimaldi et al 
[54] 
Isotretinoin: compliance 
with recommendations 
in childbearing women.  FRA EU isotretinon 
Dermatological
s 
Congeni
tal, 
familial 
and 
genetic 
disorder
s 
IC / 
Medicati
on Guide Women 
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64 2005 
Gerlach et al 
[83] 
"Therapeutic drug 
monitoring"  a strategy 
for improving drug 
safety in child and 
adolescent psychiatry 
and psychotherapy. DEU 
Not 
indicated Various 
Nervous 
System Diverse TDM 
Pediatri
c 
65 2005 
Hetland et al 
[90] 
Routine database 
registration of 
biological therapy 
increases the reporting 
of adverse events 
twentyfold in clinical 
practice. First results 
from the Danish 
Database (DANBIO).  DNK EU 
Biological
s 
Antineoplastic 
and 
immunomodula
ting agents Diverse 
Patient 
Registry All 
66 2005 Hugman [92] 
From the Uppsala 
monitoring centre: a 
review of viewpoint part 
1 and part 2.  SWE 
INTL - 
ALL -
Who 
members Various Diverse Diverse 
EM – 
Commun
ica-tion All 
67 2005 
Lederer et al 
[105] 
Reduction in 
anticoagulation-related USA USA warfarin 
Blood and 
blood forming Diverse 
Other - 
Trigger - All 
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adverse drug events 
using a trigger-based 
methodology. 
organs based 
method 
68 2005 
Shatin et al  
[144] 
Impact of mailed 
warning to prescribers 
on the co-prescription of 
tramadol and 
antidepressants.  USA USA tramadol 
Nervous 
System 
Cardiac 
Disorder
s 
EM – 
Commun
ica-tion All 
69 2005 Cotter et al [67] 
New restrictions on 
celecoxib (Celebrex) 
use and the withdrawal 
of valdecoxib (Bextra).  CAN 
INTL-
CAN/US celecoxib 
Nervous 
System 
Cardiac 
Disorder
s 
EM – 
Commun
ica-tion All 
70 2005 
FDA website 
[28] 
Dear Health Care 
Provider letter. 
Important drug warning 
and 
new information for 
Clozaril (clozapine). 
Novartis 
Pharmaceuticals 
Corporation, December USA USA clozapine 
Nervous 
System Diverse 
EM – 
Commun
ica-tion All 
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2005. 
71 2005 
FDA website  
[33] 
FDA, “FDA Public 
Health Advisory: 
Suicidality in Adults 
Being Treated with 
Antidepressant 
Medications” 30 June 
2005. USA USA Various 
Nervous 
System 
Psychiat
ric 
disorder
s 
EM – 
Commun
ica-tion Adults 
72 2005 
FDA website  
[29] 
US Food and Drug 
Administration: FDA 
Public Health Advisory: 
Deaths with 
antipsychotics in elderly 
patients with behavioral 
disturbances, April 11, 
2005, accessed January 
30, 2006. USA USA Various 
Nervous 
System 
Unknow
n 
EM – 
Commun
ica-tion 
Geriatri
c 
73 2005 
Not indicated 
[24] 
European COX-2 
review recommends 
new warnings.  GBR EU 
COX 
inhibitors 
Nervous 
System 
Cardiac 
Disorder
s 
EM – 
Commun
ica-tion All 
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74 2005 
Not indicated 
[31] 
The Food and Drug 
Administration. Public 
Health Advisory: 
suicidal thinking in 
children and adolescents 
being treated with 
Strattera (atomoxetine). 
29 September 2005. USA USA 
atomexitin
e 
Nervous 
System 
Psychiat
ric 
disorder
s 
EM – 
Commun
ica-tion 
Pediatri
c 
75 2005 Grenieret al [86] 
Nursing support 
program to decrease or 
prevent side effects of 
pegylated liposomal 
doxorubicin (PLD) in 
patients with recurrent 
epithelial ovarian cancer 
(REOC). CAN 
Not 
indicated 
doxorubici
n 
Antineoplastic 
and 
immunomodula
ting agents Diverse 
Educatio
n 
Program All 
76 2005 Mazor et al [116] 
Communicating safety 
inforamtion to 
physicians: an 
examination of Dear Dr. 
Letters.  USA USA Various Diverse Diverse 
EM – 
Commun
ica-tion All 
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77 2006 Aaronson [48] 
The "black box" 
warning and allergy 
drugs. USA USA Various 
Alimentary 
tract and 
metabolism Diverse BBW All 
78 2006 
Feldstein et al 
[73] 
Improved therapeutic 
monitoring with several 
interventions: a 
randomized trial. USA USA Various Diverse Diverse TDM All 
79 2006 
Schussel et al 
[141] 
 Prescribing of COX-2 
inhibitors in Germany 
after safety warnings 
and market withdrawals. DEU EU 
COX 
inhibitiors 
Nervous 
System 
Cardiac 
Disorder
s 
EM – 
Commun
ica-tion All 
80 2006 Sheridan [145] 
 Tysabri back on 
market.  USA USA 
natalizuma
b 
Antineoplastic 
and 
immunomodula
ting agents 
Neoplas
ms 
Patient 
Registry All 
81 2006 Wechsler [164] 
Advisory committee 
prompts FDA to 
consider black box 
warning for ADHD 
drugs.  USA USA 
Amphetam
ine-based 
drugs for 
ADHD, 
such as 
Adderall 
Nervous 
System 
Cardiac 
Disorder
s BBW All 
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and 
Dexedrine 
82 2006 Lasser et al [103] 
Adherence to black box 
warnings for 
prescription medications 
in outpatients USA USA Various Diverse Diverse BBW All 
83 2006 
FDA website 
[34] 
Medication Guide: 
Coumadin tablets 
(warfarin sodium 
tablets, USP) 
crystalline. 2006. USA USA warfarin 
Blood and 
blood forming 
organs Diverse 
EM - 
Medicati
on guide Unk 
84 2007 Jones [96] 
Update on isotretinoin 
and the iPLEDGE 
system.  USA 
Not 
indicated 
isotretinoi
n 
Dermatological
s 
Congeni
tal, 
familial 
and 
genetic 
disorder
s 
Patient 
registries 
/ 
Pharmaci
st 
registries 
Physician 
registries
- 
Pregnanc Women 
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y 
85 2007 
Morrato et al 
[120] 
 Effectiveness of risk 
management plans: a 
case study of pemoline 
using pharmacy claims 
data.  USA USA pemoline 
Nervous 
System 
Hepato-
biliary 
Disorder
s BBW 
All - 
Mainly 
Pediatri
c 
86 2007 
Muller et al 
[123] 
 Therapeutic drug 
monitoring for 
optimizing amisulpride 
therapy in patients with 
schizophrenia.  DEU EU 
amisulprid
e 
Nervous 
System Diverse TDM All 
87 2007 
Munzenberger et 
al [124] 
 Safety of topical 
calcineurin inhibitors 
for the treatment of 
atopic dermatitis.  USA USA 
topical 
calcineurin 
inhibitors 
Antineoplastic 
and 
immunomodula
ting agents 
Neoplas
ms 
EM - 
Medicati
on Guide/ 
Black 
Box 
Warning  All 
88 2007 
Oppenheimer et 
al [131] 
Impact of recent black 
box warnings in the 
allergy world.  USA USA 
long-
acting  -
agonists 
Alimentary 
tract and 
metabolism 
Neoplas
ms BBW All 
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(LABAs) 
and 
calcineurin
inhibitors  
89 2007 
Recupero et al 
[135] 
Managing risk when 
considering the use of 
atypical antipsychotics 
for elderly patients with 
dementia-related 
psychosis.  USA USA Various 
Nervous 
System 
Cardiac 
Disorder
s BBW 
Geriatri
c 
90 2007 Singh [148] 
 The FDA black box for 
EPO: what should 
nephrologists do?  USA USA epoietin 
Blood and 
blood forming 
organs 
Neoplas
ms BBW All 
91 2007 
Valente et al 
[157] 
Nurses improve 
medication safety with 
medication allergy and 
adverse drug reports.  USA 
Not 
indicated Various Diverse Diverse 
Educatio
n 
Program All 
92 2007 
Wysowski et al 
[168] 
Bleeding complications 
with warfarin use: A 
prevalent adverse effect 
resulting in regulatory USA USA warfarin 
Blood and 
blood forming 
organs 
Blood 
and 
Lympha
tic BBW All 
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action.  system 
disorder
s 
93 2007 Tanne [153] 
FDA places “black box” 
warning on antidiabetes 
drugs. USA USA Various 
Alimentary 
tract and 
metabolism 
Cardiac 
Disorder
s BBW All 
94 2007 
FDA website 
[35] 
The Food and Drug 
Administration.FDA 
proposes new warnings 
about suicidal thinking, 
behavior in young 
adults who take 
antidepressant 
medications. 2 May 
2007. USA USA Various 
Nervous 
System 
Psychiat
ric 
disorder
s BBW 
Pediatri
c 
95 2008 FDA webite [47] 
FDA ALERT - 
Simvastatin Used With 
Amiodarone. USA USA 
simvtatin& 
amiodaron
e  
Alimentary 
tract and 
metabolism/ 
CV 
Musculo
skeletal 
EM – 
Commun
ica-tion All 
96 2008 
Not indicated 
[39] 
Tegaserod: withdrawal 
from the world market. FRA INTL tegaserod 
Alimentary 
tract and 
Cardiac 
Disorder
Withdra
wal All 
175 
 
 
 
  Year 
Authors [Lit 
Review Source 
Ref #] Title 
Country 
of 
publica-
tion 
Region 
of imple-
ment as 
per 
article 
Product 
active 
ingredient 
Therapeutic 
Area 
AE - 
SOC 
Inter-
vention 
Type 
Patient 
Popu-
lation 
A treatment for 
constipation with 
cardiovascular adverse 
effects. 
metabolism s 
97 2008 
Castaneda et al 
[60] 
RevAssist: A 
comprehensive risk 
minimization 
programme for 
preventing fetal 
exposure to 
lenalidomide.  USA USA 
lenalidomi
de 
Antineoplastic 
and 
immunomodula
ting agents 
Congeni
tal, 
familial 
and 
genetic 
disorder
s RD Women 
98 2008 Mallal et al [114] 
HLA-B*5701 Screening 
for Hypersensitivity to 
Abacavir. AUS INTL abacavir 
Antiinfective 
for systemic use
Immune 
system 
disorder
s 
TDM-
Pharmac
o-
genomics All 
99 2008 
Jennings et al 
[94] 
Reducing anticoagulant 
medication adverse 
vents and avoidable 
patient harm.  USA USA 
Anticoagul
ant 
Blood and 
blood forming 
organs Diverse 
Educatio
n 
Program / 
TDM All 
100 2008 Naso [126] 
Optimizing patient 
safety by preventing USA USA olanzapine 
Nervous 
System 
Drug 
Interacti Other All 
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Popu-
lation 
combined use of 
intramuscular 
olanzapine and 
parenteral 
benzodiazepines. 
on 
101 2008 
FDA website 
[43] 
Suicidality and 
antiepileptic drugs: 
FDA alert. USA USA Various 
Nervous 
System 
Psychiat
ric 
disorder
s 
EM – 
Commun
ica-tion All 
102 2008 
von Moos et al 
[160] 
Pegylated liposomal 
doxorubicin-associated 
hand-foot syndrome: 
recommendations of an 
international panel of 
experts. CHE INTL 
doxorubici
n 
Antineoplastic 
and 
immunomodula
ting agents 
Metabo-
lism and 
nutrition 
disorder
s 
Educatio
n 
Program All 
103 2008 Wright [167] 
Tell patients about 
yellow card reporting.  GBR EU Various Diverse Diverse 
Patient 
alert card Unk 
104 2008 
UK MHRA 
website [42] 
MHRA Drug Safety 
Update on Exenatide . GBR EU exenatide 
Alimentary 
tract and 
metabolism 
Hepato-
biliary 
Disorder
s 
EM – 
Commun
ica-tion  All 
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105 2008 FDA website [6] 
Tumor necrosis factor-
alpha blockers (TNF 
blockers), Cimzia 
(certolizumab pegol), 
Enbrel (etanercept), 
Humira (adalimumab), 
and Remicade 
(infliximab) Sept 2008. USA USA Various 
Antineoplastic 
and 
immunomodula
ting agents 
Neoplas
ms 
EM – 
Commun
ica-tion All 
106 2008 Prinset al [132] 
Novel side effects of 
moxifloxacin: making a 
balanced decision again. NLD 
Not 
indicated 
moxifloxa
cin 
Antiinfective 
for systemic use
Hepato-
biliary 
Disorder
s 
EM – 
Commun
ica-tion All 
107 2008 
FDA website 
[46] 
Information on 
exenatide (marketed as 
Byetta®). USA USA exenatide 
Alimentary 
tract and 
metabolism 
Hepato-
biliary 
Disorder
s 
EM – 
Commun
ica-tion All 
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Patient 
Popu-
lation 
108 2008 Lee et al [106] 
Drug-risk 
communication to 
pharmacists: Assessing 
the impact of risk-
minimization strategies 
on the practice of 
pharmacy. USA USA Various Diverse Diverse 
EM – 
Commun
ica-tion /  
Medicati
on 
Guides All 
109 2009 Franke et al [78] 
High-alert medications 
in the pediatric intensive 
care unit.  USA USA Various Diverse Diverse 
EM – 
Commun
ica-tion 
Pediatri
c 
110 2009 
McCann et al 
[117] 
Patients' perceptions 
and experiences of 
using a mobile phone-
based advanced 
symptom management 
system (ASyMS) to 
monitor and manage 
chemotherapy related GBR EU Various 
Antineoplastic 
and 
immunomodula
ting agents 
Metabo-
lism and 
nutrition 
disorder
s Other All 
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active 
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vention 
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Popu-
lation 
toxicity.  
111 2009 
Murray et al 
[125] 
Effect of a pharmacist 
on adverse drug events 
and medication errors in 
outpatients with 
cardiovascular disease. USA USA Various Diverse Diverse 
Educatio
n 
Program All 
112 2009 Prinz [133] 
The EMEA suspends 
approval of Raptiva for 
psoriasis. Commentary. DEU EU efalizumab
Dermatological
s 
Neoplas
ms 
Withdra
wal All 
113 2009 
Pugashetti et al 
[134] 
Efalizumab 
discontinuation: a 
practical strategy. USA INTL efalizumab
Dermatological
s 
Neoplas
ms 
Withdra
wal All 
114 2009 Richins [137] 
Regulation of smoking 
cessation drugs by the 
Food and Drug USA USA 
varenicline
, 
buproprion
Nervous 
System Diverse BBW All 
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Administration. 
115 2009 
Sanfelix-Gimeno 
et al [139] 
Effectiveness of safety 
warnings in atypical 
antipsychotic drugs: an 
interrupted time-series 
analysis in Spain. ESP EU 
olanzapine 
and 
risperidone
Nervous 
System Diverse 
EM - 
Commun
ication / 
Prior 
authorisa
-tion 
policy All 
116 2009 Traynor [155] 
Close vote by FDA 
advisers favors 
propoxyphene 
withdrawal.  USA USA 
propoxy-
phene 
Nervous 
System 
Cardiac 
Disorder
s BBW All 
117 2009 
Van Geffen et al 
[158] 
Patients' perceptions of 
information received at 
the start of selective 
serotonin-reuptake 
inhibitor treatment: NLD EU 
SSRI 
inhibitors 
Nervous 
System Diverse IC All 
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Implications for 
community pharmacy.  
118 2009 
Yetzer et al 
[169] 
Medication safety 
series: take charge!  USA 
Not 
indicated Various Diverse Diverse 
Educatio
n 
Program All 
119 2009 Hitt, E [46] 
Botulinum Toxin Safety 
Warnings Updated and 
Name Changes Issued USA USA 
botulinum 
toxin 
Musculoskeleta
l system Diverse 
EM – 
Commun
ica-tion All 
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Chapter 6. Thesis Discussion 
This thesis studied some of the methodologies used in two main areas of therapeutic risk 
management.  
1) Risk detection, through the review of data mining methodologies, a review of databases 
used to perform data mining, and finally through the conduct of a data mining 
demonstration study in the Quebec health claims databases.  
2) Risk minimisation, through a systematic review of RMI characteristics in the literature 
and among regulatory agency websites. 
 
For each sub-study, advantages and limitations are discussed in further detail in the 
“Discussion” sections of each of Chapters 4 and 5 of the thesis, respectively.  However, a 
brief summary is provided here, followed by a view of the contributions these studies bring 
to the global risk management forum.  
 
Data mining study discussion summary 
This study being the first data mining study to be conducted in a Canadian health claims 
database poses a new development. Further, the fact that it is analyzing a denominator-
based methodology also contributes to its uniqueness. Using the administrative database 
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avoids the common signal detection challenges of SR databases of underreporting and 
reporting bias. It also has the potential for future analysis of signal verification and 
confirmation since claims databases are a major tool for risk evaluation studies, i.e. 
hypothesis-testing studies. Controlling for overall health status using the CDS has never 
before been attempted in a published data mining study. Accounting for the depletion of 
susceptible effect through a time window sensitivity analysis is also a new approach not 
considered in previous studies.  
 
Conversely, this study was not able to detect very rare AEs due to the low statistical power. 
The main reason being that only a random sample of approximately 10% of the elderly 
population was available.  Even the entire population of elderly may be insufficient to 
detect rare AEs, a fact that has demonstrated by a large international European 
consortium[64]. Control of confounding was performed on age, sex, and overall health 
status.   However only a basic, less refined control of the covariate of age was permitted 
because of its classification in 5-year intervals.   This constraint, imposed by the database 
custodian, is a limitation of the study. 
 
However, the data mining analysis was still able to reveal important gaps in the data mining 
and signal detection processes.  Most prior data mining studies have been conducted in SR 
databases, with the aid of denominator–independent methodology, few studies have been 
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applied to administrative claims databases using denominator-dependent methods, and none 
such studies have occurred in Canada or within a Canadian health claims database. Data 
mining and signal detection are conducted by few organisations in Canada. These are 
important gaps in the data mining and signal detection processes which we addressed 
through the application of the MaxSPRT data mining tool to a Canadian claims database, 
the RAMQ.  
 
With the data mining study, future research with this methodology could involve 
application of the method to the RAMQ database, in a real-time manner using newly 
marketed drugs provided the RAMQ database is updated regularly. However, this may 
prove a challenge because of current access constraints.  Due to excessive timelines and 
restrictive conditions for access, it does not appear feasible to obtain prospective data slices 
on a quarterly basis.  As for any drug surveillance process in Canada, potential future real-
time implementation would be greatly dependent on the timely availability of the claims 
databases. This could pose a challenge for use globally as many databases may not be 
accessible regularly even though in practice they are populated in real-time.  
This data mining study was merely a demonstration study as there are many possible 
additions that can be made to the process that was outlined. Possibly accounting for time to 
onset of AE, or residual risk periods after exposure in order to further reduce the false 
positive signals in instances where the AEs of interest have previously been identified. 
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Testing a potential solution for analysing rare AEs such as using proxies of less severe 
symptoms of the disease. Use of the database for the subsequent phase in signal detection, 
i.e. verification / confirmation of the signal, is also a potential next step with the RAMQ 
database because it contains much information on potential confounders such as 
concomitant medications. 
 
Global data mining discussion 
Over the last eight years, there has been a debate concerning the usefulness of claims 
databases for signal detection processes [28,144]. Although the use of spontaneous databases 
for signal detection is quite extensive (since 1998 [74]), only three published studies were 
located that used an administrative claims database as of 2007 [30,32,63,]  . Our study showed 
that for one drug-AE pair (rosiglitazone-acute MI), the Quebec claims database is in fact 
feasible for the application of at least one data mining algorithm: the MaxSPRT. However, 
the feasibility of using the database depends on the accuracy of the AE diagnostic codes (in 
this case ICD-9 codes), as well as the size of the database and statistical power.  The 
RAMQ database holds a maximum of 800 000 patients. The cohort used for this study 
constituted about 11% of the entire database (87, 389). However, this cohort was large 
enough to detect a signal in only one of the drug-AE pairs, the rosiglitazone-acute MI pair 
This pair  possessed a cumulative total of 52,906 patient months of exposure to 
rosiglitazone for the initial follow-up period of 3months,and 90,941 patient months for the  
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6month follow-up period. Despite elimination of prevalent acute MI cases through the 
exclusion of ICD-9 codes related to ER visits, the AE was frequent enough to produce a 
signal (a cumulative total of 118 events for the 3 month time period, RR at signal =1.26; 
and a cumulative total of 151 events for the 6month time period, RR at signal =1.18). 
The case studies that were restricted to female patients (rosiglitazone and pioglitazone and 
risk of increased fractures in female patients) however did not possess enough power to 
detect a signal. Their cumulative patient exposure were 3,064 and 1,731 patient months 
respectively for their 3 month follow-up time periods, less than one-tenth that of the 
rosiglitazone acute MI case study.  While the cumulative number of AEs for the 3-month 
time period were 12 and 6, respectively. The RR at the points of their respective Health 
Canada warnings were 1.24 and 0.72, respectively. Furthermore, the rosuvastatin-
rhabdomyolysis group did not exhibit enough occurrences of the AE to be analysed using 
the method (a cumulative total of only 9 events for the entire 10-year time period of the 
data). Based on the literature, the prevalence of rhabdomyolysis among rosuvastatin users is 
6.59% [145]  . Thus, anticipated number of events for the number of rosuvastatin users in the 
database (14,583) was 961. The low number of rhabdomyolysis cases actually observed 
shows that the tool should be used for events that are better coded and have a higher 
incidence (as was discussed earlier with the event of acute MI).  
The validity of the comparator drugs is also a subject of debate. As with previous data 
mining studies [31,63]  , comparator drugs used for the same indication as the study drug were 
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selected for the analysis in order to control for indication bias. However, it was challenging 
to find a comparator drug that had the same or similar life cycle as the study medication. In 
most cases, the comparator drug had been on the market for many more years than the 
study drug which may have led to variations in factors of patterns of use by the population  
such as: changes in the drug’s indication, contraindications, and reimbursable status over 
time, unmeasured prescription channelling, which could account for potential variances in 
AE occurrences over time, despite adjustments for age, sex, and overall health status.  
Accuracy of diagnostic codes present in physician billings databases has also been a subject 
of debate, which may also hamper the validity of data mining.  Diagnostic codes in 
hospitalization databases have been shown to be more accurate but, in Canada, these 
databases are not available in real-time; hence would not be suitable for implementation in 
a prospective safety surveillance study. 
Also because of the lag times between approval and reimbursement in public drug 
programs, the ability to cover the entire population on a timely basis is limited and 
consequently the statistical power of any study using the available data will be reduced.  
 
In real-world prospective signal detection, one may generate a very large number of false 
positive signals. This is a well-documented fact in signal detection and shall remain a 
barrier to the use of data mining [146,147]. However, we have demonstrated that the CDS 
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which has been used extensively in pharmacoepidemiologic studies, is also suitable and can 
be an important addition to the overall field of pharmacovigilance. 
 
Risk minimisation review discussion 
 
The systematic review of RMIs was accepted for publication in Drug Safety and also a 
unique study in that there are no other publications that previously summarised RMIs from 
such a variety of sources, and over such a lengthy time period. Nor had any publications 
attempted to analyse the effect of regulatory guidances on the RMIs. Because it analysed 
RMIs across regions, it is in fact a globally-relevant project that can be beneficial for 
various members of the pharmaceutical, regulatory, and academic world.  
 
Although it is a good amalgamation of data on RMIs, there may be additional RMIs that 
were not included in the study due to inconsistencies in website data availability, the fact 
that only certain regulatory websites were searched (e.g. all websites consulted were in the 
English language) could restrict the inclusiveness of this review. In addition, the specific 
classification system used in this review could lead to discrepancies and /or constraints of 
the review results. Finally, the sources available for review possessed insufficient data on 
methods. However, information such as this is not likely to be published and obtaining it 
would in all probability involve a qualitative survey of pharmaceutical companies. Due to 
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confidentiality and proprietary matters, this would most likely pose an obstacle and little 
feedback would be expected as a result.  
 
The issue of publication bias is also a factor as only more complex RMIs would be 
expected to be published in the literature. The majority of these would be those studies and 
/ or evaluations of such that are implemented by researchers, as opposed to the 
pharmaceutical companies. Consequently, it is difficult to say how comprehensive this RMI 
review actually was.  
 
Despite the challenges involved in the systematic review, a realm of useful information was 
still proficiently collected and diverse gaps were identified in the process.  
With the RMI review, future perspectives include the continued review of RMIs going 
forward to increase the reserve of information obtained from this analysis. Studies to 
identify the methods as well as methodological challenges related to the assessment of RMI 
effectiveness can be undertaken in order to comply with the guidances on risk management. 
Determining which are the most effective of the RMIs based on the results of observed 
studies, and which are the most convenient methods to be used with the various types of 
RMIs. Also, a more comprehensive website search, including other non-English speaking 
countries could also be performed. 
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Chapter 7. Thesis Conclusion 
The data mining study showed that the RAMQ databases are indeed conducive to 
quantitative signal detection although the method may need to be refined for each drug-AE 
pair individually in order to improve its performance.  
The RMI review found that the guidances on therapeutic risk management appeared to 
result in an important increase in the number of RMIs implemented within the USA, EU 
and Japan. It is also beneficial in in helping authors of risk management plans determine 
which risks are focused on in risk management plans. E.g. the fact that the major AE SOC 
classes of RMIs were those of the nervous system could serve as a trigger for 
pharmaceutical companies to look into the necessity of a RMI when faced with a similar 
AE. 
 Although both of these separate studies: the data mining study, and the RMI systematic 
review, at first glance may appear to be separate entities, they do both fit under the common 
umbrella of therapeutic risk management, namely risk detection, and risk minimisation 
respectively. Examining these two areas of risk management (as opposed to risk evaluation, 
or risk communication) was chosen because it was observed that these are the two domains 
that are lacking in general knowledge as well as methodological advances. On the contrary, 
the areas of risk evaluation and risk communication have been in place for very many 
years. E.g. Pharmacoepidemiology has been used for over 20 years in order to evaluate 
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risks associated with medications[148,149]. As such it was deemed more relevant to focus on 
these two “hot-topic” subjects of the field of risk management as there is indeed the need 
for new research in these areas [35,150,151].  
This thesis addresses the specific areas that were lacking in risk management and it is 
believed to have brought contributions of methodological nature to the data mining 
processes such as the depletion of susceptibles effect, and control of prescription 
channelling through overall health status. In addition, the effect of regulatory guidances in 
risk minimisation as well as the identification of gaps in RMI implementation was also 
performed.  
 
From a global perspective, attempts at using claims databases for signal detection are few 
and far between. Studies from only three research teams were located that were conducted 
in the US, EU, and Korea. In the future, more countries should explore the possibility of 
making use of health claims databases as a resource for drug safety signal detection.  
The observed effect of the depletion of susceptible at delaying a signal was quite profound 
in our study. The process was also relatively simple to implement. If other data mining 
groups would apply the time window sensitivity analysis in order to control for this effect, 
there should be even earlier signal detection possibilities world-wide. 
 
194 
 
 
 
Generally with signal detection studies, the power of a study is determined by the available 
size of the database. In the instance of this data mining study, the cohort obtained from the 
Quebec database was found to be too small to detect a signal for three out of the four drug-
AE pairs. Future possibilities to address this could be the allowance of a higher proportion 
of the RAMQ database for research.  
The small database size could also be addressed by a potential project to merge databases 
across provinces (such as is the case in countries such as Denmark [152]). This would create 
a larger resource of data for research. Indeed this would be a tedious and time-consuming 
task that would raise both confidentiality concerns and some politics, however in Europe, 
there is currently an ongoing initiative to create a central spontaneous database for all EU 
member states, i.e. EudraVigilance [153]. Considering this project, an attempt at combining 
perhaps two of the databases in Canada, perhaps Ontario and Saskatchewan, for the 
conduct of research does not seem vastly unreasonable.  
 
With regards to risk minimisation on a global scale, more regulatory agencies could create 
specific websites or pages with risk minimisation interventions or risk management plans 
outlined. This would serve as a more accessible resource for risk management-specific 
information. Of the sites included in the systematic review, only the FDA and the EMA had 
dedicated pages to approved risk management plans.  
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In addition, further systematic reviews encompassing websites of additional regulatory 
agencies of individual countries can be undertaken in order to obtain more information and 
be more comprehensive. 
    
Overall, the findings made within the field of therapeutic risk management from this thesis 
are expected to be used to provide additional information supporting signal detection; 
provide new guidance on data mining; help improve RMI execution, and improve drug 
safety surveillance and therapeutic risk management within the Canadian population and 
world-wide. 
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Appendix I – Summary of Data Mining Study Variables  
STUDY DRUG - 
code denomination 
commune 
REFERENCE  
DRUG 
 - code denomination 
commune 
OUTCOME / EVENT 
- ICD-9 code 
DRUG-AE PAIR 
TYPE 
COVARIABLES 
 
Rosuvastatin 
46860 
 
Other statins 47232; 47609; 
47083; 47604; 45500; 45570;  
47595; 45564 
 
Rhabdomyolysis  
 728.8 
 
Known association 
(positive) 
 
N/A 
Rosiglitazone 
47371, 47652, 
46642 
Metformin 05824; 47208; 
47807 
Acute myocardial infarction Known association 
(positive) 
- Age in 5 categories: 
i) 66-69; ii) 70-74, iii)75-79, iv) 80-84, v) 
85+) 
- Gender (dichotomous)  
- Chronic Disease Score in four categories:  
i) 0; ii)  0- 5; iii) > 5 - 10, iv)  >10 
Pioglitazone 
46678 
Metformin 05824; 47208; 
47807 
Increased fractures 800 to 829, 
733.1 
Known association 
(positive) 
- Age in 5 categories 
i) 66-69; ii) 70-74, iii)75-79, iv) 80-84, v) 
85+) 
- Chronic Disease Score in four categories:  
i) 0; ii)  0- 5; iii) > 5 - 10, iv)  >10 
Rosiglitazone 
47371, 47652, 
46642 
Metformin 05824; 47208; 
47807 
Increased fractures 800 to 829, 
733.1 
Known association 
(positive) 
- Age in 5 categories 
i) 66-69; ii) 70-74, iii)75-79, iv) 80-84, v) 
85+) 
- Chronic Disease Score in four categories:  
i) 0; ii)  0- 5; iii) > 5 - 10, iv)  >10 
i.  
 
 
 
Amitriptyline  
00429 ; 00442 ; 
46011 
Metoprolol 38275; 46763; 
46780 
Increased fractures 800 to 829, 
733.1 
Negative-Control - Age in 5 categories 
i) 66-69; ii) 70-74, iii)75-79, iv) 80-84, v) 
85+) 
- Gender (dichotomous)  
- Chronic Disease Score in four categories:  
i) 0; ii)  0- 5; iii) > 5 - 10, iv)  >10 
Alendronate 
46295; 47165; 
47662; 47747 
Atenolol 43670; 46325 Acute hepatitis 573.3 & 570.x Negative-Control  - Age in 5 categories 
i) 66-69; ii) 70-74, iii)75-79, iv) 80-84, v) 
85+) 
- Gender (dichotomous)  
- Chronic Disease Score in four categories:  
i) 0; ii)  0- 5; iii) > 5 - 10, iv)  >10 
  
 
